

# Genetic Basis for Clinical Response to CTLA-4 Blockade

New England Journal of Medicine

371, 2189-2199

DOI: [10.1056/nejmoa1406498](https://doi.org/10.1056/nejmoa1406498)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. <i>Science</i> , 1978, 202, 975-977.	6.0	185
2	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. <i>Translational Lung Cancer Research</i> , 2007, 6, 169-177.	1.3	4
3	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
4	Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2230-2232.	13.9	43
5	Antitumour immunity gets a boost. <i>Nature</i> , 2014, 515, 496-498.	13.7	90
6	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
8	Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. <i>Journal of Translational Medicine</i> , 2015, 13, 214.	1.8	84
9	Role and complexity of next-generation sequencing in melanoma. <i>Cancer Cytopathology</i> , 2015, 123, 329-330.	1.4	0
10	Cancer immunotherapy using novel tumor-associated antigenic peptides identified by genome-wide cDNA microarray analyses. <i>Cancer Science</i> , 2015, 106, 505-511.	1.7	40
11	New clinical advances in immunotherapy for the treatment of solid tumours. <i>Immunology</i> , 2015, 145, 182-201.	2.0	35
12	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
13	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <i>Blood</i> , 2015, 126, 1203-1213.	0.6	103
14	FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. <i>Cell Death Discovery</i> , 2015, 1, 15049.	2.0	37
15	Principles of Immunotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 670-672.	2.3	8
16	Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 124.	6.9	25
17	Immunogenomics: a foundation for intelligent immune design. <i>Genome Medicine</i> , 2015, 7, 116.	3.6	5
18	Overview of KRAS-Driven Genetically Engineered Mouse Models of Non-Small Cell Lung Cancer. <i>Current Protocols in Pharmacology</i> , 2015, 70, 14.35.1-14.35.16.	4.0	12
19	Targeted Therapy for Cancer in the Genomic Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 294-298.	1.0	40

#	ARTICLE	IF	CITATIONS
20	From personalized to patient-specific treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 193-197.	0.1	0
21	DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. <i>BMC Medical Genomics</i> , 2015, 8, 73.	0.7	29
22	Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer. <i>Journal of Translational Medicine</i> , 2015, 13, 247.	1.8	57
24	Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 108.	3.5	54
25	TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. <i>Genome Medicine</i> , 2015, 7, 118.	3.6	78
26	Update on checkpoint blockade therapy for lymphoma. , 2015, 3, 33.		11
27	Baseline circulating IL-17 predicts toxicity while TGF- $\beta$ 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
28	Inhibitory receptors as targets for cancer immunotherapy. <i>European Journal of Immunology</i> , 2015, 45, 1892-1905.	1.6	116
29	Genomic alterations underlying immune privilege in malignant lymphomas. <i>Current Opinion in Hematology</i> , 2015, 22, 343-354.	1.2	18
30	What have we learned from exceptional tumour responses?. <i>Current Opinion in Oncology</i> , 2015, 27, 267-275.	1.1	8
31	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 482-488.	1.1	31
32	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17
33	Precision Medicine for Metastatic Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e2-e7.	1.8	14
34	Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice. <i>Oncotarget</i> , 2015, 6, 34221-34227.	0.8	198
35	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 55.	1.3	10
36	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 125, 3413-3421.	3.9	502
37	Biomarkers of Response to Immune Modulatory Therapies in Cancer. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2015, 06, .	1.5	1
38	Therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2015, 125, 3401-3412.	3.9	640

#	ARTICLE	IF	CITATIONS
39	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. Medical Journal of Australia, 2015, 202, 115-116.	0.8	2
40	Immunity, inflammation, and cancer: an eternal fight between good and evil. Journal of Clinical Investigation, 2015, 125, 3347-3355.	3.9	572
41	Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches. Cancers, 2015, 7, 2397-2414.	1.7	61
42	TAPBPR alters MHC class I peptide presentation by functioning as a peptide exchange catalyst. ELife, 2015, 4, .	2.8	87
43	Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e275-e283.	1.8	2
44	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e535-e542.	1.8	8
45	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. Vaccines, 2015, 3, 420-428.	2.1	14
46	The Promise of Preventive Cancer Vaccines. Vaccines, 2015, 3, 467-489.	2.1	38
47	Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine. Vaccines, 2015, 3, 490-502.	2.1	43
48	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. Frontiers in Immunology, 2015, 6, 516.	2.2	79
49	Immunotherapy of Childhood Sarcomas. Frontiers in Oncology, 2015, 5, 181.	1.3	54
50	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses, 2015, 7, 5889-5901.	1.5	19
51	Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Medical Journal, 2015, 56, 1177.	0.9	49
52	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PLoS ONE, 2015, 10, e0130142.	1.1	390
53	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	0.9	51
54	Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination. Journal of Immunology Research, 2015, 2015, 1-6.	0.9	27
55	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
56	Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e239-e247.	1.8	9

#	ARTICLE	IF	CITATIONS
57	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. <i>Journal of Clinical Investigation</i> , 2015, 125, 3981-3991.	3.9	328
58	Triple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e25-e30.	1.8	93
59	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2015, 06, .	1.5	17
60	Systems Biology Approach for Cancer Vaccine Development and Evaluation. <i>Vaccines</i> , 2015, 3, 544-555.	2.1	10
61	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015, 372, 2509-2520.	13.9	7,696
62	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015, 348, 74-80.	6.0	1,735
63	High-resolution genomic analysis: the tumor-immune interface comes into focus. <i>Genome Biology</i> , 2015, 16, 65.	3.8	4
64	Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. <i>Annals of Pharmacotherapy</i> , 2015, 49, 907-937.	0.9	155
66	Polymerase $\delta$ (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients. <i>Gynecologic Oncology</i> , 2015, 138, 11-17.	0.6	68
67	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. <i>Seminars in Oncology</i> , 2015, 42, 573-586.	0.8	21
68	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3347-3355.	3.2	249
69	Matrix metalloproteinase-12 expression is increased in cutaneous melanoma and associated with tumor aggressiveness. <i>Tumor Biology</i> , 2015, 36, 8593-8600.	0.8	29
70	The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study. <i>Leukemia</i> , 2015, 29, 1621-1622.	3.3	83
71	Immune Checkpoint Modulation for Non-“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2256-2262.	3.2	90
72	Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers. <i>Journal of Clinical Oncology</i> , 2015, 33, 1993-1994.	0.8	20
73	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. <i>Annals of Oncology</i> , 2015, 26, 1488-1493.	0.6	234
74	Future Directions and New Targets in Endometrial Cancer. <i>Current Clinical Oncology</i> , 2015, , 259-271.	0.0	0
75	Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with <i>JAK3</i> Activation. <i>Cancer Immunology Research</i> , 2015, 3, 855-863.	1.6	60

#	ARTICLE	IF	CITATIONS
76	Exome Sequencing to Predict Neoantigens in Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 992-998.	1.6	50
77	Targeting the immune system in head and neck cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 157-158.	1.1	1
78	The PTEN pathway in T <sub>regs</sub> is a critical driver of the suppressive tumor microenvironment. <i>Science Advances</i> , 2015, 1, e1500845.	4.7	167
79	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015, 75, 5228-5234.	0.4	270
80	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 99-127.	0.2	4
81	The melanoma-specific graded prognostic assessment does not adequately discriminate prognosis in a modern population with brain metastases from malignant melanoma. <i>British Journal of Cancer</i> , 2015, 113, 1275-1281.	2.9	11
82	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 1984-1984.	13.9	166
83	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. <i>BMC Medicine</i> , 2015, 13, 211.	2.3	570
84	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. <i>Current Anesthesiology Reports</i> , 2015, 5, 257-267.	0.9	0
85	BRAF Alterations as Therapeutic Targets in Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1396-1403.	0.5	76
86	Prognostic and predictive immune gene signatures in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 433-444.	1.1	75
87	Potential Therapeutic Targets in Triple Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 215-223.	0.5	1
88	Overview: New Modality for Cancer Treatment. <i>Oncology</i> , 2015, 89, 33-35.	0.9	5
89	Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. <i>Oncology Reports</i> , 2015, 34, 2099-2105.	1.2	43
90	Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations. , 2015, 3, 58.		26
91	Human CD4+ T cells spontaneously detect somatic mutations in cancer cells. <i>Nature Medicine</i> , 2015, 21, 12-14.	15.2	13
92	Redundancy: A Critical Obstacle to Improving Cancer Therapy. <i>Cancer Research</i> , 2015, 75, 808-812.	0.4	50
93	Glioblastoma stem cells and stem cell-targeting immunotherapies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 449-457.	1.4	25

#	ARTICLE	IF	CITATIONS
94	Immunogenic peptide discovery in cancer genomes. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 7-16.	1.5	63
95	Immune Escape Mechanisms as a Guide for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 687-692.	3.2	801
96	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
97	Ipilimumab-induced toxicities and the gastroenterologist. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 657-666.	1.4	74
98	Cancer Immunotherapy Scores Again. <i>Cell</i> , 2015, 160, 7-9.	13.5	4
99	Biomarkers in Cancer Immunotherapy. <i>Cancer Cell</i> , 2015, 27, 12-14.	7.7	130
100	Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity. <i>Cell</i> , 2015, 160, 48-61.	13.5	2,948
101	Regulation of glucose homeostasis using radiogenetics and magnetogenetics in mice. <i>Nature Medicine</i> , 2015, 21, 14-16.	15.2	16
102	Multiple checkpoints on the long road towards cancer immunotherapy. <i>Immunology and Cell Biology</i> , 2015, 93, 323-325.	1.0	9
103	A New Initiative on Precision Medicine. <i>New England Journal of Medicine</i> , 2015, 372, 793-795.	13.9	4,081
104	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	3.3	118
105	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	1.6	145
106	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 847-856.	1.9	1,787
107	Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266.	3.2	424
108	Genomic Classification of Cutaneous Melanoma. <i>Cell</i> , 2015, 161, 1681-1696.	13.5	2,562
109	Origins, genetic landscape, and emerging therapies of small cell lung cancer. <i>Genes and Development</i> , 2015, 29, 1447-1462.	2.7	194
110	Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 263-307.	1.9	123
111	What to expect from high throughput genomics in metastatic breast cancers?. <i>Breast</i> , 2015, 24, S19-S22.	0.9	4

#	ARTICLE	IF	CITATIONS
112	Current methods of epitope identification for cancer vaccine design. <i>Vaccine</i> , 2015, 33, 7408-7414.	1.7	22
113	Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458.	0.7	15
114	2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia. <i>Biomaterials</i> , 2015, 67, 274-285.	5.7	63
115	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015, 1, 380.	3.4	66
116	From virotherapy to oncolytic immunotherapy: where are we now?. <i>Current Opinion in Virology</i> , 2015, 13, 93-100.	2.6	47
117	Cancer Immunity: Lessons From Infectious Diseases. <i>Journal of Infectious Diseases</i> , 2015, 212, S67-S73.	1.9	35
118	Cancer immunotherapy: exploiting neoepitopes. <i>Cell Research</i> , 2015, 25, 887-888.	5.7	25
119	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1257-1268.	1.6	241
120	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncotImmunology</i> , 2015, 4, e1008814.	2.1	102
121	Adoptive T-cell therapy: a need for standard immune monitoring. <i>Immunotherapy</i> , 2015, 7, 513-533.	1.0	17
122	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. <i>Vaccine</i> , 2015, 33, 7415-7422.	1.7	142
123	Synthetic Nanoparticles for Vaccines and Immunotherapy. <i>Chemical Reviews</i> , 2015, 115, 11109-11146.	23.0	623
125	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. <i>Frontiers in Immunology</i> , 2015, 6, 127.	2.2	51
126	Orchestrating an immune response against cancer with engineered immune cells expressing $\hat{1}\pm\hat{1}^2$ TCRs, CARs, and innate immune receptors: an immunological and regulatory challenge. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 893-902.	2.0	12
127	Mismatch Repair-Deficient Cancers Are Targets for Anti-PD-1 Therapy. <i>Cancer Cell</i> , 2015, 28, 11-13.	7.7	69
128	Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1193-1203.	2.0	18
129	Proteogenomics meets cancer immunology: mass spectrometric discovery and analysis of neoantigens. <i>Expert Review of Proteomics</i> , 2015, 12, 533-541.	1.3	30
130	Spectrum of gene mutations detected by next generation exome sequencing in brain metastases of lung adenocarcinoma. <i>European Journal of Cancer</i> , 2015, 51, 1803-1811.	1.3	36



#	ARTICLE	IF	CITATIONS
131	Precision medicine for metastatic breast cancer—limitations and solutions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 693-704.	12.5	272
132	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
133	PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 751-763.	1.6	20
134	The immunecheckpoints in modern oncology: the next 15 years. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 917-921.	1.4	24
135	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41
136	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. <i>Trends in Molecular Medicine</i> , 2015, 21, 482-491.	3.5	146
137	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 660-670.	3.4	51
138	Opportunities and challenges of radiotherapy for treating cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 527-540.	12.5	452
139	Tregs in gliomas - the jury is still out. <i>Neuro-Oncology</i> , 2015, 17, 769-770.	0.6	4
140	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	3.7	165
141	Antagonists of PD-1 and PD-L1 in Cancer Treatment. <i>Seminars in Oncology</i> , 2015, 42, 587-600.	0.8	259
142	The future of immune checkpoint therapy. <i>Science</i> , 2015, 348, 56-61.	6.0	3,735
143	Neoantigens in cancer immunotherapy. <i>Science</i> , 2015, 348, 69-74.	6.0	3,809
144	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	13.9	5,183
145	Mutant MHC class II epitopes drive therapeutic immune responses to cancer. <i>Nature</i> , 2015, 520, 692-696.	13.7	1,030
147	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. <i>Experimental Biology and Medicine</i> , 2015, 240, 1087-1098.	1.1	52
148	Refining the treatment of NSCLC according to histological and molecular subtypes. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 511-526.	12.5	247
149	Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2155-2161.	0.3	38

#	ARTICLE	IF	CITATIONS
150	Mutation-Specific T Cells for Immunotherapy of Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 1956-1958.	13.9	14
151	Immunotherapeutic Approaches to Sarcoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 26.	1.3	48
152	Neo approaches to cancer vaccines. <i>Science</i> , 2015, 348, 760-761.	6.0	46
153	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
154	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	5.8	134
155	The interplay of effector and regulatory T cells in cancer. <i>Current Opinion in Immunology</i> , 2015, 33, 101-111.	2.4	114
156	The development of immunotherapy in urothelial bladder cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 193-194.	12.5	8
157	Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 976-984.	3.2	196
158	Overall Survival and Long-Term Safety of Nivolumab (Antiâ€“Programmed Death 1 Antibody, BMS-936558,) Tj ETQq0 0 0 rgBT /Overlock Clinical Oncology, 2015, 33, 2004-2012.	0.8	1,035
159	The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. , 2015, 3, 15.		57
160	Translational value of mouse models in oncology drug development. <i>Nature Medicine</i> , 2015, 21, 431-439.	15.2	242
161	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 519-526.	3.4	63
162	TCR contact residue hydrophobicity is a hallmark of immunogenic CD8<sup>+</sup>T cell epitopes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1754-62.	3.3	200
163	KRAS as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2015, 21, 1797-1801.	3.2	262
164	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 373-383.	1.4	14
165	MicroRNA control of protein expression noise. <i>Science</i> , 2015, 348, 128-132.	6.0	337
166	Clinical deployment of antibodies for treatment of melanoma. <i>Molecular Immunology</i> , 2015, 67, 18-27.	1.0	11
167	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015, 84, 1259-1268.	1.2	105

#	ARTICLE	IF	CITATIONS
168	The Journey from Discoveries in Fundamental Immunology to Cancer Immunotherapy. <i>Cancer Cell</i> , 2015, 27, 439-449.	7.7	194
169	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. <i>Trends in Immunology</i> , 2015, 36, 198-216.	2.9	121
170	Immune Checkpoint Inhibitors for Urologic Cancer: The Tip of the Iceberg?. <i>European Urology</i> , 2015, 68, 280-282.	0.9	4
171	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	7.7	3,266
172	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	13.5	1,872
173	Cancer Vaccines: Can They Improve Survival?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 147-151.	0.7	6
174	Immunotherapeutic options on the horizon in breast cancer treatment. , 2015, 156, 90-101.		17
175	Biomarkers in Pharmaceutical Research. <i>Clinical Chemistry</i> , 2015, 61, 1343-1353.	1.5	48
176	Genetics and immunology: reinvigorated. <i>Oncolmunology</i> , 2015, 4, e1029705.	2.1	7
177	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
178	Gender Disparity and Mutation Burden in Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv221.	3.0	114
179	Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 2470-2477.	0.6	20
180	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	1.9	38
181	Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. <i>Journal of Immunology</i> , 2015, 195, 4028-4037.	0.4	26
182	Predictors of clinical response to immunotherapy with or without radiotherapy. <i>Journal of Radiation Oncology</i> , 2015, 4, 339-345.	0.7	17
183	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4212-4223.	3.2	33
184	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
185	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21

#	ARTICLE	IF	CITATIONS
186	The PKC/NF- $\kappa$ B Signaling Pathway Induces APOBEC3B Expression in Multiple Human Cancers. <i>Cancer Research</i> , 2015, 75, 4538-4547.	0.4	116
187	Practical Approaches to Immunotherapy in the Clinic. <i>Seminars in Oncology</i> , 2015, 42, S20-S27.	0.8	10
189	Functional and genetic deconstruction of the cellular origin in liver cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 653-667.	12.8	249
190	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
191	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	6.0	639
192	Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. <i>Journal of Biological Chemistry</i> , 2015, 290, 26562-26575.	1.6	59
193	Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1491-1500.	1.4	6
194	Genomic spectra of biliary tract cancer. <i>Nature Genetics</i> , 2015, 47, 1003-1010.	9.4	907
195	An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers. <i>Nature Genetics</i> , 2015, 47, 1067-1072.	9.4	354
196	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
197	The Next Hurdle in Cancer Immunotherapy: Overcoming the Non- $\kappa$ T-Cell-Inflamed Tumor Microenvironment. <i>Seminars in Oncology</i> , 2015, 42, 663-671.	0.8	388
198	Genetic Basis for Clinical Response to CTLA-4 Blockade. <i>New England Journal of Medicine</i> , 2015, 372, 783-783.	13.9	85
199	Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen. <i>Onc Immunology</i> , 2015, 4, e1011492.	2.1	26
200	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
201	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <i>Annals of Oncology</i> , 2015, 26, 2367-2374.	0.6	40
202	Immunotherapy in Sarcoma: Future Horizons. <i>Current Oncology Reports</i> , 2015, 17, 52.	1.8	16
203	Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. <i>Onc Immunology</i> , 2015, 4, e1005523.	2.1	2
204	Analogue peptides for the immunotherapy of human acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1357-1367.	2.0	11

#	ARTICLE	IF	CITATIONS
205	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12
206	The odds of immunotherapy success. <i>Science</i> , 2015, 350, 158-159.	6.0	87
207	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <i>Immunotherapy</i> , 2015, 7, 981-997.	1.0	5
209	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
210	CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. <i>Nature Medicine</i> , 2015, 21, 1209-1215.	15.2	605
211	Oncolytic viruses: a new class of immunotherapy drugs. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 642-662.	21.5	1,055
212	Current and future molecular profiling of cancer by next-generation sequencing: Table 1.. <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 895-899.	0.6	12
213	Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma. <i>Translational Research</i> , 2015, 166, 412-424.	2.2	65
214	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
215	Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2790-2795.	1.4	54
216	Immune checkpoint inhibitors in melanoma. <i>Melanoma Management</i> , 2015, 2, 267-284.	0.1	6
217	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
218	Immunopharmacogenomics. , 2015, , .		3
219	Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. <i>Cell</i> , 2015, 162, 1242-1256.	13.5	507
220	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
221	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	1.3	69
222	Improving Prospects for Targeting RAS. <i>Journal of Clinical Oncology</i> , 2015, 33, 3650-3659.	0.8	89
223	Immune checkpoint blockade in microsatellite instable colorectal cancers: Back to the clinic. <i>Oncolmmunology</i> , 2015, 4, e1008858.	2.1	7

#	ARTICLE	IF	CITATIONS
224	Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway. <i>Nature Genetics</i> , 2015, 47, 1194-1199.	9.4	221
225	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	1.5	9
226	Neopeptides of Cancers: Looking Back, Looking Ahead. <i>Cancer Immunology Research</i> , 2015, 3, 969-977.	1.6	59
227	Breast cancer and immunology: biomarker and therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1215-1222.	1.1	9
228	Antileukemia T-cell responses in CLL – We don't need no aberration. <i>Oncot Immunology</i> , 2015, 4, e1011527.	2.1	15
230	Engineering opportunities in cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14467-14472.	3.3	111
231	Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. <i>Cancer Research</i> , 2015, 75, 5176-5186.	0.4	14
232	The emergence of immuno-oncology companion products. <i>Personalized Medicine</i> , 2015, 12, 435-438.	0.8	3
233	Landscape of Tumor Antigens in T Cell Immunotherapy. <i>Journal of Immunology</i> , 2015, 195, 5117-5122.	0.4	124
234	Active Immunotherapy of Cancer. <i>Immunological Investigations</i> , 2015, 44, 817-836.	1.0	41
235	Could microbial therapy boost cancer immunotherapy?. <i>Science</i> , 2015, 350, 1031-1032.	6.0	36
236	Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. <i>Cancer Treatment Reviews</i> , 2015, 41, 868-876.	3.4	358
237	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. <i>Molecular Oncology</i> , 2015, 9, 2054-2062.	2.1	85
238	Benefiting from CTLA-4 blockade – a genetic rationale. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 4-4.	12.5	0
239	Checkpoint parley. <i>Nature Reviews Cancer</i> , 2015, 15, 3-3.	12.8	25
240	Checkpoint parley. <i>Nature Reviews Immunology</i> , 2015, 15, 5-5.	10.6	9
241	Immunotherapy in Colorectal Cancer. , 2016, , .		0
242	CD8 T Lymphocytes in Antitumor Immunity. , 2016, , 434-440.		0

#	ARTICLE	IF	CITATIONS
243	Neoantigen-based cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 262-262.	0.7	63
244	Checkpoint Inhibitors for Advanced Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 473-474.	0.2	2
245	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
246	Kirsten Ras* oncogene: Significance of its discovery in human cancer research. <i>Oncotarget</i> , 2016, 7, 46717-46733.	0.8	57
247	Association of <i>Fusobacterium nucleatum</i> with immunity and molecular alterations in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 557.	1.4	278
248	Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA. <i>Oncotarget</i> , 2016, 7, 65364-65373.	0.8	99
249	The genetics of uveal melanoma: current insights. <i>The Application of Clinical Genetics</i> , 2016, Volume 9, 147-155.	1.4	99
250	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	0.6	84
251	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	2.3	569
252	Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. <i>Oncotarget</i> , 2016, 7, 3403-3415.	0.8	306
253	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e175-e184.	1.8	13
254	Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy. <i>Journal of Oncology Practice</i> , 2016, 12, 649-650.	2.5	8
255	Biomarkers for Immunotherapy: Current Developments and Challenges. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e493-e503.	1.8	85
256	Genomic landscape of DNA repair genes in cancer. <i>Oncotarget</i> , 2016, 7, 23312-23321.	0.8	153
257	Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival. <i>Oncotarget</i> , 2016, 7, 10051-10063.	0.8	247
258	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	0.9	19
259	Cancer-Associated Immune Resistance and Evasion of Immune Surveillance in Colorectal Cancer. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-8.	0.7	48
260	Melanoma Cancer Stem Cells: Markers and Functions. <i>Cancers</i> , 2016, 8, 34.	1.7	36

#	ARTICLE	IF	CITATIONS
261	Versatile roles of extracellular vesicles in cancer. <i>Journal of Clinical Investigation</i> , 2016, 126, 1163-1172.	3.9	261
262	Clinical utility of nivolumab in the treatment of advanced melanoma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 313.	0.9	16
263	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
264	Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. <i>Frontiers in Oncology</i> , 2016, 6, 212.	1.3	35
265	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. <i>Frontiers in Oncology</i> , 2016, 6, 256.	1.3	39
266	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
267	Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profiling—Project HOPE. <i>Biomedical Research</i> , 2016, 37, 233-242.	0.3	12
268	Clonal Evolutionary Analysis during HER2 Blockade in HER2-Positive Inflammatory Breast Cancer: A Phase II Open-Label Clinical Trial of Afatinib +/- Vinorelbine. <i>PLoS Medicine</i> , 2016, 13, e1002136.	3.9	28
269	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. <i>PLoS ONE</i> , 2016, 11, e0155189.	1.1	112
270	Understanding the Impact of ErbB Activating Events and Signal Transduction on Antigen Processing and Presentation: MHC Expression as a Model. <i>Frontiers in Pharmacology</i> , 2016, 7, 327.	1.6	11
271	Aptamers: A New Technological Platform in Cancer Immunotherapy. <i>Pharmaceuticals</i> , 2016, 9, 64.	1.7	25
272	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 15-25.	0.2	29
273	The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. <i>Oncotarget</i> , 2016, 7, 73068-73079.	0.8	76
275	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 73-80.	1.0	10
276	Immune Checkpoint Therapy in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 73-80.	1.0	10
277	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <i>Immunotherapy</i> , 2016, 8, 821-837.	1.0	139
278	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
279	Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 470-473.	1.5	18



#	ARTICLE	IF	CITATIONS
280	Future directions in the treatment of osteosarcoma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 26-33.	1.0	228
281	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0.784314 1.0 39 BT /Over	1.0	39
282	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	3.2	182
283	Cancer Vaccines. <i>Advances in Anatomic Pathology</i> , 2016, 23, 180-191.	2.4	22
284	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	3.4	102
285	Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 2454-2463.	1.2	8
286	Update on immune therapy in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 799-808.	0.5	0
287	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. <i>Haematologica</i> , 2016, 101, 794-802.	1.7	94
288	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2130-2142.	1.9	15
289	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. <i>Cytotherapy</i> , 2016, 18, 1043-1055.	0.3	45
290	Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. <i>Neuro-Oncology</i> , 2016, 18, 1357-1366.	0.6	116
291	Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy. <i>European Journal of Immunology</i> , 2016, 46, 1351-1360.	1.6	31
292	Immunotherapy for uveal melanoma. <i>Melanoma Management</i> , 2016, 3, 125-135.	0.1	3
293	Clinicopathological characteristics associated with <scp>BRAF</scp><sup>K601E</sup> and <scp>BRAF</scp><sup>L597</sup> mutations in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 222-228.	1.5	16
294	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , 2016, 22, S1-S137.	3.2	29
296	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I "pre-analytical and analytical validation." , 2016, 4, 76.		155
297	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
298	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274

#	ARTICLE	IF	CITATIONS
301	Biochemistry of Oxidative Stress. , 2016, , .		5
302	Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders. , 2016, 4, 95.		18
303	The Role of Next-Generation Sequencing in Enabling Personalized Oncology Therapy. Clinical and Translational Science, 2016, 9, 283-292.	1.5	36
304	The cutting edge of metastatic melanoma therapy. Melanoma Management, 2016, 3, 217-229.	0.1	1
305	The "Pushmi-Pullyu" of DNA REPAIR: Clinical Synthetic Lethality. Trends in Cancer, 2016, 2, 646-656.	3.8	18
306	T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. New England Journal of Medicine, 2016, 375, 2255-2262.	13.9	1,033
307	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. Journal of Translational Medicine, 2016, 14, 232.	1.8	27
309	mRNA Cancer Vaccines. Recent Results in Cancer Research, 2016, 209, 61-85.	1.8	61
310	Learning from the "tsunami" of immune checkpoint inhibitors in 2015. Critical Reviews in Oncology/Hematology, 2016, 101, 213-220.	2.0	39
311	Disentangling the relationship between tumor genetic programs and immune responsiveness. Current Opinion in Immunology, 2016, 39, 150-158.	2.4	57
313	Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Medical Oncology, 2016, 33, 44.	1.2	40
314	Immunotherapy for genitourinary malignancies in the here and now!. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 169-170.	0.8	0
315	Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2016, 4, 463-471.	1.6	76
316	Monitoring immune responses in the tumor microenvironment. Current Opinion in Immunology, 2016, 41, 23-31.	2.4	96
317	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. European Journal of Cancer, 2016, 62, 36-45.	1.3	105
318	Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. Journal of Hematology and Oncology, 2016, 9, 47.	6.9	271
319	Neoadjuvant treatment for melanoma: current challenges and future perspectives. Melanoma Management, 2016, 3, 149-159.	0.1	1
320	Targeting neoantigens for cancer immunotherapy: Table 1.. International Immunology, 2016, 28, 365-370.	1.8	42

#	ARTICLE	IF	CITATIONS
321	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. Immunotherapy, 2016, 8, 681-686.	1.0	1
322	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. Drugs, 2016, 76, 925-945.	4.9	123
323	The present status and future prospects of peptide-based cancer vaccines. International Immunology, 2016, 28, 319-328.	1.8	104
324	Malignant melanomaâ€”The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology, 2016, 106, 25-54.	2.0	33
325	Clinical Significance of Circulating CD33+CD11b+HLA-DR <sup>+</sup> Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. Clinical Cancer Research, 2016, 22, 5661-5672.	3.2	170
326	GEP- NETS UPDATE: Genetics of neuroendocrine tumors. European Journal of Endocrinology, 2016, 174, R275-R290.	1.9	55
327	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clinical Cancer Research, 2016, 22, 5487-5496.	3.2	480
328	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137.	3.2	28
329	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. Annual Review of Pathology: Mechanisms of Disease, 2016, 11, 313-341.	9.6	15
330	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. Cancer Research, 2016, 76, 3767-3772.	0.4	124
331	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy, 2016, 8, 733-746.	1.0	28
332	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology, 2016, 37, 462-476.	2.9	232
333	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of Oncology, 2016, 27, 1492-1504.	0.6	460
334	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2016, 121, 575-577.	0.2	6
335	Microbiome and Anticancer Immunosurveillance. Cell, 2016, 165, 276-287.	13.5	366
336	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 2016, 352, 189-196.	6.0	3,421
337	Cripto-1 vaccination elicits protective immunity against metastatic melanoma. OncoImmunology, 2016, 5, e1128613.	2.1	21
338	Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective. Archives of Pathology and Laboratory Medicine, 2016, 140, 245-248.	1.2	11

#	ARTICLE	IF	CITATIONS
339	Cancer Immunotherapy Booster. <i>Cell</i> , 2016, 165, 253-255.	13.5	4
340	Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. <i>Onc Immunology</i> , 2016, 5, e1100788.	2.1	73
341	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
342	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
343	Development of molecularly targeted agents and immunotherapies in small cell lung cancer. <i>European Journal of Cancer</i> , 2016, 60, 26-39.	1.3	28
344	Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	3.2	295
345	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 1865-1874.	3.2	700
346	Targeting the Heterogeneity of Cancer with Individualized Neopeptide Vaccines. <i>Clinical Cancer Research</i> , 2016, 22, 1885-1896.	3.2	128
347	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
348	T-Cell Epitope Discovery for Therapeutic Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2016, 1403, 779-796.	0.4	11
349	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8
350	Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?. <i>Clinical Lung Cancer</i> , 2016, 17, 350-361.	1.1	100
351	FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. <i>Oncologist</i> , 2016, 21, 634-642.	1.9	379
352	PD-1 Blockade in Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1573.	3.8	5
353	Immune checkpoint inhibition in ovarian cancer. <i>International Immunology</i> , 2016, 28, 339-348.	1.8	122
354	Opportunities for immunotherapy in microsatellite instable colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1249-1259.	2.0	67
355	Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. <i>Blood Cancer Journal</i> , 2016, 6, e411-e411.	2.8	20
356	Nature Biotechnology's academic spinouts of 2015. <i>Nature Biotechnology</i> , 2016, 34, 484-492.	9.4	5

#	ARTICLE	IF	CITATIONS
357	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3127-3131.	3.2	80
358	Mass spectrometry-based antigen discovery for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 9-17.	2.4	165
359	Tumor Heterogeneity and Tumor Immunity: A Chicken-and-Egg Problem. <i>Trends in Immunology</i> , 2016, 37, 349-351.	2.9	15
360	Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. <i>Cancer Immunology Research</i> , 2016, 4, 600-610.	1.6	86
361	Re-Evaluating Clonal Dominance in Cancer Evolution. <i>Trends in Cancer</i> , 2016, 2, 263-276.	3.8	39
362	Planes, Trains, and Automobiles: Perspectives on CAR T Cells and Other Cellular Therapies for Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 318-325.	1.2	2
363	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29
364	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 703-713.	7.7	92
365	Biomarkers associated with checkpoint inhibitors. <i>Annals of Oncology</i> , 2016, 27, 1199-1206.	0.6	142
366	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	1.8	412
367	Oncolytic immunotherapy: an emerging new modality for the treatment of cancer. <i>Annals of Oncology</i> , 2016, 27, 1805-1808.	0.6	8
368	Immunostimulatory Monoclonal Antibodies and Immunomodulation: Harvesting the Crop. <i>Cancer Research</i> , 2016, 76, 2863-2867.	0.4	4
369	Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. <i>Journal of Immunology</i> , 2016, 196, 4793-4804.	0.4	10
370	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
371	Oncogenic viruses: Lessons learned using next-generation sequencing technologies. <i>European Journal of Cancer</i> , 2016, 61, 61-68.	1.3	7
372	The future of immunotherapy for sarcoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1049-1057.	1.4	21
373	Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. <i>Journal of Clinical Oncology</i> , 2016, 34, 2088-2092.	0.8	8
374	Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor-Targeted Therapies Fail. <i>Journal of Oncology Practice</i> , 2016, 12, 412-420.	2.5	11

#	ARTICLE	IF	CITATIONS
375	The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. <i>Future Oncology</i> , 2016, 12, 1833-1846.	1.1	16
376	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
377	Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 845-857.	1.6	110
378	PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. , 2016, 4, 48.		178
379	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <i>Nature Genetics</i> , 2016, 48, 1131-1141.	9.4	332
380	Genetic predisposition to melanoma. <i>Seminars in Oncology</i> , 2016, 43, 591-597.	0.8	39
381	Relationship of tumor PD-L1 expression with <i>EGFR</i> wild-type status and poor prognosis in lung adenocarcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 935-941.	0.6	49
382	Stem-like features of cancer cells on their way to metastasis. <i>Biology Direct</i> , 2016, 11, 33.	1.9	36
383	Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1377-1393.	2.0	46
384	Present Yourself! By MHC Class I and MHC Class II Molecules. <i>Trends in Immunology</i> , 2016, 37, 724-737.	2.9	566
386	The T Cell in Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 537-542.	0.2	43
387	Genetics of triple-negative breast cancer: Implications for patient care. <i>Current Problems in Cancer</i> , 2016, 40, 130-140.	1.0	24
388	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016, 2, 305-312.	3.8	11
389	Immunoterapia del melanoma. <i>Piel</i> , 2016, 31, 649-656.	0.0	0
390	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	9.4	115
391	Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade. <i>Cancer Immunology Research</i> , 2016, 4, 959-967.	1.6	428
392	Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them. <i>Expert Review of Hematology</i> , 2016, 9, 1007-1009.	1.0	10
393	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016, 4, 936-947.	1.6	132

#	ARTICLE	IF	CITATIONS
394	Mouse models in oncoimmunology. <i>Nature Reviews Cancer</i> , 2016, 16, 759-773.	12.8	267
395	The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 2792-2799.	1.3	72
396	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1230-1236.	7.7	242
398	Precision medicine from the renal cancer genome. <i>Nature Reviews Nephrology</i> , 2016, 12, 655-666.	4.1	64
399	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
400	Past, present and future of immunology in Mainz. <i>Cellular Immunology</i> , 2016, 308, 1-6.	1.4	0
402	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782.	0.8	12
403	Somatic <i>POLE</i> proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 207-216.	3.7	227
404	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
405	The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. <i>Genome Medicine</i> , 2016, 8, 79.	3.6	151
406	Targeting Immune Checkpoints in Hematologic Malignancies. <i>Pharmacological Reviews</i> , 2016, 68, 1014-1025.	7.1	36
407	Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. <i>British Journal of Cancer</i> , 2016, 115, 564-570.	2.9	88
408	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1490.	3.4	68
409	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43
410	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , 2016, 61, 152-158.	0.8	48
411	Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. <i>Immunity</i> , 2016, 45, 389-401.	6.6	496
412	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
413	Precision medicine in pheochromocytoma and paraganglioma: current and future concepts. <i>Journal of Internal Medicine</i> , 2016, 280, 559-573.	2.7	49

#	ARTICLE	IF	CITATIONS
414	The genomic landscape of cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 266-283.	1.5	144
415	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	1.7	28
416	Characterization of the Tâ€cell receptor beta chain repertoire in tumorâ€infiltrating lymphocytes. <i>Cancer Medicine</i> , 2016, 5, 2513-2521.	1.3	17
417	Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112.	0.6	8
418	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. <i>Cancer Research</i> , 2016, 76, 4602-4607.	0.4	92
419	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175
420	Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. <i>Nature Biotechnology</i> , 2016, 34, 1037-1045.	9.4	279
421	Vitamin C increases viral mimicry induced by 5-aza-2â€-deoxycytidine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10238-10244.	3.3	171
422	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	1.6	63
423	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 351-357.	0.6	8
424	Precision medicine, genomics and drug discovery: Table 1.. <i>Human Molecular Genetics</i> , 2016, 25, R166-R172.	1.4	43
425	Clinician Perspectives on Current Issues in Lung Cancer Drug Development. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1387-1396.	0.5	6
426	Circulating protein and antibody biomarker for personalized cancer immunotherapy. , 2016, 4, 46.		7
427	Unsupervised HLA Peptidome Deconvolution Improves Ligand Prediction Accuracy and Predicts Cooperative Effects in Peptideâ€HLA Interactions. <i>Journal of Immunology</i> , 2016, 197, 2492-2499.	0.4	150
428	Neoantigens encoded in the cancer genome. <i>Current Opinion in Immunology</i> , 2016, 41, 98-103.	2.4	65
429	Clinical outcomes in metastatic uveal melanoma treated with PDâ€1 and PDâ€L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
430	The efficacy of antiâ€PDâ€1 agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	2.0	236
431	Disparate clinical activity of PDâ€1 blockade in melanoma subtypes: Know thy enemy!. <i>Cancer</i> , 2016, 122, 3263-3266.	2.0	2



#	ARTICLE	IF	CITATIONS
432	Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Therapeutic Advances in Medical Oncology, 2016, 8, 360-374.	1.4	37
433	Emerging role of immunotherapy in urothelial carcinomaâ€”Advanced disease. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 538-547.	0.8	41
434	Direct identification of clinically relevant neopeptides presented on native human melanoma tissue by mass spectrometry. Nature Communications, 2016, 7, 13404.	5.8	613
435	Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. Scientific Reports, 2016, 6, 37558.	1.6	28
436	High-content molecular profiling of T-cell therapy in oncology. Molecular Therapy - Oncolytics, 2016, 3, 16009.	2.0	6
438	PD-1 blockade in Hodgkinâ€™s lymphoma: learning new tricks from an old teacher. Expert Review of Hematology, 2016, 9, 939-949.	1.0	13
439	Defining Glomerular Disease in Mechanistic Terms: Implementing an Integrative Biology Approach in Nephrology. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2054-2060.	2.2	37
440	Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer, 2016, 122, 3765-3775.	2.0	18
441	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. Oral Oncology, 2016, 61, 166-176.	0.8	11
442	Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. Oncologist, 2016, 21, 1200-1211.	1.9	211
443	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. Clinical and Translational Science, 2016, 9, 89-104.	1.5	144
444	MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair. Human Mutation, 2016, 37, 1004-1012.	1.1	6
445	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
446	Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). Journal of Neuro-Oncology, 2016, 130, 19-29.	1.4	107
447	Peptide vaccination therapy: Towards the next generation. Pathology International, 2016, 66, 547-553.	0.6	16
448	Ipilimumab in melanoma. Expert Review of Anticancer Therapy, 2016, 16, 811-826.	1.1	26
449	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. Npj Genomic Medicine, 2016, 1, .	1.7	68
450	Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?. ESMO Open, 2016, 1, e000022.	2.0	15

#	ARTICLE	IF	CITATIONS
451	Recent advances in the biology of human circulating tumour cells and metastasis. <i>ESMO Open</i> , 2016, 1, e000078.	2.0	38
452	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
453	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. <i>Genome Biology</i> , 2016, 17, 231.	3.8	746
454	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. <i>Cell Reports</i> , 2016, 17, 957-965.	2.9	22
455	Density of immunogenic antigens does not explain the presence or absence of the T-cellâ€“inflamed tumor microenvironment in melanoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7759-E7768.	3.3	328
456	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7769-E7777.	3.3	145
457	Emerging role of immunotherapy in urothelial carcinomaâ€”Immunobiology/biomarkers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 556-565.	0.8	23
458	Making urothelial carcinomas less immune to immunotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 534-537.	0.8	2
459	The Human Vaccines Project: A roadmap for cancer vaccine development. <i>Science Translational Medicine</i> , 2016, 8, 334ps9.	5.8	162
460	Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients. <i>Oncolmmunology</i> , 2016, 5, e1248327.	2.1	60
461	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. <i>BMC Medicine</i> , 2016, 14, 168.	2.3	106
463	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1249559.	2.1	51
464	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	5.8	119
465	Genetic epidemiology of melanoma. <i>European Journal of Dermatology</i> , 2016, 26, 335-339.	0.3	49
466	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025
467	Successful Treatment of a Patient with Glioblastoma and a Germline <i>POLE</i> Mutation: Where Next?. <i>Cancer Discovery</i> , 2016, 6, 1210-1211.	7.7	14
469	Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. <i>Cancer Control</i> , 2016, 23, 61-66.	0.7	14
471	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31802.	3.6	70

#	ARTICLE	IF	CITATIONS
472	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
473	Personalisierte Medizin: Strukturen, Tumorboards, Visionen. Medizinische Genetik, 2017, 28, 452-459.	0.1	5
474	Cancer immunotherapy. Current Opinion in Urology, 2016, 26, 535-542.	0.9	9
475	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. Head and Neck, 2016, 38, 1008-1016.	0.9	14
476	Immune checkpoint inhibitorâ€related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology, 2016, 85, 331-339.	1.2	177
477	Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2016, , .	0.8	6
479	Harnessing the immune system in acute myeloid leukaemia. Critical Reviews in Oncology/Hematology, 2016, 103, 62-77.	2.0	90
480	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. Journal of Hematology and Oncology, 2016, 9, 29.	6.9	21
481	Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. OncoImmunology, 2016, 5, e1177692.	2.1	52
482	Impact of genomic sequencing on precision medicine for clinical oncology. Expert Review of Precision Medicine and Drug Development, 2016, 1, 255-265.	0.4	0
483	Obesity-associated cancer: an immunological perspective. Proceedings of the Nutrition Society, 2016, 75, 125-138.	0.4	30
484	RNA splicing factors as oncoproteins and tumour suppressors. Nature Reviews Cancer, 2016, 16, 413-430.	12.8	549
485	Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma. Expert Review of Molecular Diagnostics, 2016, 16, 811-826.	1.5	41
486	Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology. , 2016, 4, .		13
487	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunology Research, 2016, 4, 669-678.	1.6	117
488	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. Modern Pathology, 2016, 29, 1028-1037.	2.9	84
489	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. Immunity, 2016, 44, 1255-1269.	6.6	797
490	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature Reviews Urology, 2016, 13, 420-431.	1.9	78

#	ARTICLE	IF	CITATIONS
491	Mouse Models of Tumor Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 1-24.	1.1	30
492	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155.	2.9	50
493	Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 41.	1.3	33
494	Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1819-1836.	0.5	31
495	Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations. <i>Seminars in Oncology</i> , 2016, 43, 501-513.	0.8	10
496	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 1805-1822.	1.1	6
497	Development and clinical application of an integrative genomic approach to personalized cancer therapy. <i>Genome Medicine</i> , 2016, 8, 62.	3.6	71
498	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
499	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	1.2	11
500	Immunotherapy for advanced melanoma: Current knowledge and future directions. <i>Journal of Dermatological Science</i> , 2016, 83, 87-94.	1.0	14
501	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. <i>Oral Oncology</i> , 2016, 58, 49-51.	0.8	0
502	Translational and clinical implications of the genetic landscape of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 597-610.	12.5	63
503	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45
504	Genomic determinants of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 32-38.	2.4	27
505	Low T-cell Receptor Diversity, High Somatic Mutation Burden, and High Neoantigen Load as Predictors of Clinical Outcome in Muscle-invasive Bladder Cancer. <i>European Urology Focus</i> , 2016, 2, 445-452.	1.6	63
506	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016, 65, 1031-1042.	1.8	219
507	When Genome Maintenance Goes Badly Awry. <i>Molecular Cell</i> , 2016, 62, 777-787.	4.5	64
508	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 169-239.	0.8	14

#	ARTICLE	IF	CITATIONS
509	Exploring the implications of distinct mutational signatures and mutation rates in aging and cancer. <i>Genome Medicine</i> , 2016, 8, 30.	3.6	13
510	Mismatch in epitope specificities between IFN $\gamma$ 3 inflamed and uninfamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35
511	Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1217.	3.4	216
512	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
513	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
514	SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. <i>Oncolimmunology</i> , 2016, 5, e1169353.	2.1	33
515	Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?. <i>Immunotherapy</i> , 2016, 8, 763-766.	1.0	10
516	Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1048929.	0.3	31
517	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
518	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	1.3	1,687
519	Immunotherapy for advanced melanoma: future directions. <i>Immunotherapy</i> , 2016, 8, 199-209.	1.0	19
520	Doubling the blockade for melanoma immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1106127.	2.1	9
521	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <i>Tumor Biology</i> , 2016, 37, 4251-4261.	0.8	78
522	Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 324-333.	0.5	28
523	Immune-checkpoint blockade " durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 77-78.	12.5	71
524	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	12.8	292
525	Acquired resistance to immunotherapy and future challenges. <i>Nature Reviews Cancer</i> , 2016, 16, 121-126.	12.8	353
526	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. <i>Oncolimmunology</i> , 2016, 5, e1071007.	2.1	21

#	ARTICLE	IF	CITATIONS
527	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
528	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	1.4	56
529	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
530	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <i>Pathology</i> , 2016, 48, 177-187.	0.3	210
531	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 1-10.	3.3	8
532	Trial Watch—Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52
533	Prime time for immune-checkpoint targeted therapy at ASCO 2015. <i>Oncolmmunology</i> , 2016, 5, e1068494.	2.1	8
534	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.2	36
535	Prognostic and predictive biomarkers in melanoma: an update. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 223-237.	1.5	23
536	Immunomonitoring in glioma immunotherapy: current status and future perspectives. <i>Journal of Neuro-Oncology</i> , 2016, 127, 1-13.	1.4	20
537	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
538	Melanoma driver mutations and immune therapy. <i>Oncolmmunology</i> , 2016, 5, e1051299.	2.1	13
539	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644
540	Enhanced Histone Deacetylase Activity in Malignant Melanoma Provokes RAD51 and FANCD2-Triggered Drug Resistance. <i>Cancer Research</i> , 2016, 76, 3067-3077.	0.4	75
541	Cancer Immunosurveillance Caught in the Act. <i>Immunity</i> , 2016, 44, 525-526.	6.6	6
542	PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 3915-3923.	3.2	91
543	Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. <i>Cell</i> , 2016, 165, 35-44.	13.5	2,437
544	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251

#	ARTICLE	IF	CITATIONS
545	Targeted Therapy of HER2-Negative Breast Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 118-121.	0.8	3
546	Improving Systemic Chemotherapy for Bladder Cancer. <i>Current Oncology Reports</i> , 2016, 18, 27.	1.8	42
547	Update on Metastatic Uveal Melanoma: Progress and Challenges. <i>BioDrugs</i> , 2016, 30, 161-172.	2.2	14
548	Direct observation of proton pumping by a eukaryotic P-type ATPase. <i>Science</i> , 2016, 351, 1469-1473.	6.0	81
549	Molecular techniques for predicting behaviour in melanocytic neoplasms. <i>Pathology</i> , 2016, 48, 142-146.	0.3	7
550	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	1.8	223
551	Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency. <i>Journal of Clinical Oncology</i> , 2016, 34, 2206-2211.	0.8	692
552	Germline determinants of clinical outcome of cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 15-26.	1.5	12
553	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
554	TCR-engineered T cells to treat tumors: Seeing but not touching?. <i>Seminars in Immunology</i> , 2016, 28, 10-21.	2.7	62
555	Targeting inhibition of Foxp3 by a CD28 2 <sup>nd</sup> -Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. <i>Biomaterials</i> , 2016, 91, 73-80.	5.7	43
556	Combination Therapies for Melanoma: A New Standard of Care?. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 99-105.	3.3	23
557	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	1.4	21
558	Adoptive cell therapy: a highly successful individualized therapy for melanoma with great potential for other malignancies. <i>Current Opinion in Immunology</i> , 2016, 39, 90-95.	2.4	23
559	Microsatellite Instability as a Biomarker for PD-1 Blockade. <i>Clinical Cancer Research</i> , 2016, 22, 813-820.	3.2	698
560	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. <i>Nature Medicine</i> , 2016, 22, 433-438.	15.2	721
561	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>Oncolmmunology</i> , 2016, 5, e1145332.	2.1	13
562	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	3.2	353



#	ARTICLE	IF	CITATIONS
563	Tumour-specific CD4 T cells eradicate melanoma via indirect recognition of tumour-derived antigen. <i>Immunology and Cell Biology</i> , 2016, 94, 593-603.	1.0	34
565	Rare cancers: a sea of opportunity. <i>Lancet Oncology</i> , The, 2016, 17, e52-e61.	5.1	76
566	Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment. <i>Nature Medicine</i> , 2016, 22, 122-124.	15.2	15
567	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
568	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <i>Cancer Discovery</i> , 2016, 6, 128-129.	7.7	17
569	Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. <i>Clinical Cancer Research</i> , 2016, 22, 3182-3191.	3.2	109
570	The impact of sequencing on diagnosis and treatment of malignant melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 423-433.	1.5	4
571	PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. <i>International Journal of Clinical Oncology</i> , 2016, 21, 462-473.	1.0	255
572	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
573	Immunotherapy of Cancer. , 2016, , .		3
574	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-“PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	0.5	48
575	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
576	Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2016, 18, 21.	1.8	39
577	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. , 2016, , 349-358.		0
578	Requirement of interleukin 7 signaling for anti-tumor immune response under lymphopenic conditions in a murine lung carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 341-354.	2.0	9
579	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2016, 387, 1909-1920.	6.3	3,077
580	Activation of cytomegalovirus-specific CD8 <sup>+</sup> T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Oncolmmunology</i> , 2016, 5, e1052930.	2.1	0
581	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	2.0	24



#	ARTICLE	IF	CITATIONS
582	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251
583	Vaccines for established cancer: overcoming the challenges posed by immune evasion. <i>Nature Reviews Cancer</i> , 2016, 16, 219-233.	12.8	580
584	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	6.0	2,445
585	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19
586	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 259-268.	3.2	30
587	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1048-1054.	3.2	226
588	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. <i>Cancer Discovery</i> , 2016, 6, 286-299.	7.7	208
589	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
590	Beyond the exome: the role of non-coding somatic mutations in cancer. <i>Annals of Oncology</i> , 2016, 27, 240-248.	0.6	31
591	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016, 39, 30-38.	2.4	23
592	The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99.	2.0	87
593	Cancer immunotherapy targeting neoantigens. <i>Seminars in Immunology</i> , 2016, 28, 22-27.	2.7	199
594	Prospects for gene-engineered T cell immunotherapy for solid cancers. <i>Nature Medicine</i> , 2016, 22, 26-36.	15.2	296
595	Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons. <i>Cancer Immunology Research</i> , 2016, 4, 248-258.	1.6	20
596	Translational Childhood Cancer Genomics. <i>JAMA Oncology</i> , 2016, 2, 384.	3.4	1
597	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. <i>Cancer Immunology Research</i> , 2016, 4, 204-214.	1.6	175
598	Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. <i>Nucleic Acids Research</i> , 2016, 44, e30-e30.	6.5	109
599	Mutanome directed cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 39, 14-22.	2.4	55

#	ARTICLE	IF	CITATIONS
600	Novel Diagnostic and Therapeutic Strategies in the Management of Patients with Cancers of Unknown Primary Site. , 2016, , 173-190.		1
601	Immune suppressive mechanisms in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016, 39, 1-6.	2.4	407
602	PD-L1 Testing in Cancer. <i>JAMA Oncology</i> , 2016, 2, 15.	3.4	116
603	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	12.5	753
604	Novel Treatments in Development for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 371-416.	0.2	15
605	<i>POLE</i> proofreading mutation, immune response and prognosis in endometrial cancer. <i>Oncolmmunology</i> , 2016, 5, e1072675.	2.1	34
606	Cancer Neoantigens and Applications for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 807-812.	3.2	188
607	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	12.5	224
608	Tumor-intrinsic oncogene pathways mediating immune avoidance. <i>Oncolmmunology</i> , 2016, 5, e1086862.	2.1	120
609	MicroRNA <i>MIR21</i> and T Cells in Colorectal Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 33-40.	1.6	29
610	The influence of subclonal resistance mutations on targeted cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 335-347.	12.5	185
611	Cancer of Unknown Primary. , 2016, , .		7
612	Personalized approaches to active immunotherapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 72-82.	3.3	41
613	Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. <i>Briefings in Bioinformatics</i> , 2016, 17, 642-656.	3.2	120
614	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary</i> , 2016, 19, 82-92.	1.6	259
615	Biomarkers for immunotherapy in genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 205-213.	0.8	14
616	Integrating chemoradiation and molecularly targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 74-83.	6.6	22
617	Advances in personalized cancer immunotherapy. <i>Breast Cancer</i> , 2017, 24, 16-24.	1.3	75

#	ARTICLE	IF	CITATIONS
618	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	3.2	35
619	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
620	Elements of cancer immunity and the cancer-immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
621	Genomic analysis and clinical management of adolescent cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 307-316.	1.5	12
622	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. <i>Science</i> , 2017, 355, .	6.0	988
623	Durable response to programmed death-1 (PD-1) blockade in a metastatic gastric cancer patient with mismatch repair deficiency and microsatellite instability. <i>Journal of Cancer Research and Practice</i> , 2017, 4, 72-75.	0.2	1
624	Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use. <i>Oral Science International</i> , 2017, 14, 1-12.	0.3	7
625	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> , 2017, 31, 51-61.	2.2	46
626	Novedades dermatológicas en el diagnóstico histopatológico y nuevos tratamientos del melanoma. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 1-2.	0.2	4
627	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 110, 106-116.	2.0	33
628	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. <i>Cancer Treatment Reviews</i> , 2017, 53, 138-145.	3.4	20
629	Strategies to design clinical studies to identify predictive biomarkers in cancer research. <i>Cancer Treatment Reviews</i> , 2017, 53, 79-97.	3.4	80
630	Near future of tumor immunology: Anticipating resistance mechanisms to immunotherapies, a big challenge for clinical trials. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 1109-1111.	1.4	7
631	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 212-220.	5.1	307
633	Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?. <i>Clinical Oncology</i> , 2017, 29, 207-217.	0.6	6
634	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1
635	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. <i>Oncolmmunology</i> , 2017, 6, e1279777.	2.1	50
636	Novel immune check point inhibiting antibodies in cancer therapy – Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	6.5	98

#	ARTICLE	IF	CITATIONS
637	Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. <i>Modern Pathology</i> , 2017, 30, 357-369.	2.9	25
638	Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 491-502.	2.0	7
639	Identification of immunoglobulin V(D)J recombinations in solid tumor specimen exome files: Evidence for high level B-cell infiltrates in breast cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 501-506.	1.4	40
640	Breast Cancer Immunology and Immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2017, 331, 1-53.	1.6	47
641	MHC class II restricted neoantigen: A promising target in tumor immunotherapy. <i>Cancer Letters</i> , 2017, 392, 17-25.	3.2	67
642	Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. <i>Oncolmunology</i> , 2017, 6, e1278330.	2.1	54
643	Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy?. <i>Journal of Translational Medicine</i> , 2017, 15, 17.	1.8	40
644	Buparlisib and the continued quest for the ideal cure. <i>Lancet Oncology, The</i> , 2017, 18, 273-274.	5.1	0
645	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. <i>Lancet Oncology, The</i> , 2017, 18, 323-335.	5.1	173
649	The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 53-75.	2.7	30
650	Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. <i>Immunity</i> , 2017, 46, 197-204.	6.6	400
651	ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. <i>Journal of Hepatology</i> , 2017, 66, 942-951.	1.8	53
652	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
653	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 303-310.	3.3	12
654	Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 3168-3180.	3.2	67
655	PD-1 and PD-L1 antibodies in cancer: current status and future directions. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 551-564.	2.0	253
656	CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. <i>Cancer Research</i> , 2017, 77, 1918-1926.	0.4	30
657	ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment. <i>Cell Reports</i> , 2017, 18, 2331-2342.	2.9	30

#	ARTICLE	IF	CITATIONS
658	Identification of coding and non-coding mutational hotspots in cancer genomes. BMC Genomics, 2017, 18, 17.	1.2	26
659	Mechanisms of Drug Resistance in Melanoma. Handbook of Experimental Pharmacology, 2017, 249, 91-108.	0.9	63
660	Precision medicine driven by cancer systems biology. Cancer and Metastasis Reviews, 2017, 36, 91-108.	2.7	38
661	Towards a better cancer precision medicine: Systems biology meets immunotherapy. Current Opinion in Systems Biology, 2017, 2, 67-73.	1.3	7
662	Efficient Nanovaccine Delivery in Cancer Immunotherapy. ACS Nano, 2017, 11, 2387-2392.	7.3	278
663	It's a long way to the top (if you want to personalize immunotherapy). , 2017, 5, 6.		2
664	TANTIGEN: a comprehensive database of tumor T cell antigens. Cancer Immunology, Immunotherapy, 2017, 66, 731-735.	2.0	66
665	A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity. Molecular Therapy, 2017, 25, 976-988.	3.7	29
666	Candidate immune biomarkers for radioimmunotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 58-68.	3.3	14
667	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Science Translational Medicine, 2017, 9, .	5.8	689
668	A comprehensive review of immunotherapies in prostate cancer. Critical Reviews in Oncology/Hematology, 2017, 113, 292-303.	2.0	55
669	JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy. Cancer Discovery, 2017, 7, 128-130.	7.7	24
670	Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge. Journal of Investigative Medicine, 2017, 65, 754-758.	0.7	37
671	Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology, 2017, 6, e1253654.	2.1	146
672	PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer. , 2017, , 115-146.		0
673	The evolving genomic landscape of urothelial carcinoma. Nature Reviews Urology, 2017, 14, 215-229.	1.9	89
674	Applications of Immunogenomics to Cancer. Cell, 2017, 168, 600-612.	13.5	198
675	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell, 2017, 168, 707-723.	13.5	3,483

#	ARTICLE	IF	CITATIONS
676	Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. <i>Cell</i> , 2017, 168, 613-628.	13.5	1,957
677	Vaccine draining lymph nodes are a source of antigen-specific B cells. <i>Vaccine</i> , 2017, 35, 1259-1265.	1.7	7
678	Tissue-specific tumorigenesis: context matters. <i>Nature Reviews Cancer</i> , 2017, 17, 239-253.	12.8	234
679	The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 850-859.	0.5	83
680	Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. <i>Immunological Reviews</i> , 2017, 276, 9-25.	2.8	13
681	Assessing microenvironment immunogenicity using tumor specimen exomes: Co-detection of TcR-V(D)J recombinations correlates with PD-1 expression. <i>International Journal of Cancer</i> , 2017, 140, 2568-2576.	2.3	25
682	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
683	HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses. <i>Oncolmmunology</i> , 2017, 6, e1293214.	2.1	23
684	Debugging the Black Box. <i>Cancer Discovery</i> , 2017, 7, 250-251.	7.7	0
685	The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 124-132.	2.0	93
686	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
687	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. <i>Nature Immunology</i> , 2017, 18, 255-262.	7.0	361
688	Immunotherapy: a new treatment paradigm in bladder cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 184-195.	1.1	40
689	Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2017, 5, 357-362.	1.6	40
690	Disease Biomarkers for Precision Medicine: Challenges and Future Opportunities. <i>Genomics, Proteomics and Bioinformatics</i> , 2017, 15, 57-58.	3.0	31
691	Resistance to immunotherapy: clouds in a bright sky. <i>Investigational New Drugs</i> , 2017, 35, 649-654.	1.2	8
692	Targeting the immune system in glioblastoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 121-131.	0.4	0
695	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	1.8	18

#	ARTICLE	IF	CITATIONS
696	The microbiome in anti-cancer therapy. <i>Seminars in Immunology</i> , 2017, 32, 74-81.	2.7	61
697	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , 2017, 6, 139-151.	1.2	12
698	MuPeXI: prediction of neo-epitopes from tumor sequencing data. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1123-1130.	2.0	177
699	Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. <i>Genome Medicine</i> , 2017, 9, 34.	3.6	2,480
700	Prostate Cancer and Immune Monitoring: Are We Heading Towards Better Selection of Patients and Treatment Strategies?. <i>European Urology</i> , 2017, 71, 788-789.	0.9	1
701	Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 131-137.	1.0	10
702	Indicators of responsiveness to immune checkpoint inhibitors. <i>Scientific Reports</i> , 2017, 7, 807.	1.6	70
703	Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. <i>Journal of Immunotherapy</i> , 2017, 40, 155-163.	1.2	5
704	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 125-130.	1.0	16
705	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 557-564.	0.9	108
706	Applied Cancer Immunogenomics. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 125-130.	1.0	16
707	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <i>Trends in Immunology</i> , 2017, 38, 513-525.	2.9	86
708	Chemosensitizing effect of shRNA-mediated ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its clinical significance. <i>Oncology Reports</i> , 2017, 37, 1989-1997.	1.2	8
709	Use of precision methods to accelerate drug development in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 109-120.	0.4	0
710	The swinging pendulum of cancer immunotherapy personalization. <i>Personalized Medicine</i> , 2017, 14, 259-270.	0.8	3
711	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29
712	Personalized T cell-mediated cancer immunotherapy: progress and challenges. <i>Current Opinion in Biotechnology</i> , 2017, 48, 142-152.	3.3	78
713	Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. <i>Oncolmmunology</i> , 2017, 6, e1320626.	2.1	89



#	ARTICLE	IF	CITATIONS
714	Human Tumor Antigens Yesterday, Today, and Tomorrow. <i>Cancer Immunology Research</i> , 2017, 5, 347-354.	1.6	94
715	Academic, Foundation, and Industry Collaboration in Finding New Therapies. <i>New England Journal of Medicine</i> , 2017, 376, 1762-1769.	13.9	57
716	T <sub>H</sub> 1 cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-1 ligand 1 expression in patients with soft tissue sarcomas. <i>Cancer</i> , 2017, 123, 3291-3304.	2.0	202
717	Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 651-659.	1.5	35
718	Trends in Scientific Discovery. , 2017, , 31-64.		0
719	Characterizing neoantigens for personalized cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2017, 46, 58-65.	2.4	59
720	Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2017, 12, e51-e55.	0.5	3
721	Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 4993-4998.	3.3	614
722	Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. <i>Annual Review of Immunology</i> , 2017, 35, 229-253.	9.5	96
723	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <i>Cancer Research</i> , 2017, 77, 3666-3671.	0.4	93
724	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
726	Investigational drugs for nasopharyngeal carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 677-685.	1.9	23
727	Tumor-Infiltrating Lymphocyte Therapy and Neoantigens. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 138-143.	1.0	30
728	Replicative DNA polymerase defects in human cancers: Consequences, mechanisms, and implications for therapy. <i>DNA Repair</i> , 2017, 56, 16-25.	1.3	84
729	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. <i>Melanoma Research</i> , 2017, 27, 24-31.	0.6	15
730	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70
731	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	13.7	643
732	Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options. <i>Oncologist</i> , 2017, 22, 680-693.	1.9	23



#	ARTICLE	IF	CITATIONS
733	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. <i>Clinics in Chest Medicine</i> , 2017, 38, 223-232.	0.8	36
735	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
736	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
737	Identifying "super responders" in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 300-311.	0.8	19
738	Systems immunology: just getting started. <i>Nature Immunology</i> , 2017, 18, 725-732.	7.0	194
739	The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. <i>Oncology</i> , 2017, 6, e1338996.	2.1	22
740	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
741	Immunotherapy: The Wave of the Future in Bladder Cancer?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, S3-S17.	0.9	8
742	Recent progress in immunotherapy for urological cancer. <i>International Journal of Urology</i> , 2017, 24, 735-742.	0.5	12
743	Immunotherapy for Breast Cancer: What Are We Missing?. <i>Clinical Cancer Research</i> , 2017, 23, 2640-2646.	3.2	176
744	Evolving adoptive cellular therapies in urological malignancies. <i>Lancet Oncology</i> , 2017, 18, e341-e353.	5.1	22
745	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
746	Targeting DNA damage response systems to impact cancer care. <i>Current Problems in Cancer</i> , 2017, 41, 247-250.	1.0	2
747	Dual Targeting Nanoparticle Stimulates the Immune System To Inhibit Tumor Growth. <i>ACS Nano</i> , 2017, 11, 5417-5429.	7.3	130
748	A molecular portrait of microsatellite instability across multiple cancers. <i>Nature Communications</i> , 2017, 8, 15180.	5.8	480
749	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017, 141, 877-886.	2.3	133
750	The Transcriptional Landscape of p53 Signalling Pathway. <i>EBioMedicine</i> , 2017, 20, 109-119.	2.7	47
751	Therapeutic T cell engineering. <i>Nature</i> , 2017, 545, 423-431.	13.7	622

#	ARTICLE	IF	CITATIONS
752	DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel. <i>Lung Cancer</i> , 2017, 110, 26-31.	0.9	59
753	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38
754	Immune and molecular correlates in melanoma treated with immune checkpoint blockade. <i>Cancer</i> , 2017, 123, 2143-2153.	2.0	119
755	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
756	The Damaging Effect of Passenger Mutations on Cancer Progression. <i>Cancer Research</i> , 2017, 77, 4763-4772.	0.4	78
757	Clinical application of a cancer genomic profiling assay to guide precision medicine decisions. <i>Personalized Medicine</i> , 2017, 14, 309-325.	0.8	22
758	Checkpoint Blockade Immunotherapy for Glioblastoma. , 2017, , 261-300.		2
759	Biallelic PMS2 Mutation and Heterozygous DICER1 Mutation Presenting as Constitutional Mismatch Repair Deficiency With Corpus Callosum Agenesis: Case Report and Review of Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e381-e387.	0.3	3
760	Epigenetic modulation in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 48-56.	1.7	50
761	Glioblastoma targeted therapy: updated approaches from recent biological insights. <i>Annals of Oncology</i> , 2017, 28, 1457-1472.	0.6	314
762	New insights into the role of <sc>EMT</sc> in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
763	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K $\beta$ . <i>Cancer Research</i> , 2017, 77, 2607-2619.	0.4	165
764	The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. <i>Cell Communication and Signaling</i> , 2017, 15, 13.	2.7	63
765	Integrated genomic analyses reveal frequent <i>TERT</i> aberrations in acral melanoma. <i>Genome Research</i> , 2017, 27, 524-532.	2.4	122
766	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	0.7	28
767	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 1368-1379.	0.6	908
768	Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. <i>Neuro-Oncology</i> , 2017, 19, 1047-1057.	0.6	325
770	The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas. <i>European Urology Focus</i> , 2017, 3, 584-589.	1.6	17

#	ARTICLE	IF	CITATIONS
771	Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. <i>Gynecologic Oncology</i> , 2017, 145, 446-452.	0.6	57
772	Optimizing Radiotherapy with Immunotherapeutic Approaches. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 53-71.	0.8	10
773	Overview of Basic Immunology for Clinical Investigators. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 1-31.	0.8	4
774	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316.	3.9	23
775	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
776	Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. <i>OncImmunology</i> , 2017, 6, e1306617.	2.1	5
777	Masterful Antibodies: Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 275-281.	1.6	31
778	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
779	Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. <i>Annals of Oncology</i> , 2017, 28, 1036-1041.	0.6	207
780	<sc>UV</sc>-induced somatic mutations elicit a functional T cell response in the <sc>YUMMER</sc> 1.7 mouse melanoma model. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 428-435.	1.5	143
781	Tumor Vaccines for Malignant Gliomas. <i>Neurotherapeutics</i> , 2017, 14, 345-357.	2.1	41
782	Connecting the Metabolic and Immune Responses to Cancer. <i>Trends in Molecular Medicine</i> , 2017, 23, 451-464.	3.5	55
783	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
784	Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. <i>Clinical Cancer Research</i> , 2017, 23, 4429-4440.	3.2	142
785	Molecular genetic and immunotherapeutic targets in metastatic melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 281-293.	1.4	16
786	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. <i>Cancer Cell</i> , 2017, 31, 476-485.	7.7	116
787	Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. <i>Nature Genetics</i> , 2017, 49, 482-483.	9.4	66
788	Celebrating parasites. <i>Nature Genetics</i> , 2017, 49, 483-484.	9.4	25

#	ARTICLE	IF	CITATIONS
789	Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, .	7.1	35
790	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	1.1	48
791	Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 17-24.	2.0	12
792	Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 431-447.	2.5	15
793	Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. <i>Oncotarget</i> , 2017, 6, e1267891.	2.1	66
794	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
795	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	2.7	35
796	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
797	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	1.8	27
799	Identification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia. <i>Cancer Immunology Research</i> , 2017, 5, 376-384.	1.6	106
800	Evolution of MHC-based technologies used for detection of antigen-responsive T cells. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 657-666.	2.0	65
801	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. <i>Cancer Immunology Research</i> , 2017, 5, 29-41.	1.6	321
803	T cell receptor gene recombinations in human tumor specimen exome files: detection of T cell receptor- $\beta$ VDJ recombinations associates with a favorable oncologic outcome for bladder cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 403-410.	2.0	22
804	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	1.7	22
805	Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3129-3138.	3.2	191
806	Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. <i>Lung Cancer</i> , 2017, 103, 44-51.	0.9	91
807	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , 2017, 27, 11-37.	5.7	185
808	Dendritic cell-based immunotherapy. <i>Cell Research</i> , 2017, 27, 74-95.	5.7	593

#	ARTICLE	IF	CITATIONS
809	Molecular approaches for classifying endometrial carcinoma. <i>Gynecologic Oncology</i> , 2017, 145, 200-207.	0.6	137
810	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1219825.	2.1	28
811	Immune Toxicities Elicited by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. <i>Cancer Research</i> , 2017, 77, 1322-1330.	0.4	188
812	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706
813	A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study O231D. <i>Gynecologic Oncology</i> , 2017, 144, 96-100.	0.6	21
814	Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. <i>Gastroenterology</i> , 2017, 152, 745-761.	0.6	838
815	How precise is precision medicine in hematology?. <i>Haematologica</i> , 2017, 102, 4-6.	1.7	7
817	Comprehensive genomic sequencing and the molecular profiles of clinically advanced breast cancer. <i>Pathology</i> , 2017, 49, 120-132.	0.3	18
818	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1260214.	2.1	11
819	Implementation of a Multicenter Biobanking Collaboration for Next-Generation Sequencing-Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. <i>Oncologist</i> , 2017, 22, 33-40.	1.9	29
820	Building proteomic tool boxes to monitor MHC class I and class II peptides. <i>Proteomics</i> , 2017, 17, 1600061.	1.3	29
821	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
822	Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3012-3024.	3.2	741
823	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncolmmunology</i> , 2017, 6, e1264565.	2.1	102
824	Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome. <i>Methods in Molecular Biology</i> , 2017, 1499, 223-236.	0.4	9
825	Emerging biomarkers for PD-1 pathway cancer therapy. <i>Biomarkers in Medicine</i> , 2017, 11, 53-67.	0.6	11
826	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
827	RNA Vaccines. <i>Methods in Molecular Biology</i> , 2017, , .	0.4	5

#	ARTICLE	IF	CITATIONS
828	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	5.8	686
829	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	13.5	968
830	T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2017, 5, 978-991.	1.6	170
831	Towards In Silico Prediction of the Immune-Checkpoint Blockade Response. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 1041-1051.	4.0	12
832	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	5.8	123
833	Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 5729-5736.	3.2	172
834	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392
835	Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. <i>Nature Communications</i> , 2017, 8, 1197.	5.8	77
836	Cancer Evolution during Immunotherapy. <i>Cell</i> , 2017, 171, 740-742.	13.5	28
837	The promises of immunotherapy in gliomas. <i>Current Opinion in Neurology</i> , 2017, 30, 650-658.	1.8	16
838	Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. <i>Cancer Cell</i> , 2017, 32, 506-519.e5.	7.7	240
839	Determining T-cell specificity to understand and treat disease. <i>Nature Biomedical Engineering</i> , 2017, 1, 784-795.	11.6	10
840	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
841	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. <i>Cell</i> , 2017, 171, 934-949.e16.	13.5	1,515
842	Immunogenic stress and death of cancer cells: Contribution of antigenicity vs adjuvanticity to immunosurveillance. <i>Immunological Reviews</i> , 2017, 280, 165-174.	2.8	82
843	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1055-1069.	1.5	24
844	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017, 171, 1042-1056.e10.	13.5	596
845	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276

#	ARTICLE	IF	CITATIONS
846	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <i>Cancer</i> , 2017, 123, 3628-3637.	2.0	57
847	Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. <i>American Journal of Clinical Pathology</i> , 2017, 148, 441-449.	0.4	19
848	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. <i>Annals of Oncology</i> , 2017, 28, 3015-3021.	0.6	79
849	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
850	Unravelling biology and shifting paradigms in cancer with single-cell sequencing. <i>Nature Reviews Cancer</i> , 2017, 17, 557-569.	12.8	280
851	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
852	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1477-1490.	0.9	24
853	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 484-494.	1.2	4
854	Optimizing tumor immune response through combination of radiation and immunotherapy. <i>Medical Oncology</i> , 2017, 34, 165.	1.2	14
856	Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes. <i>Molecular Cancer Research</i> , 2017, 15, 1722-1732.	1.5	119
857	Greener revolutions for all require transparency and diversity, not secrecy. <i>Nature Biotechnology</i> , 2017, 35, 817-818.	9.4	2
858	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	12.8	303
859	Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells. <i>Nature Communications</i> , 2017, 8, 562.	5.8	101
860	Relationship of tumor <sc>PD</sc> ( <sc>CD</sc>274) expression with lower mortality in lung high-grade neuroendocrine tumor. <i>Cancer Medicine</i> , 2017, 6, 2347-2356.	1.3	39
861	Mitochondrial Metabolism: Yin and Yang for Tumor Progression. <i>Trends in Endocrinology and Metabolism</i> , 2017, 28, 748-757.	3.1	59
862	Predictors of responses to immune checkpoint blockade in advanced melanoma. <i>Nature Communications</i> , 2017, 8, 592.	5.8	166
863	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	0.7	48
864	Neoantigen prediction and the need for validation. <i>Nature Biotechnology</i> , 2017, 35, 815-817.	9.4	69



#	ARTICLE	IF	CITATIONS
865	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. <i>Radiographics</i> , 2017, 37, 1371-1387.	1.4	56
866	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
867	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	3.2	14
868	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
869	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. <i>Oncot Immunology</i> , 2017, 6, e1356153.	2.1	89
870	The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment. <i>Scientific Reports</i> , 2017, 7, 10349.	1.6	29
871	A perspective on the impact of radiation therapy on the immune rheostat. <i>British Journal of Radiology</i> , 2017, 90, 20170272.	1.0	9
872	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. <i>Oncot Immunology</i> , 2017, 6, e1338997.	2.1	29
873	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <i>Journal of Leukocyte Biology</i> , 2017, 102, 631-643.	1.5	35
874	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 219-222.	1.0	18
875	The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics. <i>American Journal of Pathology</i> , 2017, 187, 2185-2198.	1.9	17
876	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. <i>Clinical Skin Cancer</i> , 2017, 2, 10-17.	0.1	1
877	Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. <i>Cancer Letters</i> , 2017, 405, 22-28.	3.2	17
878	The immune contexture in cancer prognosis and treatment. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 717-734.	12.5	1,590
879	Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer. <i>Cancer Science</i> , 2017, 108, 1452-1457.	1.7	37
880	Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. <i>Actas Dermo-sifilográficas</i> , 2017, 108, 721-728.	0.2	0
881	A novel method to quantify base substitution mutations at the 10 <sup>-6</sup> per bp level in DNA samples. <i>Cancer Letters</i> , 2017, 403, 152-158.	3.2	8
883	A step towards predicting checkpoint inhibitor response in kidney cancer. <i>Lancet Oncology</i> , The, 2017, 18, 982-983.	5.1	3



#	ARTICLE	IF	CITATIONS
884	Tools to define the melanoma-associated immunopeptidome. <i>Immunology</i> , 2017, 152, 536-544.	2.0	14
885	The role of the tumour microenvironment in immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T283-T295.	1.6	73
886	Genetic load makes cancer cells more sensitive to common drugs: evidence from Cancer Cell Line Encyclopedia. <i>Scientific Reports</i> , 2017, 7, 1938.	1.6	9
887	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. <i>Annals of Oncology</i> , 2017, 28, 2472-2480.	0.6	45
888	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. <i>Cell Reports</i> , 2017, 20, 1017-1028.	2.9	156
889	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515.	8.9	241
890	The importance for immunoregulation for long-term cancer control. <i>Future Oncology</i> , 2017, 13, 1619-1632.	1.1	9
891	Identification of essential genes for cancer immunotherapy. <i>Nature</i> , 2017, 548, 537-542.	13.7	668
892	Making It Personal: Neoantigen Vaccines in Metastatic Melanoma. <i>Immunity</i> , 2017, 47, 221-223.	6.6	31
893	Lung tumor exome files with T-cell receptor recombinations: a mouse model of T-cell infiltrates reflecting mutation burdens. <i>Laboratory Investigation</i> , 2017, 97, 1516-1520.	1.7	15
894	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	0.9	19
895	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	3.3	46
896	Advances in the Immunobiological Therapies for Advanced Melanoma. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 721-728.	0.2	0
897	Genetic biomarker for cancer immunotherapy. <i>Science</i> , 2017, 357, 358-358.	6.0	6
898	Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.	1.3	84
899	Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. <i>Current Opinion in Immunology</i> , 2017, 47, 103-109.	2.4	37
900	Immunogenetic Profiling for Gastric Cancers Identifies Sulfated Glycosaminoglycans as Major and Functional B Cell Antigens in Human Malignancies. <i>Cell Reports</i> , 2017, 20, 1073-1087.	2.9	41
901	Immunotherapy for Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017, 57, 29-39.	0.3	10

#	ARTICLE	IF	CITATIONS
902	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Current Treatment Options in Oncology, 2017, 18, 51.	1.3	69
903	Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open, 2017, 2, e000255.	2.0	118
904	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. European Journal of Cancer, 2017, 87, 101-112.	1.3	56
905	Personalized peptide vaccines for cancer therapy: current progress and state of the art. Expert Review of Precision Medicine and Drug Development, 2017, 2, 371-381.	0.4	9
906	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature, 2017, 551, 517-520.	13.7	532
907	Urothelial Bladder Cancer: An Update on Molecular Pathology with Clinical Implications. European Urology Supplements, 2017, 16, 272-294.	0.1	6
908	A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell and Melanoma Research, 2017, 30, 558-562.	1.5	31
909	First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology, 2017, 6, e1338235.	2.1	52
910	Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity. Journal of Immunology, 2017, 199, 974-981.	0.4	5
911	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet Oncology, The, 2017, 18, 1009-1021.	5.1	716
912	Oncolytic viruses: adenoviruses. Virus Genes, 2017, 53, 700-706.	0.7	74
913	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547, 222-226.	13.7	1,806
914	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98
915	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. Oncoimmunology, 2017, 6, e1321187.	2.1	45
916	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	12.5	787
918	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. Cytokine and Growth Factor Reviews, 2017, 36, 17-24.	3.2	23
919	Emerging role of mutations in epigenetic regulators including MLL2 derived from The Cancer Genome Atlas for cervical cancer. BMC Cancer, 2017, 17, 252.	1.1	13
920	Immunotherapy in head and neck cancer: aiming at EXTREME precision. BMC Medicine, 2017, 15, 110.	2.3	64

#	ARTICLE	IF	CITATIONS
921	Immunotherapy biomarkers 2016: overcoming the barriers. , 2017, 5, 29.		21
922	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
923	IFN $\gamma$ -Dependent Tissue-Immune Homeostasis Is Co-opted in the Tumor Microenvironment. Cell, 2017, 170, 127-141.e15.	13.5	140
924	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. Cytokine and Growth Factor Reviews, 2017, 36, 5-15.	3.2	48
925	Radiotherapy and Immune Checkpoint Blockade for Melanoma. Cancer Journal (Sudbury, Mass ), 2017, 23, 32-39.	1.0	28
926	Discovery of putative breast cancer antigens using an integrative platform of genomics-driven immunoproteomics. Proteomics, 2017, 17, 1600318.	1.3	5
927	Cancer predisposition syndromes: lessons for truly precision medicine. Journal of Pathology, 2017, 241, 226-235.	2.1	13
928	Gene-expression profiling to predict responsiveness to immunotherapy. Cancer Gene Therapy, 2017, 24, 134-140.	2.2	72
929	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. Annual Review of Cancer Biology, 2017, 1, 223-240.	2.3	20
930	â€˜Genotype/immunotypeâ€™ correlations in resected NSCLC. Annals of Oncology, 2017, 28, 7-8.	0.6	7
931	Immunotherapy in ovarian cancer. Current Problems in Cancer, 2017, 41, 48-63.	1.0	27
932	Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma. Oral Oncology, 2017, 71, 169-176.	0.8	16
933	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. Annals of Oncology, 2017, 28, 57-74.	0.6	45
934	Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 132-140.	1.1	18
935	Massive parallel sequencing of solid tumours â€œ challenges and opportunities for pathologists. Histopathology, 2017, 70, 123-133.	1.6	12
936	PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2017, 23, 454-465.	3.2	126
937	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Ca-A Cancer Journal for Clinicians, 2017, 67, 65-85.	157.7	344
938	Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors. Journal of Human Genetics, 2017, 62, 397-405.	1.1	55

#	ARTICLE	IF	CITATIONS
939	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1820-1828.	3.2	65
940	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
941	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	5.8	99
942	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
943	Preclinical and clinical development of neoantigen vaccines. <i>Annals of Oncology</i> , 2017, 28, xii11-xii17.	0.6	160
944	Targeting Neoantigens in Glioblastoma. <i>Neurosurgery</i> , 2017, 64, 165-176.	0.6	24
945	Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 19-31.	0.8	212
946	Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 91-104.	0.8	26
947	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. <i>Japanese Journal of Clinical Immunology</i> , 2017, 40, 68-77.	0.0	22
949	Whence High-Grade Serous Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 443-448.	1.8	15
950	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass )</i> , 2017, 23, 219-222.	1.0	4
951	The future of immuno-oncology. , 2017, , .		0
952	Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. <i>Blood Advances</i> , 2017, 1, 1884-1890.	2.5	40
953	Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii3-xii10.	0.6	31
954	Potential New Therapies for Pediatric Diffuse Intrinsic Pontine Glioma. <i>Frontiers in Pharmacology</i> , 2017, 8, 495.	1.6	48
955	Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells. <i>Medical Sciences (Basel, Switzerland)</i> , 2017, 5, 28.	1.3	22
956	Immunotherapy for Pediatric Brain Tumors. <i>Brain Sciences</i> , 2017, 7, 137.	1.1	24
957	The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 650.	1.8	20

#	ARTICLE	IF	CITATIONS
958	Precision Oncology: The Promise of Big Data and the Legacy of Small Data. <i>Frontiers in ICT</i> , 2017, 4, .	3.6	4
959	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
960	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	2.2	27
961	Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmetteâ€™Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. <i>Frontiers in Immunology</i> , 2017, 8, 625.	2.2	56
962	The Potential and Challenges of Exploiting the Vast But Dynamic Neopeptide Landscape for Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1113.	2.2	13
963	Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF. <i>Frontiers in Immunology</i> , 2017, 8, 1150.	2.2	7
964	An Analysis of Natural T Cell Responses to Predicted Tumor Neopeptides. <i>Frontiers in Immunology</i> , 2017, 8, 1566.	2.2	103
965	Identification and Characterization of Neoantigens As Well As Respective Immune Responses in Cancer Patients. <i>Frontiers in Immunology</i> , 2017, 8, 1702.	2.2	48
966	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1718.	2.2	36
967	Neoantigen Targetingâ€™Dawn of a New Era in Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2017, 8, 1848.	2.2	73
968	MAGE-A Antigens and Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2017, 4, 18.	1.2	54
969	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
970	Synergistic Protective Activity of Tumor-Specific Epitopes Engineered in Bacterial Outer Membrane Vesicles. <i>Frontiers in Oncology</i> , 2017, 7, 253.	1.3	50
971	Periodically Pulsed Immunotherapy in a Mathematical Model of Tumor, CD4 <sup>+</sup> T Cells, and Antitumor Cytokine Interactions. <i>Computational and Mathematical Methods in Medicine</i> , 2017, 2017, 1-12.	0.7	14
972	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	31
973	Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. <i>BioMed Research International</i> , 2017, 2017, 1-7.	0.9	65
974	Uncommon BRAF Mutations Associated with Durable Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	2
975	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15

#	ARTICLE	IF	CITATIONS
976	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
977	Systemic Chemotherapy in Muscle Invasive and Metastatic Bladder Cancer: Present and Future. <i>Urologia</i> , 2017, 84, 130-141.	0.3	8
978	Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients. <i>PLoS ONE</i> , 2017, 12, e0188174.	1.1	85
979	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	3.9	256
980	Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. <i>Nature Communications</i> , 2017, 8, 1738.	5.8	310
981	The neoepitope landscape in pediatric cancers. <i>Genome Medicine</i> , 2017, 9, 78.	3.6	77
982	Biomarkers for immunotherapy in bladder cancer: a moving target. , 2017, 5, 94.		144
983	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. , 2017, 5, 84.		5
984	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544.	0.8	89
985	Melanoma Metamorphoses: Advances in Biology and Therapy. <i>Journal of Cancer Science &amp; Therapy</i> , 2017, 09, .	1.7	2
986	Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. , 2017, , .		0
987	Therapeutic Sequencing in Metastatic Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2017, 1, 15-29.	0.2	4
988	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume11, 1175-1182.	2.0	14
989	Investigation of the Effect of Adding Stem Cells-as an Therapeutic Suggestion-on the Immune System's Response to the Cancerous Cells: A Mathematical Approach. , 2017, , .		0
990	Strong Correlation of Indoleamine 2,3-Dioxygenase 1 Expression with Basal-Like Phenotype and Increased Lymphocytic Infiltration in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2017, 8, 124-130.	1.2	28
991	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 447-456.	1.1	2
992	Is Circulating Tumor DNA (Ctdna) Use Ready For Prime Time? Applications and Challenges of Ctdna in the Era of Precision Oncology. <i>Chemotherapy</i> , 2017, 06, .	0.0	0
993	Precision Oncology: Who, How, What, When, and When Not?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 160-169.	1.8	151

#	ARTICLE	IF	CITATIONS
994	First Case Report of a Dramatic Radiographic Response to a Checkpoint Inhibitor in a Patient With Proficient Mismatch Repair Gene Expressing Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2017, 1, 1-4.	1.5	7
995	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	1.5	286
996	Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2193-2202.	0.8	209
997	Hypermutation and microsatellite instability in gastrointestinal cancers. <i>Oncotarget</i> , 2017, 8, 112103-112115.	0.8	69
998	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2535-2541.	0.8	383
999	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
1000	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 548-560.	1.8	21
1001	Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	44
1002	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	11
1003	Checkpoint cluster: biomarkers of response. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 501-508.	1.1	0
1004	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. <i>Oncotarget</i> , 2017, 8, 106132-106142.	0.8	174
1005	Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 199-212.	0.6	26
1006	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	0.9	10
1007	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	57
1008	Oncogenic pathways as the basis of primary immune ignorance. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 421-428.	1.1	0
1009	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. <i>Oncotarget</i> , 2017, 8, 3197-3205.	0.8	53
1010	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	275
1011	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <i>Translational Research</i> , 2018, 196, 62-70.	2.2	9



#	ARTICLE	IF	CITATIONS
1012	Advances of Immune Checkpoint Inhibitors in Tumor Immunotherapy. IOP Conference Series: Materials Science and Engineering, 2018, 301, 012020.	0.3	3
1013	Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma. Future Oncology, 2018, 14, 553-566.	1.1	22
1014	Nivolumab in the treatment of advanced renal cell carcinoma. Future Oncology, 2018, 14, 1679-1689.	1.1	3
1015	Immune Checkpoint Inhibition in Hodgkin Lymphoma. HemaSphere, 2018, 2, e20.	1.2	15
1016	Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Medicine, 2018, 7, 690-697.	1.3	90
1017	Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens. Methods in Molecular Biology, 2018, 1719, 209-221.	0.4	46
1018	Off-the-shelf TCR for graft-versus-leukemia without GVHD. Blood, 2018, 131, 5-7.	0.6	1
1019	Targeting Neoantigens for Personalised Immunotherapy. BioDrugs, 2018, 32, 99-109.	2.2	11
1020	Implementation of "clinical sequencing" in cancer genome medicine in Japan. Cancer Science, 2018, 109, 507-512.	1.7	31
1021	PD-L1, B7-H3, and PD-1 expression in immunocompetent vs. immunosuppressed patients with cutaneous squamous cell carcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 805-814.	2.0	41
1022	Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors. Molecular Cancer Therapeutics, 2018, 17, 869-882.	1.9	20
1023	The possibility of cancer immune editing in gliomas. A critical review. Oncoimmunology, 2018, 7, e1445458.	2.1	35
1024	Molecular Alterations and Buparlisib Efficacy in Patients with Squamous Cell Carcinoma of the Head and Neck: Biomarker Analysis from BERIL-1. Clinical Cancer Research, 2018, 24, 2505-2516.	3.2	32
1025	Increased risk of hematologic malignancies in primary immunodeficiency disorders: opportunities for immunotherapy. Clinical Immunology, 2018, 190, 22-31.	1.4	27
1026	The role of molecular enrichment on future therapies in hepatocellular carcinoma. Journal of Hepatology, 2018, 69, 237-247.	1.8	95
1027	Computationally-Guided Development of a Stromal Inflammation Histologic Biomarker in Lung Squamous Cell Carcinoma. Scientific Reports, 2018, 8, 3941.	1.6	11
1028	Peptidomics. Methods in Molecular Biology, 2018, , .	0.4	5
1029	DNA mismatch repair in cancer. , 2018, 189, 45-62.		356



#	ARTICLE	IF	CITATIONS
1030	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	13.9	2,469
1031	Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 106-115.	1.2	5
1032	The function and dysfunction of memory CD8 <sup>+</sup> T cells in tumor immunity. <i>Immunological Reviews</i> , 2018, 283, 194-212.	2.8	121
1033	Melanoma: What do all the mutations mean?. <i>Cancer</i> , 2018, 124, 3490-3499.	2.0	131
1034	Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity. <i>Clinical Cancer Research</i> , 2018, 24, 3560-3571.	3.2	72
1035	Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. <i>Nature Communications</i> , 2018, 9, 1317.	5.8	94
1036	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	1.8	184
1037	Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. <i>Cancer</i> , 2018, 124, 2169-2173.	2.0	86
1038	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
1039	The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. <i>Cancer Cell</i> , 2018, 33, 570-580.	7.7	911
1040	Current state of immunotherapy for glioblastoma. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 422-442.	12.5	873
1041	Personalized cancer vaccines: adjuvants are important, too. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1911-1918.	2.0	44
1042	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
1043	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018, 173, 624-633.e8.	13.5	113
1044	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
1045	Cancer immunotherapy-targeted glypican-3 or neoantigens. <i>Cancer Science</i> , 2018, 109, 531-541.	1.7	40
1046	Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens. <i>Cancer Science</i> , 2018, 109, 542-549.	1.7	45
1047	Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment. <i>Trends in Cancer</i> , 2018, 4, 119-137.	3.8	247

#	ARTICLE	IF	CITATIONS
1048	Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2018, 13, 636-648.	0.5	67
1049	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 259-268.	4.3	11
1050	Therapeutic cancer vaccines: From initial findings to prospects. <i>Immunology Letters</i> , 2018, 196, 11-21.	1.1	75
1051	Immuno-oncology-101: overview of major concepts and translational perspectives. <i>Seminars in Cancer Biology</i> , 2018, 52, 1-11.	4.3	39
1052	A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. <i>Translational Oncology</i> , 2018, 11, 311-329.	1.7	204
1053	TGF $\beta$ 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
1054	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
1055	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
1056	Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2413-2425.	0.6	223
1057	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <i>Oncogenesis</i> , 2018, 7, 2.	2.1	68
1058	The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 358-369.	1.6	46
1059	Ultraviolet light and melanoma. <i>Journal of Pathology</i> , 2018, 244, 578-585.	2.1	47
1060	The value of cell-free DNA for molecular pathology. <i>Journal of Pathology</i> , 2018, 244, 616-627.	2.1	91
1061	T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. <i>Scandinavian Journal of Immunology</i> , 2018, 87, e12643.	1.3	24
1062	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
1063	Emerging Biomarkers in Cutaneous Melanoma. <i>Molecular Diagnosis and Therapy</i> , 2018, 22, 203-218.	1.6	35
1064	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. <i>Cancer</i> , 2018, 124, 2086-2103.	2.0	141
1065	Epigenetic modifiers as new immunomodulatory therapies in solid tumours. <i>Annals of Oncology</i> , 2018, 29, 812-824.	0.6	73

#	ARTICLE	IF	CITATIONS
1066	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncolmmunology</i> , 2018, 7, e1433516.	2.1	31
1071	Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. <i>Cancer Medicine</i> , 2018, 7, 746-756.	1.3	348
1072	Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. <i>Annals of Oncology</i> , 2018, 29, 271-279.	0.6	106
1073	Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information. <i>Annals of Oncology</i> , 2018, 29, 1030-1036.	0.6	126
1074	Gene Expression Signatures Characterized by Longitudinal Stability and Interindividual Variability Delineate Baseline Phenotypic Groups with Distinct Responses to Immune Stimulation. <i>Journal of Immunology</i> , 2018, 200, j1701099.	0.4	5
1075	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517
1076	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974.	0.8	26
1077	Immunogenomics: A Negative Prostate Cancer Outcome Associated with TcR- $\beta$ Recombinations. <i>Cancer Microenvironment</i> , 2018, 11, 41-49.	3.1	18
1078	Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. <i>Oncolmmunology</i> , 2018, 7, e1423173.	2.1	16
1079	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 1296-1304.	3.2	146
1080	Nivolumab for the treatment of urothelial cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 215-221.	1.1	18
1081	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. <i>Clinical Cancer Research</i> , 2018, 24, 1326-1336.	3.2	281
1082	Shared cancer neoantigens: Making private matters public. <i>Journal of Experimental Medicine</i> , 2018, 215, 5-7.	4.2	46
1083	Cytoskeleton and ECM tumor mutant peptides: Increased protease sensitivities and potential consequences for the HLA class I mutant epitope reservoir. <i>International Journal of Cancer</i> , 2018, 142, 988-998.	2.3	11
1085	Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2018, 13, 521-532.	0.5	119
1086	Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018, 244, 586-597.	2.1	41
1087	Scavenger Receptor Type B1 and Lipoprotein Nanoparticle Inhibit Myeloid-Derived Suppressor Cells. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 686-697.	1.9	56
1088	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23

#	ARTICLE	IF	CITATIONS
1089	Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 85-96.	0.5	43
1090	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
1091	Peptide-Based Therapeutic Cancer Vaccines. , 2018, , 249-261.		2
1092	BCG and Anti-PDL-1 Ab in Bladder Cancers. , 2018, , 357-369.		0
1093	PD-L1 and Other Immunological Diagnosis Tools. , 2018, , 371-385.		2
1094	Predictors of Response to Immune Checkpoint Blockade. , 2018, , 525-544.		0
1095	Challenges of Oncoimmunology for Ovarian and Breast Cancers. , 2018, , 607-619.		0
1096	Checkpoint inhibitors in breast cancer – Current status. <i>Cancer Treatment Reviews</i> , 2018, 63, 122-134.	3.4	112
1097	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028837.	2.3	7
1098	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. <i>Seminars in Cancer Biology</i> , 2018, 52, 26-38.	4.3	49
1099	Precision Molecular Pathology of Bladder Cancer. <i>Molecular Pathology Library</i> , 2018, , .	0.1	0
1100	Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010–2014. <i>Oncologist</i> , 2018, 23, 481-488.	1.9	77
1101	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
1102	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1424674.	2.1	43
1103	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018, 29, 301-310.	0.6	98
1104	Treatment Paradigms in Bladder Cancer: Clinical Implications of Histological and Molecular Analysis. <i>Molecular Pathology Library</i> , 2018, , 85-101.	0.1	0
1105	Mechanisms of Metastasis. , 2018, , 1-35.		0
1106	Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 472-483.	0.6	42

#	ARTICLE	IF	CITATIONS
1107	Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 316-320.	3.0	171
1108	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers. <i>Leukemia and Lymphoma</i> , 2018, 59, 1949-1958.	0.6	4
1109	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.	6.0	898
1110	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. <i>Seminars in Cancer Biology</i> , 2018, 52, 158-165.	4.3	4
1111	Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab. <i>Clinical Cancer Research</i> , 2018, 24, 3857-3866.	3.2	150
1112	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	7.7	725
1113	Population-level distribution and putative immunogenicity of cancer neoepitopes. <i>BMC Cancer</i> , 2018, 18, 414.	1.1	32
1114	Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 81.	1.8	28
1115	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2018, 11, 31.	6.9	256
1116	The perfect personalized cancer therapy: cancer vaccines against neoantigens. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 86.	3.5	82
1117	Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. , 2018, 6, 27.		17
1118	CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival. <i>Acta Neuropathologica Communications</i> , 2018, 6, 18.	2.4	26
1120	Immunotherapy of Hepatocellular Carcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 292-297.	0.8	27
1121	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 487-493.	1.7	26
1122	APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. <i>Oncogene</i> , 2018, 37, 3924-3936.	2.6	204
1123	Mutation load estimation model as a predictor of the response to cancer immunotherapy. <i>Npj Genomic Medicine</i> , 2018, 3, 12.	1.7	55
1124	<scp>CD8</scp> lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. <i>Cancer Reports</i> , 2018, 1, e1002.	0.6	8
1125	Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. <i>Future Oncology</i> , 2018, 14, 2293-2302.	1.1	25

#	ARTICLE	IF	CITATIONS
1126	The emerging clinical relevance of genomics in cancer medicine. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 353-365.	12.5	351
1127	Harnessing and Optimizing the Interplay between Immunotherapy and Radiotherapy to Improve Survival Outcomes. <i>Molecular Cancer Research</i> , 2018, 16, 1209-1214.	1.5	7
1129	Antibody based therapy for childhood solid cancers. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 153-162.	3.8	1
1130	New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. <i>Journal of Thoracic Oncology</i> , 2018, 13, 752-766.	0.5	102
1131	Sensitive and frequent identification of high avidity neo-epitope-specific CD8 + T cells in immunotherapy-naïve ovarian cancer. <i>Nature Communications</i> , 2018, 9, 1092.	5.8	122
1132	Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. <i>Immunotherapy</i> , 2018, 10, 423-425.	1.0	1
1133	Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments. <i>Annual Review of Chemical and Biomolecular Engineering</i> , 2018, 9, 105-127.	3.3	161
1134	Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2851-2858.	3.2	65
1135	Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. <i>Immunity</i> , 2018, 48, 417-433.	6.6	416
1136	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
1137	Personalized vaccines for cancer immunotherapy. <i>Science</i> , 2018, 359, 1355-1360.	6.0	697
1138	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 4771-4784.	3.2	29
1139	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
1140	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. <i>European Journal of Cancer</i> , 2018, 94, 179-186.	1.3	82
1141	Immune signatures predicting responses to immunomodulatory antibody therapy. <i>Current Opinion in Immunology</i> , 2018, 51, 91-96.	2.4	7
1142	BCR-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. <i>Cellular and Molecular Immunology</i> , 2018, 15, 15-26.	4.8	5
1143	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-peptide Multimer Staining Assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 342-353.	0.7	12
1144	T-cell receptor-engineered T cells for cancer treatment: current status and future directions. <i>Protein and Cell</i> , 2018, 9, 254-266.	4.8	124

#	ARTICLE	IF	CITATIONS
1145	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a027086.	2.9	11
1146	Big Bang Tumor Growth and Clonal Evolution. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a028381.	2.9	38
1147	Intrinsic and extrinsic causes of malignancies in patients with primary immunodeficiency disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 59-68.e4.	1.5	99
1148	The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94.	1.5	3
1149	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2842-2849.	1.4	85
1150	Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 311-325.	2.0	40
1151	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
1152	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. <i>European Urology Focus</i> , 2018, 4, 442-454.	1.6	10
1153	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	3.2	68
1154	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253
1155	Immunotherapy regimens for metastatic colorectal carcinomas. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 250-254.	1.4	14
1156	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 334-340.	3.2	323
1157	Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. <i>Seminars in Cancer Biology</i> , 2018, 52, 216-227.	4.3	14
1158	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
1159	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
1160	Cholangiocarcinoma "evolving concepts and therapeutic strategies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 95-111.	12.5	1,051
1161	Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 141-151.	2.0	58
1162	Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e15-e21.	0.6	263



#	ARTICLE	IF	CITATIONS
1163	Microenvironment and Lung Cancer. , 2018, , 121-128.e4.		1
1164	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	2.4	37
1165	Emerging biomarkers for cancer immunotherapy in melanoma. Seminars in Cancer Biology, 2018, 52, 207-215.	4.3	42
1166	The Prevalence and Impact of Neurological Disease in Cancer. , 2018, , 3-10.		0
1167	An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. Molecular Therapy, 2018, 26, 379-389.	3.7	78
1168	Prostate cancer immunotherapy. Current Opinion in Urology, 2018, 28, 15-24.	0.9	40
1169	Treatment of Advanced Prostate Cancerâ€”A Review of Current Therapies and Future Promise. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030635.	2.9	128
1170	Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Modern Pathology, 2018, 31, 418-428.	2.9	75
1171	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
1172	Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. , 2018, , 13-38.		0
1173	Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments. Cancer Research, 2018, 78, 463-474.	0.4	70
1174	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. Cancer Research, 2018, 78, 475-488.	0.4	61
1175	Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells. Cancer Immunology Research, 2018, 6, 139-150.	1.6	172
1176	Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18, 168-182.	10.6	736
1177	Mechanisms of Tumor Cellâ€”Intrinsic Immune Evasion. Annual Review of Cancer Biology, 2018, 2, 213-228.	2.3	65
1178	Navigating the â€œNo Man's Landâ€”of TKI-Failed EGFR-Mutated Nonâ€”Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 2018, 20, 92-98.	2.3	24
1179	Medical bioinformatics in melanoma. Current Opinion in Oncology, 2018, 30, 113-117.	1.1	13
1180	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Molecular Therapy, 2018, 26, 435-445.	3.7	39



#	ARTICLE	IF	CITATIONS
1181	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
1182	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
1183	New developments in immunotherapy for pediatric solid tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 30-39.	1.0	16
1184	Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. <i>Annual Review of Cancer Biology</i> , 2018, 2, 313-336.	2.3	230
1185	Drug development in the era of precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 183-196.	21.5	294
1186	Viral subversion of APOBEC3s: Lessons for anti-tumor immunity and tumor immunotherapy. <i>International Reviews of Immunology</i> , 2018, 37, 151-164.	1.5	11
1187	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
1188	Biomarkers: Delivering on the expectation of molecularly driven, quantitative health. <i>Experimental Biology and Medicine</i> , 2018, 243, 313-322.	1.1	13
1189	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38
1190	Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. <i>International Journal of Gynecological Pathology</i> , 2018, 37, 581-589.	0.9	4
1191	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
1193	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
1194	Melanoma Immunotherapy. <i>Current Cancer Research</i> , 2018, , 307-331.	0.2	0
1195	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
1196	Regulatory T-cell Genes Drive Altered Immune Microenvironment in Adult Solid Cancers and Allow for Immune Contextual Patient Subtyping. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 103-112.	1.1	27
1197	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
1198	Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 393-398.	0.5	230
1199	Cellular and Molecular Mechanisms of Autoimmune Hepatitis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 247-292.	9.6	107

#	ARTICLE	IF	CITATIONS
1200	Interferon- $\beta$ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4. <i>Cancer Research</i> , 2018, 78, 436-450.	0.4	96
1201	Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types. <i>Cancer Immunology Research</i> , 2018, 6, 87-97.	1.6	106
1202	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. <i>Cancer Letters</i> , 2018, 414, 166-173.	3.2	207
1203	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. <i>Laboratory Investigation</i> , 2018, 98, 41-50.	1.7	30
1204	A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1386827.	2.1	3
1205	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
1206	The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 381-392.	2.0	113
1207	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
1208	Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology. <i>Cancer Cytopathology</i> , 2018, 126, 11-19.	1.4	28
1209	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 7-24.	1.0	23
1210	Breast Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 511-520.	3.2	567
1211	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. <i>Neuroendocrinology</i> , 2018, 106, 89-100.	1.2	14
1212	Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?. <i>Journal of Clinical Oncology</i> , 2018, 36, 631-632.	0.8	165
1213	Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 610-617.	0.6	192
1214	Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	1.5	0
1215	Precision Medicine in Non-Small Cell Lung Cancer: Current Standards in Pathology and Biomarker Interpretation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 708-715.	1.8	30
1216	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
1218	DNA Repair Deficiency and Immunotherapy Response. <i>Journal of Clinical Oncology</i> , 2018, 36, 1710-1713.	0.8	31

#	ARTICLE	IF	CITATIONS
1219	Tumor Mutation Burden: Is It Ready for the Clinic?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2978-2979.	0.8	16
1220	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. <i>Translational Lung Cancer Research</i> , 2018, 7, 668-677.	1.3	56
1221	Immune profiling of microsatellite instability-high and polymerase $\mu$ (POLE)-mutated metastatic colorectal tumors identifies predictors of response to anti-PD-1 therapy. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 404-415.	0.6	49
1222	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
1223	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. <i>Journal of Thoracic Disease</i> , 2018, 10, S2195-S2197.	0.6	3
1224	Immune checkpoint inhibitors in small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S460-S467.	0.6	46
1225	Methods of measurement for tumor mutational burden in tumor tissue. <i>Translational Lung Cancer Research</i> , 2018, 7, 661-667.	1.3	166
1226	Tumor mutational burden as predictive factor of response to immunotherapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S358-S361.	1.3	8
1227	Approach to evaluating tumor mutational burden in routine clinical practice. <i>Translational Lung Cancer Research</i> , 2018, 7, 678-681.	1.3	23
1229	Understanding and quantifying the immune microenvironment in hepatocellular carcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 107-107.	1.5	1
1230	Classification of tumor microenvironment immune types based on immune response-associated gene expression. <i>International Journal of Oncology</i> , 2019, 54, 219-228.	1.4	12
1231	Network assessment of demethylation treatment in melanoma: Differential transcriptome-methylome and antigen profile signatures. <i>PLoS ONE</i> , 2018, 13, e0206686.	1.1	2
1233	Advanced small cell lung cancer (SCLC): new challenges and new expectations. <i>Annals of Translational Medicine</i> , 2018, 6, 145-145.	0.7	64
1234	Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens. <i>World Journal of Gastroenterology</i> , 2018, 24, 5418-5432.	1.4	77
1235	Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	1
1236	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
1238	The Partnership for Accelerating Cancer Therapies. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 111-114.	1.0	8
1239	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. <i>BMC Cancer</i> , 2018, 18, 1082.	1.1	42

#	ARTICLE	IF	CITATIONS
1240	<i>BRCA1/2</i> and <i>TP53</i> mutation status associates with <i>PD-1</i> and <i>PD-L1</i> expression in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17501-17511.	0.8	70
1241	Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening. <i>Scientific Reports</i> , 2018, 8, 17366.	1.6	13
1242	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018, 7, 28.	2.0	99
1243	Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. <i>Oncotarget</i> , 2018, 9, 7949-7960.	0.8	49
1244	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. <i>Lung Cancer</i> , 2018, 126, 162-169.	0.9	2
1245	The Clinical Impact of the Genomic Landscape of Mismatch Repairâ€“Deficient Cancers. <i>Cancer Discovery</i> , 2018, 8, 1518-1528.	7.7	77
1246	The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status. <i>PLoS ONE</i> , 2018, 13, e0207227.	1.1	21
1247	Radiotherapy induces responses of lung cancer to CTLA-4 blockade. <i>Nature Medicine</i> , 2018, 24, 1845-1851.	15.2	626
1248	TGF-Î²-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure. <i>Nature Communications</i> , 2018, 9, 4692.	5.8	388
1249	Therapy Implications of DNA Mismatch Repair Deficiency, Microsatellite Instability, and Tumor Mutation Burden. <i>Advances in Molecular Pathology</i> , 2018, 1, 193-208.	0.2	5
1250	Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. <i>JCI Insight</i> , 2018, 3, .	2.3	40
1251	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. <i>Oncotarget</i> , 2018, 9, 10635-10649.	0.8	41
1252	A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the OncoPrint Tumor Mutation Load Assay. <i>Translational Lung Cancer Research</i> , 2018, 7, 616-630.	1.3	41
1253	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
1254	Cancer research in the era of immunogenomics. <i>ESMO Open</i> , 2018, 3, e000475.	2.0	14
1255	Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 5361.	5.8	294
1256	Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591881628.	1.4	56
1257	Advances in Next-Generation Sequencing Bioinformatics for Clinical Diagnostics. <i>Advances in Molecular Pathology</i> , 2018, 1, 149-166.	0.2	4

#	ARTICLE	IF	CITATIONS
1258	Classification of triple-negative breast cancers based on Immunogenomic profiling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 327.	3.5	329
1259	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. <i>PLoS ONE</i> , 2018, 13, e0208422.	1.1	14
1260	Molecular pathways in the development and treatment of oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 9-15.	1.0	21
1261	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 1-41.	0.8	6
1262	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
1263	Immune checkpoint inhibitors: recent progress and potential biomarkers. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-11.	3.2	1,410
1264	Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers. <i>Frontiers in Immunology</i> , 2018, 9, 2728.	2.2	39
1265	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
1267	Prime time for immunotherapy in advanced urothelial cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 24-32.	0.7	2
1268	Targeted therapy or immunotherapy? Optimal treatment in hepatocellular carcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2018, 10, 108-114.	0.8	25
1269	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
1270	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
1271	Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 1.	1.8	30
1272	Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3925-3930.	1.8	106
1273	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759.	4.2	34
1274	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
1275	Activation of viral defense signaling in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879310.	1.4	14
1276	The role of cancer stem cells in the modulation of anti-tumor immune responses. <i>Seminars in Cancer Biology</i> , 2018, 53, 189-200.	4.3	80

#	ARTICLE	IF	CITATIONS
1277	Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma. <i>World Neurosurgery</i> , 2018, 120, e601-e610.	0.7	29
1278	Roles of the immune system in cancer: from tumor initiation to metastatic progression. <i>Genes and Development</i> , 2018, 32, 1267-1284.	2.7	1,326
1279	Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2018, 14, 167-174.	1.0	0
1280	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
1281	Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. <i>Cancer Immunology Research</i> , 2018, 6, 1122-1128.	1.6	81
1282	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5973-5989.	1.0	94
1283	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
1284	Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option. , 2018, 6, 102.		141
1285	Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1401-1416.	1.6	28
1286	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	6.0	1,575
1287	Genes at the Crossroad of Primary Immunodeficiencies and Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2544.	2.2	15
1288	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. <i>PLoS ONE</i> , 2018, 13, e0206223.	1.1	149
1289	Defective transcription elongation in a subset of cancers confers immunotherapy resistance. <i>Nature Communications</i> , 2018, 9, 4410.	5.8	17
1290	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1884-1896.	0.5	78
1291	Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10702-E10711.	3.3	50
1292	Precision medicine in oncology: what is it exactly and where are we?. <i>Personalized Medicine</i> , 2018, 15, 351-353.	0.8	8
1293	Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. <i>Cell</i> , 2018, 175, 1244-1258.e26.	13.5	182
1294	The CTLA-4 rs231775 GG genotype is associated with favorable 90-day survival in Caucasian patients with sepsis. <i>Scientific Reports</i> , 2018, 8, 15140.	1.6	13

#	ARTICLE	IF	CITATIONS
1295	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 1025-1039.	0.9	11
1296	Analysis of point mutations and copy number variation in Grade II and III meningioma. <i>Experimental and Molecular Pathology</i> , 2018, 105, 328-333.	0.9	18
1297	Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. <i>ACS Nano</i> , 2018, 12, 11041-11061.	7.3	200
1298	Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.	2.9	6
1300	The DNA damage response in immunotherapy and radiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 527-533.	0.6	24
1301	An assessment of prognostic immunity markers in breast cancer. <i>Npj Breast Cancer</i> , 2018, 4, 35.	2.3	41
1302	Exploring optimal sequencing of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 494-505.	0.6	26
1303	SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 89.	1.5	18
1304	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	13.5	1,260
1305	Killer immunoglobulin-like receptor genotype did not correlate with response to anti-PD-1 antibody treatment in a Japanese cohort. <i>Scientific Reports</i> , 2018, 8, 15962.	1.6	4
1306	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab. , 2018, 6, 107.		52
1307	Unique true predicted neoantigens (TPNAs) correlates with anti-tumor immune control in HCC patients. <i>Journal of Translational Medicine</i> , 2018, 16, 286.	1.8	24
1308	Advanced basal cell cancer: concise review of molecular characteristics and novel targeted and immune therapeutics. <i>Annals of Oncology</i> , 2018, 29, 2192-2199.	0.6	35
1309	Immunoengineering through cancer vaccines â€œ A personalized and multi-step vaccine approach towards precise cancer immunity. <i>Journal of Controlled Release</i> , 2018, 289, 125-145.	4.8	31
1310	A Comprehensive Survey of Immune Cytolytic Activity-Associated Gene Co-Expression Networks across 17 Tumor and Normal Tissue Types. <i>Cancers</i> , 2018, 10, 307.	1.7	4
1311	A machine learning approach for somatic mutation discovery. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
1312	T Cellâ€™Inflamed versus Non-T Cellâ€™Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. <i>Cancer Immunology Research</i> , 2018, 6, 990-1000.	1.6	297
1313	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. <i>Drugs</i> , 2018, 78, 1443-1457.	4.9	70



#	ARTICLE	IF	CITATIONS
1314	Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models. <i>Breast Cancer Research</i> , 2018, 20, 108.	2.2	81
1315	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolmunology</i> , 2018, 7, e1511506.	2.1	121
1316	TSNAdb: A Database for Tumor-specific Neoantigens from Immunogenomics Data Analysis. <i>Genomics, Proteomics and Bioinformatics</i> , 2018, 16, 276-282.	3.0	97
1317	Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. <i>Cell</i> , 2018, 175, 159-170.e16.	13.5	127
1318	Clinical Relevance of Genomic Changes in Recurrent Pediatric Solid Tumors. <i>Translational Oncology</i> , 2018, 11, 1390-1397.	1.7	6
1319	Translational Biomarkers: Application in the Clinical Development of Combination Therapies. , 2018, , 223-248.		0
1320	Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. <i>Oncolmunology</i> , 2018, 7, e1501137.	2.1	120
1321	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
1322	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018, 29, 2175-2182.	0.6	20
1323	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: What is the Evidence?. <i>Journal of Neoplasm</i> , 2018, 03, .	0.1	2
1324	Immune Checkpoint Inhibition in Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 310.	1.3	103
1325	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. <i>PLoS ONE</i> , 2018, 13, e0191926.	1.1	17
1326	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
1327	Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 196-207.	0.6	18
1328	Immunological-based approaches for cancer therapy. <i>Clinics</i> , 2018, 73, e429s.	0.6	7
1329	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
1330	Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic. <i>Biomedicines</i> , 2018, 6, 14.	1.4	66
1331	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27389.	0.8	25



#	ARTICLE	IF	CITATIONS
1332	Identifying neoantigens for use in immunotherapy. <i>Mammalian Genome</i> , 2018, 29, 714-730.	1.0	28
1333	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
1334	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. <i>Journal of Autoimmunity</i> , 2018, 95, 77-99.	3.0	141
1335	Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 124, 248-254.	0.9	61
1336	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. <i>Cancer Research</i> , 2018, 78, 6486-6496.	0.4	176
1337	Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	0.8	5
1338	Novel immunotherapy approaches to follicular lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 194-199.	0.9	8
1339	MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. <i>European Journal of Cancer</i> , 2018, 98, 10-16.	1.3	57
1340	<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018, 8, 822-835.	7.7	1,108
1341	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i> -Not-Amplified Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 5673-5684.	3.2	92
1342	Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1/PD-L1 immunotherapy. <i>Medical Hypotheses</i> , 2018, 116, 111-113.	0.8	19
1343	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
1344	Challenges with biomarkers in cancer drug discovery and development. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 685-690.	2.5	28
1345	Molecular Targeted Therapy for Epithelial Ovarian Cancer. , 2018, , 153-166.		0
1346	JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1205-e1215.	1.1	46
1347	TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma. <i>EBioMedicine</i> , 2018, 32, 119-124.	2.7	61
1348	HLA Typing. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	4
1349	Innovations for Next-Generation Antibody-Drug Conjugates. <i>Cancer Drug Discovery and Development</i> , 2018, , .	0.2	8

#	ARTICLE	IF	CITATIONS
1350	Combining ADCs with Immuno-Oncology Agents. <i>Cancer Drug Discovery and Development</i> , 2018, , 11-44.	0.2	5
1351	A Convergence-Based Framework for Cancer Drug Resistance. <i>Cancer Cell</i> , 2018, 33, 801-815.	7.7	181
1352	Genomic Features of Response to Combination Immunotherapy in Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 791-793.	7.7	20
1353	Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. <i>Nature Communications</i> , 2018, 9, 1894.	5.8	65
1354	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 657-670.	3.3	14
1355	Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 635-643.	3.7	60
1356	Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1466768.	2.1	48
1357	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76
1358	Blockade of the Checkpoint Inhibitor Pathways and Activated T-Cell Therapy in Brain Tumors. , 2018, , 669-680.		0
1360	Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models. <i>Cancer Science</i> , 2018, 109, 2119-2129.	1.7	22
1361	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 9-18.	0.2	18
1362	Precision medicine and drug targeting. , 2018, , 155-166.		1
1363	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46
1364	Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer. <i>Translational Oncology</i> , 2018, 11, 1171-1187.	1.7	94
1365	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. <i>Cancers</i> , 2018, 10, 245.	1.7	34
1366	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
1367	Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. <i>Biomaterials</i> , 2018, 182, 82-91.	5.7	77
1368	Biomarkers of response to immune checkpoint blockade in cancer treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 108-120.	2.0	61

#	ARTICLE	IF	CITATIONS
1369	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3114.	5.8	122
1370	The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel. <i>Journal of Cancer</i> , 2018, 9, 2302-2307.	1.2	23
1371	Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1019-1040.	0.9	55
1372	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
1373	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2018, 24, 5368-5380.	3.2	189
1374	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878622.	1.4	5
1375	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 639-646.	3.3	1
1376	Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 639-650.	12.5	152
1377	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 14.	2.2	356
1378	Type I Interferon-Independent Dendritic Cell Priming and Antitumor T Cell Activation Induced by a <i>Mycoplasma fermentans</i> Lipopeptide. <i>Frontiers in Immunology</i> , 2018, 9, 496.	2.2	16
1379	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. <i>Frontiers in Immunology</i> , 2018, 9, 610.	2.2	46
1380	Approaches to Improve Chemically Defined Synthetic Peptide Vaccines. <i>Frontiers in Immunology</i> , 2018, 9, 884.	2.2	54
1381	Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy. <i>Frontiers in Immunology</i> , 2018, 9, 946.	2.2	19
1382	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. <i>Frontiers in Oncology</i> , 2018, 8, 27.	1.3	71
1383	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
1384	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53
1385	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	1.3	60
1386	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118

#	ARTICLE	IF	CITATIONS
1387	Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies. , 2018, 6, 70.		28
1388	Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. Biomedicines, 2018, 6, 76.	1.4	10
1390	Pathogenesis of Skin Carcinomas and a Stem Cell as Focal Origin. Frontiers in Medicine, 2018, 5, 165.	1.2	14
1391	Colorectal Cancers: An Update on Their Molecular Pathology. Cancers, 2018, 10, 26.	1.7	128
1392	Understanding Intratumor Heterogeneity and Evolution in NSCLC and Potential New Therapeutic Approach. Cancers, 2018, 10, 212.	1.7	17
1393	Immunotherapy of melanoma. Wspolczesna Onkologia, 2018, 2018, 61-67.	0.7	78
1394	Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. Journal of Controlled Release, 2018, 285, 56-66.	4.8	28
1395	Naturally Occurring Canine Melanoma as a Predictive Comparative Oncology Model for Human Mucosal and Other Triple Wild-Type Melanomas. International Journal of Molecular Sciences, 2018, 19, 394.	1.8	78
1396	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock		12
1397	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Science Translational Medicine, 2018, 10, .	5.8	425
1398	Wnt3a/β2-Catenin Signaling Conditions Differentiation of Partially Exhausted T-effector Cells in Human Cancers. Cancer Immunology Research, 2018, 6, 941-952.	1.6	34
1399	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. The Cochrane Library, 0, , .	1.5	6
1400	Novel frontiers in detecting cancer metastasis. Clinical and Experimental Metastasis, 2018, 35, 403-412.	1.7	8
1401	Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878665.	1.4	105
1402	Underlying Causes and Therapeutic Targeting of the Inflammatory Tumor Microenvironment. Frontiers in Cell and Developmental Biology, 2018, 6, 56.	1.8	54
1403	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. Trends in Immunology, 2018, 39, 536-548.	2.9	152
1404	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 15.	6.9	155
1407	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111

#	ARTICLE	IF	CITATIONS
1408	Multiplex bead-based measurement of humoral immune responses against tumor-associated antigens in stage II melanoma patients of the EORTC18961 trial. <i>Oncolmmunology</i> , 2018, 7, e1428157.	2.1	18
1409	Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. <i>Annual Review of Biomedical Data Science</i> , 2018, 1, 1-27.	2.8	27
1410	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. <i>Oncolmmunology</i> , 2018, 7, e1490854.	2.1	200
1411	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	6.9	303
1412	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. <i>Nature Medicine</i> , 2018, 24, 1550-1558.	15.2	2,791
1413	Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 285.	1.3	89
1414	Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600 mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 101, 229-235.	1.3	29
1415	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	4.9	34
1416	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. <i>Nature Biotechnology</i> , 2018, 36, 847-856.	9.4	564
1417	A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. <i>Nature Communications</i> , 2018, 9, 3196.	5.8	145
1418	Predicting Antigen Presentation—What Could We Learn From a Million Peptides?. <i>Frontiers in Immunology</i> , 2018, 9, 1716.	2.2	159
1419	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	3.2	152
1420	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , 2018, 50, 1271-1281.	9.4	438
1421	New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment. <i>Biomedicines</i> , 2018, 6, 87.	1.4	8
1422	Intron retention is a source of neoepitopes in cancer. <i>Nature Biotechnology</i> , 2018, 36, 1056-1058.	9.4	212
1423	Identification of non-mutated neoantigens presented by TAP-deficient tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2325-2337.	4.2	64
1424	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
1425	Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. <i>Cancer Medicine</i> , 2018, 7, 4517-4529.	1.3	34

#	ARTICLE	IF	CITATIONS
1426	Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. <i>Cell</i> , 2018, 174, 1559-1570.e22.	13.5	183
1427	Heterogeneous Integration Technology Demonstrations for Future Healthcare, IoT, and AI Computing Solutions. , 2018, , .		35
1428	The Cancer Omics Atlas: an integrative resource for cancer omics annotations. <i>BMC Medical Genomics</i> , 2018, 11, 63.	0.7	20
1429	Engineering Platforms for T Cell Modulation. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 277-362.	1.6	8
1430	Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 1613.	2.2	83
1431	Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies. <i>FASEB Journal</i> , 2018, 32, 5063-5077.	0.2	7
1432	Using Exome and Amplicon-Based Sequencing Data for High-Resolution HLA Typing with ATHLATES. <i>Methods in Molecular Biology</i> , 2018, 1802, 203-213.	0.4	3
1433	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
1434	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 477-494.	12.5	208
1435	Immunobiology of the Melanoma Microenvironment. , 2018, , 133-142.		0
1438	Driving cars to the clinic for solid tumors. <i>Gene Therapy</i> , 2018, 25, 165-175.	2.3	67
1439	Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses. <i>Journal of Immunological Methods</i> , 2018, 460, 51-62.	0.6	23
1440	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
1441	Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 782-790.	2.3	28
1442	Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers. <i>Scientific Reports</i> , 2018, 8, 8990.	1.6	31
1443	Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. <i>PLoS ONE</i> , 2018, 13, e0190058.	1.1	37
1444	Methods for improving the immunogenicity and efficacy of cancer vaccines. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 765-784.	1.4	13
1445	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162

#	ARTICLE	IF	CITATIONS
1446	Checkpoint blockade in esophagogastric cancer. <i>Journal of Surgical Oncology</i> , 2018, 118, 77-85.	0.8	9
1447	Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 180-188.	3.0	74
1448	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 1063-1069.	3.2	257
1449	Functional genomics: paving the way for more successful cancer immunotherapy. <i>Briefings in Functional Genomics</i> , 2019, 18, 86-98.	1.3	6
1450	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 69-77.	3.0	60
1451	Implementing precision cancer medicine in the genomic era. <i>Seminars in Cancer Biology</i> , 2019, 55, 16-27.	4.3	24
1452	Acquired resistance to cancer immunotherapy. <i>Seminars in Immunopathology</i> , 2019, 41, 31-40.	2.8	34
1453	Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. <i>Journal of Medical Genetics</i> , 2019, 56, 43-49.	1.5	49
1454	Mutation heterogeneity between primary gastric cancers and their matched lymph node metastases. <i>Gastric Cancer</i> , 2019, 22, 323-334.	2.7	17
1455	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 485-495.	1.4	3
1456	Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. <i>International Journal of Cancer</i> , 2019, 144, 1135-1146.	2.3	12
1457	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57
1458	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. <i>Journal of Autoimmunity</i> , 2019, 104, 102310.	3.0	57
1459	Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 6511-6523.	3.2	62
1460	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. <i>Frontiers in Oncology</i> , 2019, 9, 618.	1.3	9
1461	Review of systemic agents in the treatment of advanced cutaneous squamous cell carcinoma. <i>Future Oncology</i> , 2019, 15, 3171-3184.	1.1	11
1462	Molecular Genetics of Melanocytic Neoplasia. , 2019, , 123-145.		1
1463	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. <i>Cell</i> , 2019, 178, 933-948.e14.	13.5	301



#	ARTICLE	IF	CITATIONS
1464	Tumor mutation burden: from comprehensive mutational screening to the clinic. <i>Cancer Cell International</i> , 2019, 19, 209.	1.8	116
1465	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. <i>Advances in Therapy</i> , 2019, 36, 2638-2678.	1.3	145
1466	Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2019, 19, 495-509.	12.8	573
1467	Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 733-751.	0.6	6
1468	Alternative mRNA splicing in cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2019, 19, 675-687.	10.6	169
1469	Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics. <i>Leukemia and Lymphoma</i> , 2019, 60, 3350-3362.	0.6	1
1470	Neoadjuvant therapy of locally/regionally advanced melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986695.	1.4	21
1471	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e909-e912.	0.9	1
1472	Mutation-Derived Neoantigens for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1856.	2.2	78
1473	Tumor mutational burden. <i>Cancer Cytopathology</i> , 2019, 127, 735-736.	1.4	43
1474	Tissue Site and the Cancer Immunity Cycle. <i>Trends in Cancer</i> , 2019, 5, 593-603.	3.8	37
1475	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. , 2019, 7, 183.		231
1476	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
1477	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients. <i>Clinical Chemistry</i> , 2019, 65, 1228-1238.	1.5	178
1478	Immuno-oncology for surgeons. <i>British Journal of Surgery</i> , 2019, 106, 1273-1282.	0.1	2
1479	Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade. <i>JAMA Oncology</i> , 2019, 5, 1195.	3.4	431
1480	The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. <i>Clinical Oncology</i> , 2019, 31, 834-843.	0.6	48
1481	Pembrolizumab for the treatment of cervical cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 871-877.	1.4	24

#	ARTICLE	IF	CITATIONS
1482	Role of tumor gene mutations in treatment response to immune checkpoint blockades. Precision Clinical Medicine, 2019, 2, 100-109.	1.3	11
1483	Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study. , 2019, 7, 180.		137
1484	Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 2019, 96, 77-88.	0.8	57
1485	Precision neuroradiology: mapping the nodes and networks that link genes to behaviour. British Journal of Radiology, 2019, 92, 20190093.	1.0	3
1486	Acral Lentiginous Melanoma. , 2019, , 1-28.		1
1487	Intracellular targets as source for cleaner targets for the treatment of solid tumors. Biochemical Pharmacology, 2019, 168, 275-284.	2.0	8
1488	AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report. Case Reports in Oncology, 2019, 12, 456-465.	0.3	18
1489	Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer. Frontiers in Immunology, 2019, 10, 1654.	2.2	101
1490	Possible Biomarkers for Cancer Immunotherapy. Cancers, 2019, 11, 935.	1.7	35
1491	Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology, 2019, 16, 465-483.	1.9	119
1492	Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget, 2019, 10, 4018-4025.	0.8	118
1493	Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer, 2019, 125, 3312-3319.	2.0	90
1494	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
1495	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. Cell, 2019, 178, 585-599.e15.	13.5	162
1496	Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy. Nature Communications, 2019, 10, 3236.	5.8	47
1497	Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Outcome of Immune Checkpoint Inhibitors. Cancer Investigation, 2019, 37, 265-274.	0.6	31
1498	Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing. Frontiers in Immunology, 2019, 10, 1505.	2.2	34
1499	Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. Computational and Structural Biotechnology Journal, 2019, 17, 1020-1030.	1.9	86

#	ARTICLE	IF	CITATIONS
1500	Attack and Defense in Cellular Decision-Making: Lessons from Machine Learning. <i>Physical Review X</i> , 2019, 9, .	2.8	3
1501	T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance. <i>Immunological Reviews</i> , 2019, 290, 127-147.	2.8	180
1502	Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. <i>Oncotarget</i> , 2019, 10, 3835-3839.	0.8	8
1503	Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2019, 23, 507-520.	1.6	39
1504	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
1505	Fibroblasts in cancer: Defining target structures for therapeutic intervention. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 111-121.	3.3	14
1506	Optimizing panel-based tumor mutational burden (TMB) measurement. <i>Annals of Oncology</i> , 2019, 30, 1496-1506.	0.6	123
1507	Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1609-1624.	0.9	8
1508	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 <sup>+</sup> T cell responses. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	66
1509	Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome. <i>International Journal of Clinical Oncology</i> , 2019, 24, 999-1011.	1.0	57
1510	data- and model-driven approach for cancer treatment. <i>Onkologe</i> , 2019, 25, 132-137.	0.7	3
1511	Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors. <i>ESMO Open</i> , 2019, 4, e000531.	2.0	60
1512	Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. , 2019, 7, 264.		66
1513	Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade. <i>Cell Systems</i> , 2019, 9, 375-382.e4.	2.9	88
1514	Death and the Miser: microbiota regulate the outcome of checkpoint inhibition immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 831-834.	1.1	3
1515	Low-grade glioma harbors few CD8 T cells, which is accompanied by decreased expression of chemo-attractants, not immunogenic antigens. <i>Scientific Reports</i> , 2019, 9, 14643.	1.6	44
1516	CTLA-4 (CD152): A versatile receptor for immune-based therapy. <i>Seminars in Immunology</i> , 2019, 42, 101298.	2.7	49
1517	Cellular therapy approaches harnessing the power of the immune system for personalized cancer treatment. <i>Seminars in Immunology</i> , 2019, 42, 101306.	2.7	17

#	ARTICLE	IF	CITATIONS
1518	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	49
1519	Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003863.	0.5	21
1520	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
1521	pTuneos: prioritizing tumor neoantigens from next-generation sequencing data. <i>Genome Medicine</i> , 2019, 11, 67.	3.6	53
1522	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. <i>Cancer Cell</i> , 2019, 36, 597-612.e8.	7.7	100
1523	Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1079-1088.	1.5	15
1524	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
1525	Immunogenomics of Colorectal Tumors: Facts and Hypotheses on an Evolving Saga. <i>Trends in Cancer</i> , 2019, 5, 779-788.	3.8	22
1526	New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?. <i>Annals of Translational Medicine</i> , 2019, 7, S135-S135.	0.7	13
1527	Immunotherapy in head and neck cancer: The great challenge of patient selection. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 144, 102829.	2.0	14
1529	Comprehensive Outline of Whole Exome Sequencing Data Analysis Tools Available in Clinical Oncology. <i>Cancers</i> , 2019, 11, 1725.	1.7	27
1531	Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas. <i>Neuropathology</i> , 2019, 39, 413-424.	0.7	14
1532	Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab. <i>Journal of Thoracic Disease</i> , 2019, 11, 3757-3768.	0.6	29
1533	An agonistic anti-Toll-like receptor 4 monoclonal antibody as an effective adjuvant for cancer immunotherapy. <i>Immunology</i> , 2019, 158, 136-149.	2.0	10
1534	The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T Cell Repertoire. <i>Photochemistry and Photobiology</i> , 2019, 95, 1288-1305.	1.3	96
1535	Machine Learning for Cancer Immunotherapies Based on Epitope Recognition by T Cell Receptors. <i>Frontiers in Genetics</i> , 2019, 10, 1141.	1.1	34
1536	DeepHLApan: A Deep Learning Approach for Neoantigen Prediction Considering Both HLA-Peptide Binding and Immunogenicity. <i>Frontiers in Immunology</i> , 2019, 10, 2559.	2.2	84
1537	Prostate cancer: any room left for immunotherapies?. <i>Immunotherapy</i> , 2019, 11, 69-74.	1.0	14

#	ARTICLE	IF	CITATIONS
1538	Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value. <i>Oncologist</i> , 2019, 24, e1055-e1069.	1.9	36
1539	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1832.	2.2	73
1540	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
1541	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
1542	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	3.2	58
1543	Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6023-6032.	1.0	25
1545	Neoantigen vaccine: an emerging tumor immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 128.	7.9	398
1546	Exploring the Pathological Mechanism of Bladder Cancer Based on Tumor Mutational Burden Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-9.	0.9	9
1547	Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4251.	1.8	29
1548	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
1549	The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers. <i>Cancer Treatment Reviews</i> , 2019, 79, 101887.	3.4	49
1550	Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. <i>European Journal of Cancer</i> , 2019, 120, 65-74.	1.3	33
1551	Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. <i>Molecules</i> , 2019, 24, 3214.	1.7	106
1552	Toward in silico Identification of Tumor Neoantigens in Immunotherapy. <i>Trends in Molecular Medicine</i> , 2019, 25, 980-992.	3.5	36
1553	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019, 11, 1325.	1.7	7
1554	UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. <i>Cell</i> , 2019, 179, 219-235.e21.	13.5	270
1555	Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy. <i>Cancer Immunology Research</i> , 2019, 7, 1824-1836.	1.6	40
1556	Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. , 2019, 7, 249.		61

#	ARTICLE	IF	CITATIONS
1557	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.2	2
1558	The potential combinational immunotherapies for treatment of hepatocellular carcinoma. <i>Journal of Interventional Medicine</i> , 2019, 2, 47-51.	0.2	3
1559	Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 189-196.	1.8	3
1560	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	5.6	80
1561	Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 59-68.	0.4	15
1562	VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models. <i>Neoplasia</i> , 2019, 21, 1036-1050.	2.3	17
1563	Suppression of tumor antigen presentation during aneuploid tumor evolution contributes to immune evasion. <i>Onc Immunology</i> , 2019, 8, 1657374.	2.1	36
1564	A video-based, flipped classroom, simulation curriculum for dermatologic surgery: A prospective, multi-institution study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1271-1276.	0.6	35
1565	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	0.6	394
1566	Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7413-7423.	3.2	211
1567	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	1.6	50
1568	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1935-1947.	0.5	69
1569	Matched Whole-Genome Sequencing (WGS) and Whole-Exome Sequencing (WES) of Tumor Tissue with Circulating Tumor DNA (ctDNA) Analysis: Complementary Modalities in Clinical Practice. <i>Cancers</i> , 2019, 11, 1399.	1.7	27
1570	Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1807-1817.	0.5	27
1571	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2019, 30, 1902-1913.	0.6	144
1572	Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in <i>MLH1</i> <sup>-/-</sup> Mice. <i>Cancers</i> , 2019, 11, 1485.	1.7	7
1573	High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma. <i>Journal of Immunology</i> , 2019, 203, 2577-2587.	0.4	21
1574	Double Immune Checkpoint Blockade in Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2019, 3, 163-170.	0.2	1

#	ARTICLE	IF	CITATIONS
1575	Complete and Prolonged Response to Immune Checkpoint Blockade in <i>POLE</i> -Mutated Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-5.	1.5	20
1576	&lt;p&gt;Review and perspective on adjuvant and neoadjuvant immunotherapies in NSCLC&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 7329-7336.	1.0	19
1577	Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?. <i>Clinical Cancer Research</i> , 2019, 25, 3210-3219.	3.2	35
1578	Implementing TMB measurement in clinical practice: considerations on assay requirements. <i>ESMO Open</i> , 2019, 4, e000442.	2.0	257
1579	Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 14.	1.3	33
1580	OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy. <i>Journal of Leukocyte Biology</i> , 2019, 105, 915-933.	1.5	22
1581	Regulatory T cells in cancer immunosuppression â€” implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	12.5	872
1582	Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma. <i>Cancer Research</i> , 2019, 79, 1113-1123.	0.4	45
1583	Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2640-2645.	3.3	22
1584	Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas. <i>Scientific Reports</i> , 2019, 9, 358.	1.6	33
1585	&lt;p&gt;Efficacy and safety of nivolumab for metastatic biliary tract cancer&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 861-867.	1.0	31
1586	The innate immune architecture of lung tumors and its implication in disease progression. <i>Journal of Pathology</i> , 2019, 247, 589-605.	2.1	32
1587	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. <i>Frontiers of Medicine</i> , 2019, 13, 32-44.	1.5	25
1588	Role of Biomarkers in Prediction of Response to Therapeutics in Metastatic Renal-Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e454-e460.	0.9	14
1589	Immunotherapy for genitourinary tumors. <i>International Journal of Urology</i> , 2019, 26, 326-333.	0.5	8
1590	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
1591	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. <i>Nano Today</i> , 2019, 27, 28-47.	6.2	34
1592	High tumor mutation burden predicts better efficacy of immunotherapy: a pooled analysis of 103078 cancer patients. <i>Oncoimmunology</i> , 2019, 8, e1629258.	2.1	96



#	ARTICLE	IF	CITATIONS
1593	Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 1336.	2.2	57
1594	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. <i>American Journal of Transplantation</i> , 2019, 19, 3223-3232.	2.6	31
1595	Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. <i>Genome Medicine</i> , 2019, 11, 40.	3.6	179
1596	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. , 2019, 7, 156.		65
1597	Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. <i>Cancers</i> , 2019, 11, 846.	1.7	66
1598	Prospects for a personalized peptide vaccine against lung cancer. <i>Expert Review of Vaccines</i> , 2019, 18, 703-709.	2.0	9
1599	Determinants for Neoantigen Identification. <i>Frontiers in Immunology</i> , 2019, 10, 1392.	2.2	99
1600	Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15R $\alpha$ Complexes Enhances Tumor Control. <i>Cancer Immunology Research</i> , 2019, 7, 1371-1380.	1.6	45
1601	Checkpoint inhibitors in pancreatic cancer. <i>Cancer Treatment Reviews</i> , 2019, 78, 17-30.	3.4	146
1602	Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades. <i>Frontiers in Immunology</i> , 2019, 10, 1113.	2.2	128
1603	Evaluation of the efficacy of immunotherapy for non-resectable mucosal melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1171-1178.	2.0	48
1604	Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group. <i>European Journal of Cancer</i> , 2019, 116, 67-76.	1.3	58
1605	The 100 top-cited studies in cancer immunotherapy. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 2282-2292.	1.9	26
1606	Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2352-2358.e3.	0.3	23
1607	Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers. <i>Methods in Molecular Biology</i> , 2019, 1999, 3-29.	0.4	3
1608	Multilayered Heterogeneity of Glioblastoma Stem Cells: Biological and Clinical Significance. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1139, 1-21.	0.8	14
1610	&lt;p&gt;High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2987-2995.	0.9	28
1611	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019, 20, 835-851.	7.0	277

#	ARTICLE	IF	CITATIONS
1612	Colorectal cancer: A paradigmatic model for cancer immunology and immunotherapy. <i>Molecular Aspects of Medicine</i> , 2019, 69, 123-129.	2.7	30
1613	Deciphering Mechanisms of UVR-Induced Tumoral Immune Checkpoint Regulation against Melanoma. <i>Cancer Research</i> , 2019, 79, 2805-2807.	0.4	2
1614	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 589-601.	1.1	8
1615	β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. <i>Cancer Discovery</i> , 2019, 9, 1124-1141.	7.7	498
1616	Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay. <i>Oncologist</i> , 2019, 24, e1401-e1408.	1.9	9
1618	Induction of anti-cancer T cell immunity by in situ vaccination using systemically administered nanomedicines. <i>Cancer Letters</i> , 2019, 459, 192-203.	3.2	23
1619	Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2019, 2019, 1-10.	0.6	7
1620	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
1621	Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e126-e140.	1.8	28
1622	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 305-343.	157.7	203
1623	New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. <i>Cancers</i> , 2019, 11, 694.	1.7	23
1624	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
1625	Somatic mutations render human exome and pathogen DNA more similar. <i>PLoS ONE</i> , 2019, 14, e0197949.	1.1	0
1626	Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1061-1068.	1.0	26
1627	Tumor genomic alterations in severe-combined immunodeficiency bare-lymphocyte syndrome genes are associated with high mutational burden and disproportional neo-antigen rates. , 2019, 7, 123.		2
1628	Nivolumab plus ipilimumab in non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2287-2302.	1.1	42
1629	The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes. <i>Targeted Oncology</i> , 2019, 14, 247-252.	1.7	17
1630	Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 810.e1-810.e5.	0.8	3

#	ARTICLE	IF	CITATIONS
1631	Translation of cancer immunotherapy from the bench to the bedside. <i>Advances in Cancer Research</i> , 2019, 143, 1-62.	1.9	28
1632	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. <i>Cancer Letters</i> , 2019, 457, 74-85.	3.2	15
1633	Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma. <i>Journal of Oncology</i> , 2019, 2019, 1-7.	0.6	34
1634	The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. <i>OncImmunity</i> , 2019, 8, 1608132.	2.1	37
1635	&lt;p&gt;Assessment of tumor mutation burden calculation from gene panel sequencing data&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 3401-3409.	1.0	38
1636	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1021-1031.	0.5	79
1637	Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. <i>Cancer Immunology Research</i> , 2019, 7, 1148-1161.	1.6	56
1638	Balancing sensitivity and specificity in distinguishing TCR groups by CDR sequence similarity. <i>BMC Bioinformatics</i> , 2019, 20, 241.	1.2	18
1639	PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 193.	3.5	61
1640	Patients Selection for Immunotherapy in Solid Tumors: Overcome the NaÃ“ve Vision of a Single Biomarker. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	37
1641	Portrait of a cancer: mutational signature analyses for cancer diagnostics. <i>BMC Cancer</i> , 2019, 19, 457.	1.1	84
1642	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
1643	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80
1644	Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma. <i>Scientific Reports</i> , 2019, 9, 7449.	1.6	43
1645	The Discovery of Biomarkers in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 484-497.	1.9	31
1646	The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival. <i>Communications Biology</i> , 2019, 2, 135.	2.0	49
1647	Cancer stem cell immunology and immunotherapy: Harnessing the immune system against cancer's source. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 119-188.	0.9	32
1648	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 509-515.	1.4	16

#	ARTICLE	IF	CITATIONS
1649	PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. <i>Frontiers in Oncology</i> , 2019, 9, 343.	1.3	47
1650	Immunogenic neoantigens derived from gene fusions stimulate T cell responses. <i>Nature Medicine</i> , 2019, 25, 767-775.	15.2	282
1651	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
1652	Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response. <i>Science</i> , 2019, 364, 485-491.	6.0	395
1653	Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma. <i>Genome Medicine</i> , 2019, 11, 28.	3.6	107
1654	Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors. <i>Pathology Research and Practice</i> , 2019, 215, 152395.	1.0	21
1655	Immune checkpoint inhibition for the treatment of mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 697-706.	1.4	18
1656	Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541984637.	0.8	48
1657	Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy. <i>Journal of Translational Medicine</i> , 2019, 17, 131.	1.8	17
1658	Immune-phenotyping of pleomorphic dermal sarcomas suggests this entity as a potential candidate for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 973-982.	2.0	21
1659	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. <i>Cancer Science</i> , 2019, 110, 1480-1490.	1.7	238
1660	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. , 2019, 7, 104.		43
1661	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
1662	Cancer nanomedicine for combination cancer immunotherapy. <i>Nature Reviews Materials</i> , 2019, 4, 398-414.	23.3	658
1663	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
1664	Burden of unique and low prevalence somatic mutations correlates with cancer survival. <i>Scientific Reports</i> , 2019, 9, 4848.	1.6	49
1665	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
1666	Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 435-443.	1.9	8

#	ARTICLE	IF	CITATIONS
1667	Antigen Targets for the Development of Immunotherapies in Leukemia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1397.	1.8	10
1668	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
1669	Genomic correlates of response to immune checkpoint blockade. <i>Nature Medicine</i> , 2019, 25, 389-402.	15.2	346
1670	The neoepitope landscape of breast cancer: implications for immunotherapy. <i>BMC Cancer</i> , 2019, 19, 200.	1.1	68
1671	Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). <i>Lung Cancer</i> , 2019, 130, 179-186.	0.9	31
1672	Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 81-90.	1.0	25
1673	Mutations in DNA repair genes are associated with increased neoantigen burden and a distinct immunophenotype in lung squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 3235.	1.6	60
1674	Turning “Cold” Into “Hot” Tumors” Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 163.	1.3	85
1675	Palladium based nanoparticles for the treatment of advanced melanoma. <i>Scientific Reports</i> , 2019, 9, 3255.	1.6	18
1676	Immunotherapy: Current Status and Future Perspectives. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1030-1040.	1.1	24
1677	Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. <i>Journal of Immunology</i> , 2019, 202, 2806-2816.	0.4	22
1678	Microsatellite instability in endometrial cancer: New purpose for an old test. <i>Cancer</i> , 2019, 125, 2154-2163.	2.0	23
1679	Precision therapy in advanced urothelial cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 81-93.	0.4	4
1680	How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, 884-896.	0.6	78
1681	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	3.9	151
1682	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
1683	RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. <i>EBioMedicine</i> , 2019, 41, 146-155.	2.7	31
1684	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32

#	ARTICLE	IF	CITATIONS
1685	Host tissue determinants of tumour immunity. <i>Nature Reviews Cancer</i> , 2019, 19, 215-227.	12.8	150
1686	FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab. , 2019, 7, 23.		20
1687	Intratumor genetic heterogeneity in squamous cell carcinoma of the oral cavity. <i>Head and Neck</i> , 2019, 41, 2514-2524.	0.9	22
1688	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
1689	Finally, after decades, immune checkpoint inhibitors dethroned the standard of care of small-cell lung cancer. <i>Immunotherapy</i> , 2019, 11, 457-460.	1.0	5
1690	Next generation sequencing and anti-cancer therapy. <i>Journal of the Korean Medical Association</i> , 2019, 62, 119.	0.1	4
1691	Identification of a neoantigen epitope in a melanoma patient with good response to anti-PD-1 antibody therapy. <i>Immunology Letters</i> , 2019, 208, 52-59.	1.1	13
1692	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 784-796.	1.6	141
1693	Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 146.	3.5	246
1694	Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity. <i>Frontiers in Immunology</i> , 2019, 10, 824.	2.2	29
1695	Quantitative Prediction of the Landscape of T Cell Epitope Immunogenicity in Sequence Space. <i>Frontiers in Immunology</i> , 2019, 10, 827.	2.2	68
1696	Update on systemic therapy for colorectal cancer: biologics take sides. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 9-9.	1.5	22
1697	Current Landscape of Immunotherapy in Breast Cancer. <i>JAMA Oncology</i> , 2019, 5, 1205.	3.4	260
1698	The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients's sex. <i>International Journal of Cancer</i> , 2019, 145, 2840-2849.	2.3	60
1699	Translating insights into tumor evolution to clinical practice: promises and challenges. <i>Genome Medicine</i> , 2019, 11, 20.	3.6	58
1700	Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition. , 2019, 7, 89.		108
1701	Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. , 2019, 7, 87.		60
1702	Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia. <i>Oncotarget</i> , 2019, 10, 869-882.	0.8	25

#	ARTICLE	IF	CITATIONS
1703	Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 333.	2.2	234
1704	Multiple sclerosis outcomes after cancer immunotherapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 1336-1342.	1.2	75
1705	cRGD target liposome delivery system promoted immunogenic cell death through enhanced anticancer potency of a thymidine conjugate under UVA activation as a cancer vaccine. <i>European Journal of Medicinal Chemistry</i> , 2019, 167, 499-509.	2.6	13
1706	Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 154-166.	1.8	15
1707	Immunophenotypes of pancreatic ductal adenocarcinoma: Meta-analysis of transcriptional subtypes. <i>International Journal of Cancer</i> , 2019, 145, 1125-1137.	2.3	30
1708	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. <i>Modern Pathology</i> , 2019, 32, 1053-1064.	2.9	40
1709	Releasing the Immune System Brakes Using siRNAs Enhances Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 176.	1.7	18
1710	Peptide vaccines in early breast cancer. <i>Breast</i> , 2019, 44, 128-134.	0.9	12
1711	A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2925-2934.	3.2	43
1712	Patterns of Genomic Instability in Breast Cancer. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 198-211.	4.0	68
1713	Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment (Review). <i>Oncology Letters</i> , 2019, 17, 2583-2591.	0.8	16
1714	Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 773-785.	2.0	94
1715	Poly-specific neoantigen-targeted cancer vaccines delay patient derived tumor growth. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 78.	3.5	32
1716	Genetic and Environmental Determinants of Immune Response to Cutaneous Melanoma. <i>Cancer Research</i> , 2019, 79, 2684-2696.	0.4	45
1717	Immune targets in the tumor microenvironment treated by radiotherapy. <i>Theranostics</i> , 2019, 9, 1215-1231.	4.6	96
1718	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
1719	Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. <i>Cancer Cell</i> , 2019, 35, 238-255.e6.	7.7	547
1720	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657



#	ARTICLE	IF	CITATIONS
1721	KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. <i>Future Oncology</i> , 2019, 15, 1057-1066.	1.1	132
1722	BRN2 suppresses apoptosis, reprograms DNA damage repair, and is associated with a high somatic mutation burden in melanoma. <i>Genes and Development</i> , 2019, 33, 310-332.	2.7	35
1723	Genome-Wide CRISPR Screening Identifies JAK1 Deficiency as a Mechanism of T-Cell Resistance. <i>Frontiers in Immunology</i> , 2019, 10, 251.	2.2	17
1724	Association of Disease Recurrence With Survival Outcomes in Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck Treated With Multimodality Therapy. <i>JAMA Dermatology</i> , 2019, 155, 442.	2.0	27
1725	Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. <i>JAMA Oncology</i> , 2019, 5, 696.	3.4	380
1726	Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. <i>Nature Immunology</i> , 2019, 20, 326-336.	7.0	1,148
1727	Homologous recombination deficiency in triple negative breast cancer. <i>Breast</i> , 2019, 45, 15-21.	0.9	58
1728	DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. <i>Gastroenterology</i> , 2019, 156, 890-903.	0.6	48
1729	Blood tumor mutational burden: are we ready for clinical implementation?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1906-S1908.	0.6	6
1730	New emerging targets in cancer immunotherapy: the role of neoantigens. <i>ESMO Open</i> , 2019, 4, e000684.	2.0	20
1731	Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 820-828.	1.9	87
1732	Neoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2019, 7, S305-S305.	0.7	2
1733	Latest Immunotherapy Methods in Non-small Cell Lung Cancer Treatment. <i>Juntendo Medical Journal</i> , 2019, 65, 444-450.	0.1	1
1734	Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response. <i>Genome Medicine</i> , 2019, 11, 71.	3.6	78
1735	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display. <i>Frontiers in Immunology</i> , 2019, 10, 2766.	2.2	23
1736	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
1737	Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481988419.	1.4	62
1738	Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1798.	1.7	99

#	ARTICLE	IF	CITATIONS
1739	28 Drug Development in the 21st Century: Monoclonal Antibodies and Immunotherapy. , 2019, , .		0
1740	Cutaneous and Pulmonary Sarcoid-Like Reaction Induced by Nivolumab. Journal of Clinical Rheumatology, 2021, 27, S460-S464.	0.5	7
1741	Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Nonâ€“Small-Cell Lung Cancer. JCO Precision Oncology, 2019, 3, 1-12.	1.5	58
1742	Driving innovation for rare skin cancers: utilizing common tumours and machine learning to predict immune checkpoint inhibitor response. Immuno-Oncology Technology, 2019, 4, 1-7.	0.2	2
1743	Tumour mutational burden: primary versus metastatic tissue creates systematic bias. Immuno-Oncology Technology, 2019, 4, 8-14.	0.2	26
1744	Determination of Mismatch Repair Status in Human Cancer and Its Clinical Significance: Does One Size Fit All?. Advances in Anatomic Pathology, 2019, 26, 270-279.	2.4	29
1745	Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4. Genome Medicine, 2019, 11, 87.	3.6	44
1746	&lt;p&gt;Blocking TGF-Î² Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor&lt;/p&gt;. OncoTargets and Therapy, 2019, Volume 12, 9527-9538.	1.0	93
1747	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 1161.	1.3	96
1748	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine, 2019, 25, 1916-1927.	15.2	541
1749	pMHC Structural Comparisons as a Pivotal Element to Detect and Validate T-Cell Targets for Vaccine Development and Immunotherapyâ€“A New Methodological Proposal. Cells, 2019, 8, 1488.	1.8	3
1750	High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy. Cancers, 2019, 11, 1824.	1.7	36
1751	Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nature Genetics, 2019, 51, 1741-1748.	9.4	59
1752	A view on drug resistance in cancer. Nature, 2019, 575, 299-309.	13.7	1,391
1753	Precision Cancer Trials With Immunomodulatory Agents. Cancer Journal (Sudbury, Mass ), 2019, 25, 287-295.	1.0	3
1754	Melanoma vaccines: clinical status and immune endpoints. Melanoma Research, 2019, 29, 109-118.	0.6	19
1755	Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses. Frontiers in Immunology, 2019, 10, 2799.	2.2	9
1757	Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report. Journal of Immunotherapy, 2019, 42, 274-277.	1.2	9

#	ARTICLE	IF	CITATIONS
1758	Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2019, 42, 251-264.	1.2	13
1759	Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541989002.	0.8	33
1760	Genetic instability as a driver for immune surveillance. , 2019, 7, 345.		9
1761	Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications. <i>Frontiers in Oncology</i> , 2019, 9, 1287.	1.3	22
1762	MHC-II neoantigens shape tumour immunity and response to immunotherapy. <i>Nature</i> , 2019, 574, 696-701.	13.7	563
1763	Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis. <i>Medicine (United States)</i> , 2019, 98, e17832.	0.4	37
1764	The tumor microenvironment in renal cell cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 194-199.	1.1	36
1765	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
1766	Promising Colorectal Cancer Biomarkers for Precision Prevention and Therapy. <i>Cancers</i> , 2019, 11, 1932.	1.7	26
1767	Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 1715-1720.	15.2	194
1768	Innovation in Oncology Drug Development. <i>Journal of Oncology</i> , 2019, 2019, 1-16.	0.6	10
1769	Predicting marker for early progression in unresectable melanoma treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2019, 24, 323-327.	1.0	17
1770	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. <i>Gut</i> , 2019, 68, 159-171.	6.1	246
1771	A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. <i>Molecular Cancer Research</i> , 2019, 17, 109-119.	1.5	28
1772	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
1773	Immune Checkpoints. , 2019, , 19-43.		0
1774	Immune Checkpoint Inhibitors in Gastrointestinal Malignancies. , 2019, , 77-101.		0
1775	Gynecologic Malignancies. , 2019, , 135-155.		0

#	ARTICLE	IF	CITATIONS
1776	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. <i>Journal of Surgical Research</i> , 2019, 236, 209-215.	0.8	24
1777	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
1778	Multicenter experience with large panel next-generation sequencing in patients with advanced solid cancers in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 174-182.	0.6	4
1779	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. <i>Nature Biotechnology</i> , 2019, 37, 55-63.	9.4	203
1780	Ushering in Integrated T Cell Repertoire Profiling in Cancer. <i>Trends in Cancer</i> , 2019, 5, 85-94.	3.8	19
1781	Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 181-192.	1.0	13
1782	A non-functional neoepitope specific CD8 <sup>+</sup> T-cell response induced by tumor derived antigen exposure <i>in vivo</i> . <i>Oncot Immunology</i> , 2019, 8, 1553478.	2.1	16
1783	Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. <i>Dermatologic Surgery</i> , 2019, 45, 1-16.	0.4	20
1784	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
1785	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. <i>Breast Care</i> , 2019, 14, 53-59.	0.8	13
1786	MMP7 sensitivity of mutant ECM proteins: An indicator of melanoma survival rates and T-cell infiltration. <i>Clinical Biochemistry</i> , 2019, 63, 85-91.	0.8	5
1787	Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. <i>Journal of Thoracic Oncology</i> , 2019, 14, 237-244.	0.5	241
1788	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. <i>Cancer Letters</i> , 2019, 442, 279-286.	3.2	34
1789	Genetics of Renal Cell Carcinoma. , 2019, , 39-54.		1
1790	Recent Advances in Anti-cancer Protein/Peptide Delivery. <i>Bioconjugate Chemistry</i> , 2019, 30, 305-324.	1.8	113
1791	Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 171-182.	2.0	93
1792	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
1793	Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K <i>BRAF</i> -Mutant Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 1272-1279.	3.2	57

#	ARTICLE	IF	CITATIONS
1794	Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 458-465.	1.6	43
1795	The evolving clinical landscape for dendritic cell vaccines and cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 75-79.	1.0	20
1796	No Evidence of Microsatellite Instability and Loss of Mismatch-Repair-Protein Expression in Squamous Cell Carcinoma of the Penis. <i>Pathobiology</i> , 2019, 86, 145-151.	1.9	19
1797	Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. <i>Annals of Oncology</i> , 2019, 30, 219-235.	0.6	340
1798	Update on the current revolution in cancer immunotherapy. <i>Immunotherapy</i> , 2019, 11, 15-20.	1.0	12
1799	Promotion of TRAIL/Apo2L-induced apoptosis by low-dose interferon- $\gamma$ in human malignant melanoma cells. <i>Journal of Cellular Physiology</i> , 2019, 234, 13510-13524.	2.0	11
1800	Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools. <i>International Journal of Molecular Sciences</i> , 2019, 20, 151.	1.8	24
1801	It Is a Capital Mistake to Theorize Who to Treat with Checkpoint Inhibitors before One Has Data. <i>Trends in Cancer</i> , 2019, 5, 79-82.	3.8	4
1802	Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. , 2019, 7, 12.		67
1803	Improving cancer-specific outcomes in solid organ transplant recipients: Where to begin?. <i>Cancer</i> , 2019, 125, 838-842.	2.0	3
1804	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
1805	Radiotherapy and immunotherapy: a synergistic effect in cancer care. <i>Medical Journal of Australia</i> , 2019, 210, 47-53.	0.8	53
1806	Somatic mutations and immune checkpoint biomarkers. <i>Respirology</i> , 2019, 24, 215-226.	1.3	9
1807	Correlate tumor mutation burden with immune signatures in human cancers. <i>BMC Immunology</i> , 2019, 20, 4.	0.9	149
1808	The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 175-188.	2.0	25
1809	The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers. <i>Clinical Oncology</i> , 2019, 31, 81-90.	0.6	30
1810	The changing face of treatment for metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 61-70.	1.1	10
1811	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 407-420.	1.4	39

#	ARTICLE	IF	CITATIONS
1812	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. <i>Clinical Cancer Research</i> , 2019, 25, 2116-2126.	3.2	390
1813	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. <i>World Journal of Urology</i> , 2019, 37, 1773-1784.	1.2	22
1814	PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 337-345.	0.5	25
1815	Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma. <i>Journal of Dermatological Science</i> , 2019, 93, 33-40.	1.0	15
1816	Predictive Biomarkers and Targeted Therapies in the Skin. , 2019, , 463-474.		0
1817	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. <i>Blood</i> , 2019, 133, 550-565.	0.6	57
1818	Cancer Neoantigens. <i>Annual Review of Immunology</i> , 2019, 37, 173-200.	9.5	384
1819	Predictive biomarkers of response for immune checkpoint inhibitors in nonâ€“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 106, 144-159.	1.3	164
1820	Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. <i>Journal of Pathology</i> , 2019, 247, 539-551.	2.1	142
1821	Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment. <i>Immunogenetics</i> , 2019, 71, 71-86.	1.2	7
1822	Size matters: Dissecting key parameters for panelâ€“based tumor mutational burden analysis. <i>International Journal of Cancer</i> , 2019, 144, 848-858.	2.3	131
1823	A B cell-derived gene expression signature associates with an immunologically active tumor microenvironment and response to immune checkpoint blockade therapy. <i>Oncolmmunology</i> , 2019, 8, e1513440.	2.1	20
1824	Mechanisms of Resistance to Immune Checkpoint Blockade. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 41-54.	3.3	83
1825	Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Antiâ€“PD-1/PD-L1 Therapy in Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 88-96.e6.	1.1	90
1826	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
1827	HER2 signaling regulates the tumor immune microenvironment and trastuzumab efficacy. <i>Oncolmmunology</i> , 2019, 8, e1512942.	2.1	57
1828	Dendritic cells as cancer therapeutics. <i>Seminars in Cell and Developmental Biology</i> , 2019, 86, 77-88.	2.3	50
1829	Genetic status of KRAS influences Transforming Growth Factor-beta (TGF-Î²) signaling: An insight into Neuropilin-1 (NRP1) mediated tumorigenesis. <i>Seminars in Cancer Biology</i> , 2019, 54, 72-79.	4.3	32

#	ARTICLE	IF	CITATIONS
1830	Phenotypic Clustering of Left Ventricular Diastolic Function Parameters. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1149-1161.	2.3	92
1831	TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class II low cancers. <i>Molecular Immunology</i> , 2019, 113, 43-49.	1.0	36
1832	MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity. <i>Journal of Proteomics</i> , 2019, 191, 48-57.	1.2	11
1833	Bioinformatics for precision oncology. <i>Briefings in Bioinformatics</i> , 2019, 20, 778-788.	3.2	49
1834	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	1.5	33
1835	Effect of COPD on Inflammation, Lymphoid Functions and Progression-Free Survival during First-Line Chemotherapy in Advanced Non-small Cell Lung Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 1117-1128.	0.9	6
1836	A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction. <i>Briefings in Bioinformatics</i> , 2020, 21, 1119-1135.	3.2	127
1837	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
1838	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. <i>Molecular Imaging and Biology</i> , 2020, 22, 47-65.	1.3	4
1839	The Sunbelt Melanoma Trial. <i>Annals of Surgical Oncology</i> , 2020, 27, 28-34.	0.7	20
1840	Response of patients with melanoma to immune checkpoint blockade—insights gleaned from analysis of a new mathematical mechanistic model. <i>Journal of Theoretical Biology</i> , 2020, 485, 110033.	0.8	17
1841	Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 723-733.	5.7	102
1842	Tumour-intrinsic resistance to immune checkpoint blockade. <i>Nature Reviews Immunology</i> , 2020, 20, 25-39.	10.6	856
1843	Nivolumab for the treatment of small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 5-13.	1.0	4
1844	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. <i>Oncologist</i> , 2020, 25, e147-e159.	1.9	220
1845	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
1846	<i>Pathology, Biomarkers, and Molecular Diagnostics</i> . , 2020, , 225-253.e8.		4
1847	<i>neoepiscopes</i> improves neopeptide prediction with multivariant phasing. <i>Bioinformatics</i> , 2020, 36, 713-720.	1.8	23



#	ARTICLE	IF	CITATIONS
1848	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	1.4	47
1849	Dendritic cells in cancer immunology and immunotherapy. <i>Nature Reviews Immunology</i> , 2020, 20, 7-24.	10.6	1,401
1850	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
1851	Physical Plasma Treatment of Eight Human Cancer Cell Lines Demarcates Upregulation of CD112 as a Common Immunomodulatory Response Element. <i>IEEE Transactions on Radiation and Plasma Medical Sciences</i> , 2020, 4, 343-349.	2.7	6
1852	Translating gammadelta ( $\gamma\delta$ ) T cells and their receptors into cancer cell therapies. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 169-184.	21.5	265
1853	The Cancer Immunotherapy Biomarker Testing Landscape. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 706-724.	1.2	57
1854	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	4.3	30
1855	Mutated RAS: Targeting the "Untargetable" with T Cells. <i>Clinical Cancer Research</i> , 2020, 26, 537-544.	3.2	25
1856	Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. <i>Clinical Cancer Research</i> , 2020, 26, 545-551.	3.2	100
1857	Functional analysis of RPS27 mutations and expression in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 466-479.	1.5	14
1858	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
1859	Detection of neoantigen-reactive T cell clones based on the clonal expansion using next-generation sequencing of T cell receptor $\beta$ complementarity-determining region 3. <i>Journal of Immunological Methods</i> , 2020, 476, 112679.	0.6	3
1860	Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients. <i>Clinical and Translational Oncology</i> , 2020, 22, 1390-1398.	1.2	12
1861	Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. <i>Gynecologic Oncology</i> , 2020, 156, 523-529.	0.6	31
1862	Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. <i>Oral Oncology</i> , 2020, 101, 104525.	0.8	39
1863	Ultraviolet radiation and cutaneous melanoma: a historical perspective. <i>Melanoma Research</i> , 2020, 30, 113-125.	0.6	20
1864	Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy. <i>Biomaterials Science</i> , 2020, 8, 1045-1057.	2.6	20
1865	Tumour associated glycans: A route to boost immunotherapy?. <i>Clinica Chimica Acta</i> , 2020, 502, 167-173.	0.5	24

#	ARTICLE	IF	CITATIONS
1866	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
1867	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 1119-1128.	3.3	140
1868	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 450-464.	3.2	62
1869	High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities. <i>Targeted Oncology</i> , 2020, 15, 127-138.	1.7	23
1870	Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models. <i>Clinical and Translational Oncology</i> , 2020, 22, 1094-1104.	1.2	2
1871	Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Nonâ€“Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e151-e163.	1.1	9
1872	Second-line therapies in advanced biliary tract cancers. <i>Lancet Oncology</i> , The, 2020, 21, e29-e41.	5.1	77
1873	Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors. <i>BMC Genomics</i> , 2020, 21, 2.	1.2	124
1875	The double-edged sword of cancer mutations: exploiting neoepitopes for the fight against cancer. <i>Mutagenesis</i> , 2020, 35, 69-78.	1.0	1
1876	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 2908-2920.	3.2	30
1877	Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy. <i>Melanoma Research</i> , 2020, 30, 213-218.	0.6	4
1878	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	3.4	19
1879	An Immune-Stimulatory Helixâ€“Loopâ€“Helix Peptide: Selective Inhibition of CTLA-4â€“B7 Interaction. <i>ACS Chemical Biology</i> , 2020, 15, 360-368.	1.6	16
1880	Immunogenomics: steps toward personalized medicines. , 2020, , 73-90.		0
1881	Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies to further improve survival. <i>Autoimmunity Reviews</i> , 2020, 19, 102456.	2.5	12
1882	A scoring system for the electrostatic complementarities of Tâ€“cell receptors and cancerâ€“mutant amino acids: multiâ€“cancer analyses of associated survival rates. <i>Immunology</i> , 2020, 159, 373-383.	2.0	23
1883	Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma. <i>Current Opinion in Oncology</i> , 2020, 32, 91-97.	1.1	7
1884	Tumor Mutation Burden and Checkpoint Immunotherapy Markers in NUT Midline Carcinoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 495-500.	0.6	16

#	ARTICLE	IF	CITATIONS
1885	Oncogene addiction and tumor mutational burden in non-small cell lung cancer: Clinical significance and limitations. <i>Thoracic Cancer</i> , 2020, 11, 205-215.	0.8	22
1886	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
1887	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
1888	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	8.2	501
1889	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. <i>OncImmunity</i> , 2020, 9, 1684713.	2.1	12
1890	Follicular Lymphoma. , 2020, , .		0
1891	P5 eHealth: An Agenda for the Health Technologies of the Future. , 2020, , .		21
1892	Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 39.	1.0	22
1893	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
1894	Extracellular Vesicles as Biomarkers in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 2825.	1.7	66
1895	The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients. <i>Life</i> , 2020, 10, 219.	1.1	11
1896	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. <i>Nature Medicine</i> , 2020, 26, 1865-1877.	15.2	62
1897	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. <i>AAPS Journal</i> , 2020, 22, 132.	2.2	27
1898	Challenges and Opportunities for Pancreatic Cancer Immunotherapy. <i>Cancer Cell</i> , 2020, 38, 788-802.	7.7	273
1900	The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1231-1245.	0.6	13
1901	Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17687.	1.6	14
1902	Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis. <i>International Immunopharmacology</i> , 2020, 89, 107090.	1.7	12
1903	An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer. <i>Life Sciences</i> , 2020, 261, 118368.	2.0	8

#	ARTICLE	IF	CITATIONS
1904	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	1.4	3
1905	A Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7304.	1.8	11
1906	CTNNB1 mutation suppresses infiltration of immune cells in hepatocellular carcinoma through miRNA-mediated regulation of chemokine expression. <i>International Immunopharmacology</i> , 2020, 89, 107043.	1.7	18
1907	The Resistance Mechanisms of Lung Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 568059.	1.3	47
1908	Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high-risk human papillomavirus cervical carcinomas. <i>Cancer Medicine</i> , 2020, 9, 8243-8257.	1.3	4
1909	Synthesis, characterization, and fungicidal activity of novel Fangchinoline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115778.	1.4	6
1910	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
1911	Immunotherapy for Metastatic Prostate Cancer: Current and Emerging Treatment Options. <i>Urologic Clinics of North America</i> , 2020, 47, 487-510.	0.8	10
1912	Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. <i>British Journal of Cancer</i> , 2020, 123, 1253-1261.	2.9	59
1913	Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. <i>Scientific Reports</i> , 2020, 10, 11387.	1.6	33
1914	T cell receptor therapy against melanoma—Immunotherapy for the future?. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12927.	1.3	8
1915	Characterization of Neoantigen Load Subgroups in Gynecologic and Breast Cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 702.	2.0	8
1916	Baseline Frequency of Inflammatory Cxcl9-Expressing Tumor-Associated Macrophages Predicts Response to Avelumab Treatment. <i>Cell Reports</i> , 2020, 32, 107873.	2.9	42
1917	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	127
1918	Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. <i>Drug Resistance Updates</i> , 2020, 53, 100718.	6.5	103
1919	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
1920	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
1921	Cross-species oncogenic signatures of breast cancer in canine mammary tumors. <i>Nature Communications</i> , 2020, 11, 3616.	5.8	58

#	ARTICLE	IF	CITATIONS
1922	Aberrantly expressed HORMAD1 disrupts nuclear localization of MCM8â€“MCM9 complex and compromises DNA mismatch repair in cancer cells. <i>Cell Death and Disease</i> , 2020, 11, 519.	2.7	25
1923	Tumor mutational burden is not predictive of cytotoxic chemotherapy response. <i>Oncolimmunology</i> , 2020, 9, 1781997.	2.1	8
1924	Predicting Cross-Reactivity and Antigen Specificity of T Cell Receptors. <i>Frontiers in Immunology</i> , 2020, 11, 565096.	2.2	45
1925	Towards a Systems Immunology Approach to Unravel Responses to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 582744.	2.2	9
1926	Association between tumor mutation burden and immune infiltration in ovarian cancer. <i>International Immunopharmacology</i> , 2020, 89, 107126.	1.7	26
1927	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
1928	Aspirin and risk of different cancers: an umbrella meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1333-1333.	0.7	3
1929	Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 602328.	1.6	30
1930	Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. <i>Nature Cancer</i> , 2020, 1, 1188-1203.	5.7	114
1931	Somatic mutational landscapes of adherens junctions and their functional consequences in cutaneous melanoma development. <i>Theranostics</i> , 2020, 10, 12026-12043.	4.6	4
1932	Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade. <i>Immunity</i> , 2020, 53, 1215-1229.e8.	6.6	131
1933	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	5.7	22
1934	The Neoantigen Landscape of Mycosis Fungoides. <i>Frontiers in Immunology</i> , 2020, 11, 561234.	2.2	6
1935	Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival. <i>Frontiers in Oncology</i> , 2020, 10, 571545.	1.3	12
1936	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12
1937	Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. <i>Nature Communications</i> , 2020, 11, 5992.	5.8	87
1938	Integrated molecular drivers coordinate biological and clinical states in melanoma. <i>Nature Genetics</i> , 2020, 52, 1373-1383.	9.4	36
1939	The evolving landscape of predictive biomarkers in immunoâ€“oncology with a focus on spatial technologies. <i>Clinical and Translational Immunology</i> , 2020, 9, e1215.	1.7	23

#	ARTICLE	IF	CITATIONS
1940	Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors. <i>Cell</i> , 2020, 183, 1634-1649.e17.	13.5	103
1941	Comprehensive Evaluation of Immune-Checkpoint DNA Cancer Vaccines in a Rat Cholangiocarcinoma Model. <i>Vaccines</i> , 2020, 8, 703.	2.1	8
1942	A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2020, 10, 20575.	1.6	10
1943	Immune Checkpoint Blockade Therapy for Hepatocellular Carcinoma: Clinical Challenges and Considerations. <i>Frontiers in Oncology</i> , 2020, 10, 590058.	1.3	5
1944	Immune checkpoints and their inhibitors: Reappraisal of a novel diagnostic and therapeutic dimension in the urologic malignancies. <i>Seminars in Oncology</i> , 2020, 47, 367-379.	0.8	6
1945	Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 602705.	1.3	20
1946	Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers. <i>Innovation(China)</i> , 2020, 1, 100041.	5.2	31
1947	The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?. <i>Molecular Cancer</i> , 2020, 19, 170.	7.9	32
1948	RNA sequencing: new technologies and applications in cancer research. <i>Journal of Hematology and Oncology</i> , 2020, 13, 166.	6.9	229
1949	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
1950	Breast Cancer Heterogeneity and Response to Novel Therapeutics. <i>Cancers</i> , 2020, 12, 3271.	1.7	40
1951	Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. <i>International Journal of Medical Sciences</i> , 2020, 17, 3200-3213.	1.1	18
1952	Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. <i>Frontiers in Oncology</i> , 2020, 10, 1206.	1.3	21
1953	Antitumour dendritic cell vaccination in a priming and boosting approach. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 635-652.	21.5	148
1954	Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. <i>Nature Cancer</i> , 2020, 1, 873-881.	5.7	253
1955	Discovery through clinical sequencing in oncology. <i>Nature Cancer</i> , 2020, 1, 774-783.	5.7	29
1956	Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer. <i>Cancer Cell International</i> , 2020, 20, 373.	1.8	52
1957	CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 1620.	2.2	44

#	ARTICLE	IF	CITATIONS
1958	Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer. <i>Targeted Oncology</i> , 2020, 15, 523-530.	1.7	7
1959	Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5990-6002.	3.2	28
1960	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 242-257.	0.4	8
1961	PD-L1 Expression Affects Neoantigen Presentation. <i>IScience</i> , 2020, 23, 101238.	1.9	9
1962	A novel predictive model incorporating immune-related gene signatures for overall survival in melanoma patients. <i>Scientific Reports</i> , 2020, 10, 12462.	1.6	16
1963	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28
1964	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	5.8	61
1965	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	3.4	61
1966	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
1967	Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1303-1307.	1.2	26
1968	Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5484.	1.8	36
1969	Advanced Non-Small Cell Lung Cancer Patients With Low Tumor Mutation Burden Might Derive Benefit From Immunotherapy. <i>Journal of Immunotherapy</i> , 2020, 43, 189-195.	1.2	14
1970	Intracellular signaling modules linking DNA damage to secretome changes in senescent melanoma cells. <i>Melanoma Research</i> , 2020, 30, 336-347.	0.6	6
1971	The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China. <i>Experimental Hematology and Oncology</i> , 2020, 9, 17.	2.0	21
1972	Circulating Cell-Free Nucleic Acids as Epigenetic Biomarkers in Precision Medicine. <i>Frontiers in Genetics</i> , 2020, 11, 844.	1.1	32
1973	Targeting the immune milieu in gastrointestinal cancers. <i>Journal of Gastroenterology</i> , 2020, 55, 909-926.	2.3	7
1974	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
1975	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	0.9	99



#	ARTICLE	IF	CITATIONS
1976	Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab. Journal of International Medical Research, 2020, 48, 030006052093749.	0.4	3
1977	Immune Cytolytic Activity as an Indicator of Immune Checkpoint Inhibitors Treatment for Prostate Cancer. Frontiers in Bioengineering and Biotechnology, 2020, 8, 930.	2.0	17
1978	Genomic Profiling Comparison of Germline BRCA and Non-BRCA Carriers Reveals CCNE1 Amplification as a Risk Factor for Non-BRCA Carriers in Patients With Triple-Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 583314.	1.3	7
1979	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. Genome Biology, 2020, 21, 263.	3.8	15
1980	Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy. Journal of the Royal Society Interface, 2020, 17, 20200736.	1.5	13
1981	Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Scientific Reports, 2020, 10, 18336.	1.6	6
1982	Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 2020, 8, 615.	2.1	59
1983	Mutation position is an important determinant for predicting cancer neoantigens. Journal of Experimental Medicine, 2020, 217, .	4.2	73
1984	Pervasive chromosomal instability and karyotype order in tumour evolution. Nature, 2020, 587, 126-132.	13.7	221
1985	Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 6350-6361.	3.2	35
1986	Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding Predictions. Journal of Immunology, 2020, 205, 1962-1977.	0.4	7
1987	Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility â€” a prospective, translational study. Molecular Oncology, 2020, 14, 2727-2743.	2.1	14
1988	Current advances in the diagnosis and personalized treatment of breast cancer: lessons from tumor biology. Personalized Medicine, 2020, 17, 399-420.	0.8	7
1989	Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma. Cancer Medicine, 2020, 9, 8498-8518.	1.3	24
1990	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1874, 188420.	3.3	34
1992	Association of <i>MUC16</i> Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors. JAMA Network Open, 2020, 3, e2013201.	2.8	54
1993	Duration of immunotherapy in patients with advanced lung adenocarcinoma with negative driver genes: case report and literature review. Thoracic Cancer, 2020, 11, 3001-3006.	0.8	5
1994	The evolving field of Dermatocancerology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDVâ€”UEMS and EORTC Cutaneous Lymphoma Task Force. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2183-2197.	1.3	22

#	ARTICLE	IF	CITATIONS
1995	An update on the immune landscape in lung and head and neck cancers. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 505-517.	157.7	93
1996	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
1997	Somatic POLE exonuclease domain mutations elicit enhanced intratumoral immune responses in stage II colorectal cancer. , 2020, 8, e000881.		22
1998	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22910-22919.	3.3	32
1999	Is There a Role for Immunotherapy in Prostate Cancer?. <i>Cells</i> , 2020, 9, 2051.	1.8	65
2000	A novel scoring method based on RNA-seq immunograms describing individual cancer-immunity interactions. <i>Cancer Science</i> , 2020, 111, 4031-4040.	1.7	32
2001	Integrative genomic analysis of salivary duct carcinoma. <i>Scientific Reports</i> , 2020, 10, 14995.	1.6	12
2002	Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3807-3820.	1.8	16
2003	Cancers from Novel <i>Pole</i> -Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. <i>Cancer Research</i> , 2020, 80, 5606-5618.	0.4	14
2004	Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. <i>Gut Pathogens</i> , 2020, 12, 43.	1.6	43
2005	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020, 12, 1457-1476.	1.0	37
2006	CAR T-Cell Cancer Therapy Targeting Surface Cancer/Testis Antigens. <i>Frontiers in Immunology</i> , 2020, 11, 1568.	2.2	20
2007	Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1644.	1.3	48
2008	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	5.8	46
2009	Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 6453-6463.	3.2	92
2010	Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma. <i>ESMO Open</i> , 2020, 5, e000707.	2.0	3
2011	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. <i>Melanoma Management</i> , 2020, 7, MMT43.	0.1	7
2012	Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients. <i>Cancers</i> , 2020, 12, 2359.	1.7	30

#	ARTICLE	IF	CITATIONS
2013	Identification of an Immune-Related Gene Signature to Improve Prognosis Prediction in Colorectal Cancer Patients. <i>Frontiers in Genetics</i> , 2020, 11, 607009.	1.1	18
2014	Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure. <i>Scientific Reports</i> , 2020, 10, 21530.	1.6	49
2015	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	1.7	12
2016	Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. , 2020, 8, e001849.		40
2017	Neo-Antigen mRNA Vaccines. <i>Vaccines</i> , 2020, 8, 776.	2.1	49
2018	Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 593989.	1.3	20
2019	Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE—an enhanced deconvolution method. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	11
2020	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. <i>Science</i> , 2020, 370, 1328-1334.	6.0	273
2021	Radiation and immunotherapy: emerging mechanisms of synergy. <i>Journal of Thoracic Disease</i> , 2020, 12, 7011-7023.	0.6	28
2022	Acute Cholecystitis Following Ipilimumab and Nivolumab Treatment for Metastatic Melanoma. <i>American Surgeon</i> , 2020, , 000313482096627.	0.4	1
2023	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36
2024	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112
2025	CSF1R and HCST: Novel Candidate Biomarkers Predicting the Response to Immunotherapy in Non-Small Cell Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382097066.	0.8	13
2026	Immune Responses and Antitumor Effect through Delivering to Antigen Presenting Cells by Optimized Conjugates Consisting of CpG-DNA and Antigenic Peptide. <i>Bioconjugate Chemistry</i> , 2020, 31, 2585-2595.	1.8	5
2027	De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. <i>Communications Biology</i> , 2020, 3, 645.	2.0	30
2028	Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies. <i>Breast Care</i> , 2020, 15, 470-480.	0.8	11
2029	PrÄazisionsmedizin bei NSCLC im Zeitalter der Immuntherapie: Neue Biomarker zur Selektion der am besten geeigneten Therapie oder des am besten geeigneten Patienten. <i>Karger Kompass Pneumologie</i> , 2020, 8, 300-317.	0.0	1
2030	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	7.7	388

#	ARTICLE	IF	CITATIONS
2031	Potential predictive value of SCN4A mutation status for immune checkpoint inhibitors in melanoma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 131, 110633.	2.5	6
2032	Diverse Neoantigens and the Development of Cancer Therapies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 113-128.	1.0	15
2033	The influence of tumour mutational burden on renal cancer immune infiltration and survival. <i>Annals of Translational Medicine</i> , 2020, 8, 271-271.	0.7	0
2034	Precision medicine for the diagnosis and treatment of carbapenem-resistant Enterobacterales: time to think from a different perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 721-740.	2.0	12
2035	Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study. , 2020, 8, e000166.		17
2036	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
2037	MHC-I genotype and tumor mutational burden predict response to immunotherapy. <i>Genome Medicine</i> , 2020, 12, 45.	3.6	70
2038	Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. <i>Cancers</i> , 2020, 12, 1125.	1.7	43
2039	Immune Escape Mediated by Exosomal PD-L1 in Cancer. <i>Advanced Biology</i> , 2020, 4, e2000017.	3.0	19
2040	Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28338.	0.8	20
2041	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
2042	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. <i>Diagnostic Pathology</i> , 2020, 15, 50.	0.9	34
2043	Novel tumor mutation score versus tumor mutation burden in predicting survival after immunotherapy in pan-cancer patients from the MSK-IMPACT cohort. <i>Annals of Translational Medicine</i> , 2020, 8, 446-446.	0.7	16
2044	Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer. <i>Facial Plastic Surgery</i> , 2020, 36, 200-210.	0.5	7
2045	Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines. <i>Nature Biomedical Engineering</i> , 2020, 4, 636-648.	11.6	44
2046	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46
2047	Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. <i>Human Pathology</i> , 2020, 100, 15-23.	1.1	27
2048	Promising Immuno-Oncology Options for the Future: Cellular Therapies and Personalized Cancer Vaccines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e253-e258.	1.8	8

#	ARTICLE	IF	CITATIONS
2049	Biomarkers in Precision Cancer Immunotherapy: Promise and Challenges. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e275-e291.	1.8	32
2050	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. PLoS ONE, 2020, 15, e0233260.	1.1	63
2052	Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient. Cellular and Molecular Immunology, 2020, 17, 684-692.	4.8	12
2053	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
2054	Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma. , 2020, 8, e000375.		14
2055	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339
2056	Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. Current Oncology, 2020, 27, 106-114.	0.9	17
2057	Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. Theranostics, 2020, 10, 6399-6410.	4.6	26
2058	Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clinical Cancer Research, 2020, 26, 5120-5128.	3.2	79
2059	PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?. Clinical Cancer Research, 2020, 26, 5287-5296.	3.2	88
2060	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers, 2020, 12, 1502.	1.7	145
2061	A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour. Journal of Pathology, 2020, 252, 22-28.	2.1	2
2062	Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. Lung Cancer, 2020, 146, 36-41.	0.9	12
2063	Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecologic Oncology, 2020, 158, 570-575.	0.6	43
2064	Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma. Nature Cancer, 2020, 1, 635-652.	5.7	26
2065	Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response. Pigment Cell and Melanoma Research, 2020, 33, 878-888.	1.5	5
2066	Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093033.	1.4	25
2067	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. Urologic Clinics of North America, 2020, 47, 293-303.	0.8	25

#	ARTICLE	IF	CITATIONS
2068	IConMHC: a deep learning convolutional neural network model to predict peptide and MHC-I binding affinity. <i>Immunogenetics</i> , 2020, 72, 295-304.	1.2	4
2069	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4122-4130.	0.7	7
2070	Prevalence of <i>PRKDC</i> mutations and association with response to immune checkpoint inhibitors in solid tumors. <i>Molecular Oncology</i> , 2020, 14, 2096-2110.	2.1	21
2071	Clinical significance of tumour mutation burden in immunotherapy across multiple cancer types: an individual meta-analysis. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1023-1031.	0.6	8
2072	Melanoma brain metastases: review of histopathological features and immune-molecular aspects. <i>Melanoma Management</i> , 2020, 7, MMT44.	0.1	8
2073	Endogenous Retrovirus Transcript Levels Are Associated with Immunogenic Signatures in Multiple Metastatic Cancer Types. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1889-1897.	1.9	10
2074	Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4071.	1.8	23
2075	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51
2076	Genomic profiling in renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 435-451.	4.1	99
2077	Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication. <i>Future Oncology</i> , 2020, 16, 1751-1766.	1.1	20
2078	Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. <i>Nature Reviews Urology</i> , 2020, 17, 271-291.	1.9	32
2079	ecTMB: a robust method to estimate and classify tumor mutational burden. <i>Scientific Reports</i> , 2020, 10, 4983.	1.6	17
2080	Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method. <i>Translational Lung Cancer Research</i> , 2020, 9, 71-81.	1.3	9
2081	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
2082	Immune-Based Approaches for the Treatment of Pediatric Malignancies. <i>Annual Review of Cancer Biology</i> , 2020, 4, 353-370.	2.3	7
2083	Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 155.	1.8	32
2084	Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 683-687.	2.0	16
2085	Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. <i>British Journal of Cancer</i> , 2020, 122, 1309-1314.	2.9	77

#	ARTICLE	IF	CITATIONS
2086	Refractory solitary cervical lymph node metastasis after esophageal squamous cell carcinoma surgery and its successful treatment with immune checkpoint inhibitor. <i>Medicine (United States)</i> , 2020, 99, e19440.	0.4	3
2087	Leukemia-induced dysfunctional TIM-3+CD4+ bone marrow T cells increase risk of relapse in pediatric B-precursor ALL patients. <i>Leukemia</i> , 2020, 34, 2607-2620.	3.3	31
2088	Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine. <i>Neuro-Oncology</i> , 2020, 22, 1276-1288.	0.6	51
2089	An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. <i>Cell Death Discovery</i> , 2020, 6, 14.	2.0	18
2090	Primary CNS lymphoma commonly expresses immune response biomarkers. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa018.	0.4	24
2091	Computational methods in tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, 209-259.	0.4	3
2092	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
2093	Pre-existing heterologous T cell immunity and neoantigen immunogenicity. <i>Clinical and Translational Immunology</i> , 2020, 9, e01111.	1.7	26
2094	Immunotherapeutic Potential of TGF- $\beta$ 2 Inhibition and Oncolytic Viruses. <i>Trends in Immunology</i> , 2020, 41, 406-420.	2.9	55
2095	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
2096	Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	108
2097	Inhibition of MICA and MICB Shedding Elicits NK-Cell-Mediated Immunity against Tumors Resistant to Cytotoxic T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 769-780.	1.6	72
2098	Inflammatory Mechanisms of HCC Development. <i>Cancers</i> , 2020, 12, 641.	1.7	114
2099	Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2020, 107, 625-633.	1.5	40
2100	Spontaneous mutations in the single TTN gene represent high tumor mutation burden. <i>Npj Genomic Medicine</i> , 2020, 5, 33.	1.7	71
2101	The Combination Options and Predictive Biomarkers of PD-1/PD-L1 Inhibitors in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 300.	1.3	26
2102	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73
2103	MDM2, MDM4 and EGFR Amplifications and Hyperprogression in Metastatic Acral and Mucosal Melanoma. <i>Cancers</i> , 2020, 12, 540.	1.7	55



#	ARTICLE	IF	CITATIONS
2104	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	1.8	39
2105	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1177-1189.	0.5	81
2106	Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 223.	2.2	54
2107	Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 978-990.	0.6	87
2108	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4579.	1.8	66
2109	Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud. , 2020, 8, e000381.		35
2110	The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 113.	1.6	52
2111	Toward Systems Biomarkers of Response to Immune Checkpoint Blockers. <i>Frontiers in Oncology</i> , 2020, 10, 1027.	1.3	16
2112	Role of DNA repair defects in predicting immunotherapy response. <i>Biomarker Research</i> , 2020, 8, 23.	2.8	47
2113	The Association of <i>MUC16</i> Mutation with Tumor Mutation Burden and Its Prognostic Implications in Cutaneous Melanoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1792-1799.	1.1	15
2114	Tumor Mutational Burden and PD-L1 Expression in Non-Small-Cell Lung Cancer (NSCLC) in Southwestern China. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 5191-5198.	1.0	3
2115	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
2116	Evidence That STK19 Is Not an NRAS-dependent Melanoma Driver. <i>Cell</i> , 2020, 181, 1395-1405.e11.	13.5	13
2117	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
2118	Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis. <i>Clinical Cancer Research</i> , 2020, 26, 4842-4851.	3.2	72
2119	Chromosome Abnormalities: New Insights into Their Clinical Significance in Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 562-570.	2.0	36
2120	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. <i>Clinical and Translational Immunology</i> , 2020, 9, e1145.	1.7	7
2121	Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. <i>Neuro-Oncology</i> , 2020, 22, 1425-1438.	0.6	37

#	ARTICLE	IF	CITATIONS
2122	Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. <i>Annals of Oncology</i> , 2020, 31, 1216-1222.	0.6	128
2123	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. <i>Nature Medicine</i> , 2020, 26, 181-187.	15.2	158
2124	neoANT-HILL: an integrated tool for identification of potential neoantigens. <i>BMC Medical Genomics</i> , 2020, 13, 30.	0.7	6
2125	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. <i>Clinical Cancer Research</i> , 2020, 26, 2859-2870.	3.2	75
2126	Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 24.	2.8	15
2127	Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. <i>Nature Communications</i> , 2020, 11, 896.	5.8	98
2128	Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity. <i>Nature Communications</i> , 2020, 11, 951.	5.8	34
2129	T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies. <i>Frontiers in Immunology</i> , 2020, 11, 276.	2.2	38
2130	Identification of Antigenic Targets. <i>Trends in Cancer</i> , 2020, 6, 299-318.	3.8	6
2131	Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes. <i>Science Immunology</i> , 2020, 5, .	5.6	39
2132	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
2133	Germline Features Associated with Immune Infiltration in Solid Tumors. <i>Cell Reports</i> , 2020, 30, 2900-2908.e4.	2.9	35
2134	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020, 25, 481-487.	1.9	77
2135	Tumor antigens in glioma. <i>Seminars in Immunology</i> , 2020, 47, 101385.	2.7	34
2136	Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies. <i>Cancers</i> , 2020, 12, 392.	1.7	47
2137	miRNAs as Key Players in the Management of Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 415.	1.8	23
2138	Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. <i>Cells</i> , 2020, 9, 417.	1.8	32
2139	Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 93-100.	1.7	27

#	ARTICLE	IF	CITATIONS
2140	Prevalence and mutational determinants of high tumor mutation burden in breast cancer. <i>Annals of Oncology</i> , 2020, 31, 387-394.	0.6	244
2141	Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens. <i>Nature Biotechnology</i> , 2020, 38, 320-332.	9.4	210
2142	Identification of gene expression profiles and immune cell infiltration signatures between low and high tumor mutation burden groups in bladder cancer. <i>International Journal of Medical Sciences</i> , 2020, 17, 89-96.	1.1	37
2143	Molecular analysis of primary melanoma T cells identifies patients at risk for metastatic recurrence. <i>Nature Cancer</i> , 2020, 1, 197-209.	5.7	30
2144	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
2145	Enabling Precision Oncology Through Precision Diagnostics. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 97-121.	9.6	50
2146	Molecular profiling for precision cancer therapies. <i>Genome Medicine</i> , 2020, 12, 8.	3.6	447
2147	Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune-Oncology Therapies: A Tutorial for Clinical Pharmacologists. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 858-870.	2.3	24
2148	Prediction of cancer neoepitopes needs new rules. <i>Seminars in Immunology</i> , 2020, 47, 101387.	2.7	19
2149	Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan. <i>Journal of Dermatology</i> , 2020, 47, 356-362.	0.6	15
2150	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. <i>Cancers</i> , 2020, 12, 230.	1.7	9
2151	Mechanism- and Immune Landscape-Based Ranking of Therapeutic Responsiveness of 22 Major Human Cancers to Next Generation Anti-CTLA-4 Antibodies. <i>Cancers</i> , 2020, 12, 284.	1.7	9
2152	Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment. <i>Diagnostic Pathology</i> , 2020, 15, 6.	0.9	55
2153	Biomarkers for immunotherapy response in head and neck cancer. <i>Cancer Treatment Reviews</i> , 2020, 84, 101977.	3.4	153
2154	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 883-892.	1.2	5
2155	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
2156	Prospects of biological and synthetic pharmacotherapies for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 305-317.	1.4	16
2157	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127

#	ARTICLE	IF	CITATIONS
2158	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
2159	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
2160	Tumor Mutational Burden and <i>PTEN</i> Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2565-2572.	3.2	138
2161	Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 2989.	2.2	86
2162	The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. <i>Cell</i> , 2020, 180, 407-409.	13.5	2
2163	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. <i>Cancer Gene Therapy</i> , 2020, 27, 841-853.	2.2	94
2164	HPV Involvement in the Tumor Microenvironment and Immune Treatment in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2020, 12, 1060.	1.7	40
2165	Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics. <i>Frontiers in Genetics</i> , 2020, 11, 221.	1.1	33
2166	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	3.4	446
2167	Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1441-1450.	1.2	11
2168	Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 402-416.	1.1	16
2169	Advances in theranostic biomarkers for tumor immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2020, 56, 79-90.	2.8	27
2170	Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts. <i>European Journal of Cancer</i> , 2020, 131, 40-50.	1.3	143
2171	Antibodies specific for disease-associated antigens (DAA) expressed in non-malignant diseases reveal potential new tumor-associated antigens (TAA) for immunotherapy or immunoprevention. <i>Seminars in Immunology</i> , 2020, 47, 101394.	2.7	8
2172	Multimodal preclinical platform predicts clinical response of melanoma to immunotherapy. <i>Nature Medicine</i> , 2020, 26, 781-791.	15.2	75
2173	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107
2174	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. , 2020, 8, e000147.		329
2175	<i>PRKDC</i> : new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32

#	ARTICLE	IF	CITATIONS
2176	Lifting the innate immune barriers to antitumor immunity. , 2020, 8, e000695.		50
2177	Beyond Tumor PD-L1: Emerging Genomic Biomarkers for Checkpoint Inhibitor Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e47-e57.	1.8	30
2178	Primary Resistance to PD-1-Based Immunotherapyâ€”A Study in 319 Patients with Stage IV Melanoma. Cancers, 2020, 12, 1027.	1.7	17
2179	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. International Journal of Molecular Sciences, 2020, 21, 2856.	1.8	31
2180	Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration. Journal of Cancer, 2020, 11, 3858-3870.	1.2	22
2181	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chinese Medical Journal, 2020, 133, 853-862.	0.9	21
2182	Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. PLoS ONE, 2020, 15, e0231038.	1.1	3
2183	Enhanced Upconversion Luminescence-Guided Synergistic Antitumor Therapy Based on Photodynamic Therapy and Immune Checkpoint Blockade. Chemistry of Materials, 2020, 32, 4627-4640.	3.2	50
2184	Polyomavirusâ€”Driven Merkel cell carcinoma: Prospects for therapeutic vaccine development. Molecular Carcinogenesis, 2020, 59, 807-821.	1.3	32
2186	PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunology, Immunotherapy, 2020, 69, 1505-1517.	2.0	58
2187	Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Reports, 2020, 31, 107502.	2.9	69
2188	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nature Communications, 2020, 11, 1839.	5.8	15
2189	Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 2020, 11, 1897.	5.8	165
2190	Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic concordance within the cancer genome atlas cohort. , 2020, 8, e000613.		15
2191	Epitherapy and immune checkpoint blockade: using epigenetic reinvigoration of exhausted and dysfunctional T cells to reimburse immunotherapy response. BMC Immunology, 2020, 21, 22.	0.9	14
2192	Reliable Analysis of Clinical Tumor-Only Whole-Exome Sequencing Data. JCO Clinical Cancer Informatics, 2020, 4, 321-335.	1.0	20
2193	Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Medicine, 2020, 12, 33.	3.6	67
2194	Tumor-infiltrating immune cells in hepatocellular carcinoma: Tregs is correlated with poor overall survival. PLoS ONE, 2020, 15, e0231003.	1.1	33

#	ARTICLE	IF	CITATIONS
2195	Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 162.	1.8	21
2196	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations. <i>Frontiers in Immunology</i> , 2020, 11, 373.	2.2	27
2197	The Multifactorial Role of PARP-1 in Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 739.	1.7	31
2198	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. <i>Modern Pathology</i> , 2020, 33, 1910-1921.	2.9	40
2199	Sex-associated molecular differences for cancer immunotherapy. <i>Nature Communications</i> , 2020, 11, 1779.	5.8	144
2200	Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. <i>International Journal of Surgery Oncology</i> , 2017, 2, e43-e43.	0.2	5
2201	Resistance mechanisms to immune checkpoints' blockade by monoclonal antibody drugs in cancer immunotherapy: Focus on myeloma. <i>Journal of Cellular Physiology</i> , 2021, 236, 791-805.	2.0	13
2202	Hot or Not: Tumor Mutational Burden (TMB) as a Biomarker of Immunotherapy Response in Genitourinary Cancers. <i>Urology</i> , 2021, 147, 119-126.	0.5	19
2203	Tumor mutation burden in blood predicts benefit from neoadjuvant chemo/radiotherapy in locally advanced rectal cancer. <i>Genomics</i> , 2021, 113, 957-966.	1.3	11
2204	PD-L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non-small cell lung cancer?. <i>Journal of Gene Medicine</i> , 2021, 23, e3294.	1.4	14
2205	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
2206	Immunotherapy for advanced melanoma: current situation in Japan. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 3-9.	0.6	11
2207	NF2 mutation status and tumor mutational burden correlate with immune cell infiltration in meningiomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 169-176.	2.0	12
2208	Immune responses in genomically simple SWI/SNF-deficient cancers. <i>Cancer</i> , 2021, 127, 172-180.	2.0	7
2209	Classification of gastric cancers based on immunogenomic profiling. <i>Translational Oncology</i> , 2021, 14, 100888.	1.7	4
2210	T cell regeneration after immunological injury. <i>Nature Reviews Immunology</i> , 2021, 21, 277-291.	10.6	99
2211	Trends in the prognosis of metastatic melanoma in the era of targeted therapy and immunotherapy: A single-institution survey in Japan. <i>Journal of Dermatology</i> , 2021, 48, 75-79.	0.6	3
2212	Immunotherapy in non-muscle-invasive bladder cancer: current status and future directions. <i>World Journal of Urology</i> , 2021, 39, 1319-1329.	1.2	30

#	ARTICLE	IF	CITATIONS
2213	Targeting <scp>CTLA</scp>â€”4 in cancer: Is it the ideal companion for <scp>PD</scp>â€”1 blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41.	2.3	23
2214	Understanding tumour cell heterogeneity and its implication for immunotherapy in liver cancer using single-cell analysis. <i>Journal of Hepatology</i> , 2021, 74, 700-715.	1.8	60
2215	Neoantigen prediction in human breast cancer using RNA sequencing data. <i>Cancer Science</i> , 2021, 112, 465-475.	1.7	13
2216	Pathogens: Our Allies against Cancer?. <i>Molecular Therapy</i> , 2021, 29, 10-12.	3.7	9
2217	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. <i>Radiographics</i> , 2021, 41, 120-143.	1.4	27
2218	Predicting immunotherapy response through genomics. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 1-9.	1.5	12
2219	Understanding the tumor microenvironment for effective immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 1474-1498.	5.0	130
2220	Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 111-128.	0.9	5
2221	Clinical application of next generation sequencing in lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 868-873.	0.6	3
2222	State-of-the-art genome inference in the human MHC. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 131, 105882.	1.2	22
2223	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
2224	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	2.0	22
2225	Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?. <i>Clinical Cancer Research</i> , 2021, 27, 1236-1241.	3.2	222
2226	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	1.9	33
2227	Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. <i>Annals of Oncology</i> , 2021, 32, 384-394.	0.6	70
2228	A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 419-427.	0.5	33
2229	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. <i>Nano Today</i> , 2021, 36, 101023.	6.2	45
2230	The Peptide Vaccine of the Future. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100022.	2.5	94



#	ARTICLE	IF	CITATIONS
2231	A New Pipeline to Predict and Confirm Tumor Neoantigens Predict Better Response to Immune Checkpoint Blockade. <i>Molecular Cancer Research</i> , 2021, 19, 498-506.	1.5	8
2232	Pembrolizumab for advanced cervical cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 221-228.	1.1	17
2234	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	3.2	70
2235	A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas. <i>Advances in Therapy</i> , 2021, 38, 707-720.	1.3	5
2236	DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity. <i>Cancer Cell</i> , 2021, 39, 96-108.e6.	7.7	153
2237	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
2238	HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started. <i>International Journal of Immunogenetics</i> , 2021, 48, 193-200.	0.8	11
2239	Recurrent co-occurring alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 641-647.	1.5	7
2240	A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival. <i>British Journal of Cancer</i> , 2021, 124, 760-769.	2.9	13
2241	Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 605-617.	1.5	4
2242	The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 629-640.	1.5	6
2243	Unique TP53 neoantigen and the immune microenvironment in long-term survivors of Hepatocellular carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 667-677.	2.0	34
2244	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. <i>Modern Pathology</i> , 2021, 34, 252-263.	2.9	78
2245	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 133-146.	0.6	3
2246	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
2247	Chimeric antigen receptor T-cell therapy for melanoma. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 209-223.	1.3	12
2248	Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110185.	1.4	9
2249	Luminal A breast cancer resistance mechanisms and emerging treatments. , 2021, , 1-22.		2

#	ARTICLE	IF	CITATIONS
2250	Characterization of CD8 <sup>+</sup> T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions. <i>OncImmunology</i> , 2021, 10, 1870062.	2.1	7
2251	Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy. <i>OncImmunology</i> , 2021, 10, 1868130.	2.1	17
2252	Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges. <i>Journal of the National Cancer Institute</i> , 2021, 113, 823-832.	3.0	31
2253	Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. <i>Cell</i> , 2021, 184, 384-403.e21.	13.5	94
2254	Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 215-229.	12.5	486
2255	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	9.4	139
2256	Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis. <i>In Vivo</i> , 2021, 35, 475-482.	0.6	19
2257	Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4472-4485.	1.9	12
2258	Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing. <i>Annals of Translational Medicine</i> , 2021, 9, 140-140.	0.7	4
2259	Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. <i>OncImmunology</i> , 2021, 10, 1927313.	2.1	27
2260	The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy. <i>Cancers</i> , 2021, 13, 134.	1.7	67
2261	Identification of the Relationships between Tumor Mutation Burden with Immune Infiltrates in Liver Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 2880-2890.	0.0	0
2262	Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. <i>Blood Reviews</i> , 2021, 45, 100709.	2.8	24
2263	Empirical and Rational Design of T Cell Receptor-Based Immunotherapies. <i>Frontiers in Immunology</i> , 2020, 11, 585385.	2.2	19
2264	Systemic Therapy for Locally Advanced and Metastatic Non-Melanoma Skin Cancer. , 2021, , 353-366.		0
2266	T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine. <i>Viruses</i> , 2021, 13, 199.	1.5	21
2267	The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. <i>Cancers</i> , 2021, 13, 210.	1.7	86
2268	Research advance in tumor specific antigens: a narrative review. <i>AME Medical Journal</i> , 0, 6, 35-35.	0.4	3

#	ARTICLE	IF	CITATIONS
2269	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	1.7	20
2270	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. <i>Oncotarget</i> , 2021, 10, 1860586.	2.1	40
2271	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
2272	Microbial Antigen-Presenting Extracellular Vesicles Derived from Genetically Modified Tumor Cells Promote Antitumor Activity of Dendritic Cells. <i>Pharmaceutics</i> , 2021, 13, 57.	2.0	9
2274	Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. <i>BMC Urology</i> , 2021, 21, 29.	0.6	15
2275	Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?. <i>Seminars in Cancer Biology</i> , 2021, 77, 67-82.	4.3	12
2276	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
2277	Melanoma Single-Cell Biology in Experimental and Clinical Settings. <i>Journal of Clinical Medicine</i> , 2021, 10, 506.	1.0	5
2278	Tumor immunogenomic signatures improve a prognostic model of melanoma survival. <i>Journal of Translational Medicine</i> , 2021, 19, 78.	1.8	4
2279	SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance. <i>ELife</i> , 2021, 10, .	2.8	9
2280	m <sup>6</sup> A modification patterns and tumor immune landscape in clear cell renal carcinoma. , 2021, 9, e001646.		42
2281	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
2282	NLR5/CITA expression correlates with efficient response to checkpoint blockade immunotherapy. <i>Scientific Reports</i> , 2021, 11, 3258.	1.6	19
2283	Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2 <sup>-</sup> Breast Cancer Patient With High Tumor Mutational Burden. <i>Frontiers in Oncology</i> , 2020, 10, 588080.	1.3	7
2284	Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 592811.	1.3	10
2285	Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. <i>Cancers</i> , 2021, 13, 813.	1.7	27
2286	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	7.7	103
2287	Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 600506.	1.8	5

#	ARTICLE	IF	CITATIONS
2288	Association of clinico-genomic characteristics with tumor mutational burden in small cell lung cancer patients. <i>Future Oncology</i> , 2021, 17, 423-433.	1.1	2
2289	Combination Therapy with iRGD-antiCD3 and PD-1 Blockade Enhances Antitumor Potency of Cord Blood-Derived T Cells. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 835-844.	1.0	4
2290	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. <i>Cell Reports Medicine</i> , 2021, 2, 100194.	3.3	77
2291	Distinct T cell receptor repertoire diversity of clinically defined high-grade serous ovarian cancer treatment subgroups. <i>IScience</i> , 2021, 24, 102053.	1.9	6
2292	Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2367-2378.	2.0	7
2293	Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	19
2294	Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14.	13.5	485
2295	Potential of circulating immune cells as biomarkers of nivolumab treatment efficacy for advanced hepatocellular carcinoma. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 144-150.	0.6	8
2296	Dynamics of thymus function and T cell receptor repertoire breadth in health and disease. <i>Seminars in Immunopathology</i> , 2021, 43, 119-134.	2.8	29
2297	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
2298	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	6.6	95
2299	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	0.5	1
2300	Personal Neoantigen Vaccines for the Treatment of Cancer. <i>Annual Review of Cancer Biology</i> , 2021, 5, 259-276.	2.3	13
2301	Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 630773.	2.2	22
2302	The microbiome and human cancer. <i>Science</i> , 2021, 371, .	6.0	506
2303	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4
2304	Immunotherapy biomarkers: the long and winding road. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 323-324.	12.5	14
2305	A 10-gene prognostic signature points to LIMCH1 and HLA-DQB1 as important players in aggressive cervical cancer disease. <i>British Journal of Cancer</i> , 2021, 124, 1690-1698.	2.9	15

#	ARTICLE	IF	CITATIONS
2307	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	1.3	5
2308	Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy. <i>IScience</i> , 2021, 24, 102248.	1.9	7
2309	Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 373-386.	2.0	10
2310	Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 1199.	1.7	2
2311	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. <i>Cancers</i> , 2021, 13, 1188.	1.7	27
2312	Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. <i>Frontiers in Immunology</i> , 2021, 12, 655697.	2.2	126
2313	A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma. <i>Communications Biology</i> , 2021, 4, 383.	2.0	20
2314	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. <i>Cancer Treatment Reviews</i> , 2021, 94, 102169.	3.4	14
2315	Tumor mutational burden as a predictor of immunotherapy response in breast cancer. <i>Oncotarget</i> , 2021, 12, 394-400.	0.8	56
2316	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
2317	Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. <i>Nature Reviews Cancer</i> , 2021, 21, 298-312.	12.8	553
2318	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	13.7	187
2319	Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective. <i>Cancer Cell</i> , 2021, 39, 394-406.e4.	7.7	63
2320	Targeting Genome Stability in Melanoma—A New Approach to an Old Field. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3485.	1.8	4
2321	Immunotherapy for pancreatic cancer: chasing the light at the end of the tunnel. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 261-278.	2.1	16
2322	CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors. <i>Cancer Discovery</i> , 2021, 11, 1844-1859.	7.7	37
2323	FAT3 Mutation Is Associated With Tumor Mutation Burden and Poor Prognosis in Esophageal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 603660.	1.3	13
2324	Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2021, 10, 2618-2626.	1.3	2

#	ARTICLE	IF	CITATIONS
2326	Classification of pediatric gliomas based on immunological profiling: Implications for immunotherapy strategies. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 34-47.	2.0	18
2327	Clinical and immunological effects of mRNA vaccines in malignant diseases. <i>Molecular Cancer</i> , 2021, 20, 52.	7.9	90
2328	Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	111
2329	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021, 5, 21.	2.3	12
2330	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29
2331	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
2332	CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1440.	1.7	88
2333	The Clinical Implications of Tumor Mutational Burden in Osteosarcoma. <i>Frontiers in Oncology</i> , 2020, 10, 595527.	1.3	14
2334	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
2335	Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy. <i>Cancers</i> , 2021, 13, 1863.	1.7	6
2338	Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17.	4.3	70
2339	Identification of Prognostic Glycolysis-Related lncRNA Signature in Tumor Immune Microenvironment of Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 645084.	1.6	27
2340	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. <i>PLoS ONE</i> , 2021, 16, e0248097.	1.1	5
2341	Green Propolis Compounds (Baccharin and p-Coumaric Acid) Show Beneficial Effects in Mice for Melanoma Induced by B16f10. <i>Medicines (Basel, Switzerland)</i> , 2021, 8, 20.	0.7	11
2342	Brain Tumor Vaccines. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 225-234.	0.8	4
2343	Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	74
2344	Current Perspectives on the Use of off the Shelf CAR-T/NK Cells for the Treatment of Cancer. <i>Cancers</i> , 2021, 13, 1926.	1.7	17
2345	Construction of an immune-related lncRNA signature with prognostic significance for bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 4326-4339.	1.6	19

#	ARTICLE	IF	CITATIONS
2346	Epigenomics and immunotherapeutic advances in pediatric brain tumors. <i>Npj Precision Oncology</i> , 2021, 5, 34.	2.3	9
2347	Analysis of tumor mutation burden combined with immune infiltrates in endometrial cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 551-551.	0.7	5
2348	Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3837.	1.8	22
2349	Virus-Like Particle-Drug Conjugates Induce Protective, Long-lasting Adaptive Antitumor Immunity in the Absence of Specifically Targeted Tumor Antigens. <i>Cancer Immunology Research</i> , 2021, 9, 693-706.	1.6	18
2350	Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma. <i>Cancers</i> , 2021, 13, 1819.	1.7	16
2351	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
2352	The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 171-180.	0.8	9
2353	Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1639.	1.7	13
2354	In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burden. <i>Cytotherapy</i> , 2021, 23, 320-328.	0.3	8
2355	Panels and models for accurate prediction of tumor mutation burden in tumor samples. <i>Npj Precision Oncology</i> , 2021, 5, 31.	2.3	7
2356	Tumor mutational burden and immune infiltrates in renal cell carcinoma and matched brain metastases. <i>ESMO Open</i> , 2021, 6, 100057.	2.0	13
2357	Is immunotherapy in the future of therapeutic management of sarcomas?. <i>Journal of Translational Medicine</i> , 2021, 19, 173.	1.8	18
2358	Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. <i>Nature Communications</i> , 2021, 12, 2048.	5.8	66
2359	Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN) Tj ETQq1 1 0.784314 rgBT /Overlook 479, 1067-1072.	1.4	4
2360	Towards customized cancer vaccines: a promising field in personalized cancer medicine. <i>Expert Review of Vaccines</i> , 2021, 20, 545-557.	2.0	2
2361	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	0.5	62
2362	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1006.	1.8	45
2363	Addressing resistance to immune checkpoint inhibitor therapy: An urgent unmet need. <i>Future Oncology</i> , 2021, 17, 1401-1439.	1.1	17



#	ARTICLE	IF	CITATIONS
2364	Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. <i>Advances in Therapy</i> , 2021, 38, 2759-2778.	1.3	11
2365	Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 663264.	1.3	19
2366	Identification and validation of viral antigens sharing sequence and structural homology with tumor-associated antigens (TAAs).. , 2021, 9, e002694.		19
2367	Significance of tumor mutation burden and immune infiltration in thymic epithelial tumors. <i>Thoracic Cancer</i> , 2021, 12, 1995-2006.	0.8	10
2368	Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 206-218.	2.1	7
2369	Beneficial autoimmunity improves cancer prognosis. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 591-602.	12.5	63
2370	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
2371	Identification of unanimous immune subtypes for different hormone receptor phenotypes of human breast cancer with potential prognostic significance. <i>International Immunopharmacology</i> , 2021, 94, 107473.	1.7	2
2372	Multi-step screening of neoantigensâ€™™ HLA- and TCR-interfaces improves prediction of survival. <i>Scientific Reports</i> , 2021, 11, 9983.	1.6	4
2373	Challenges in bioinformatics approaches to tumor mutation burden analysis. <i>Oncology Letters</i> , 2021, 22, 555.	0.8	4
2374	Immunotherapy and radiation for high-grade glioma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2537-2570.	0.4	6
2376	Immu-Mela: An open resource for exploring immunotherapy-related multidimensional genomic profiles in melanoma. <i>Journal of Genetics and Genomics</i> , 2021, 48, 361-368.	1.7	3
2377	Immune checkpoint inhibitors in endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103306.	2.0	23
2378	Next-generation sequencing for the management of sarcomas with no known driver mutations. <i>Current Opinion in Oncology</i> , 2021, 33, 315-322.	1.1	13
2379	Casp8 acts through A20 to inhibit PDâ€¹L1 expression: The mechanism and its implication in immunotherapy. <i>Cancer Science</i> , 2021, 112, 2664-2678.	1.7	15
2380	Cytidine Deaminase APOBEC3A Regulates PD-L1 Expression in Cancer Cells in a JNK/c-JUN-Dependent Manner. <i>Molecular Cancer Research</i> , 2021, 19, 1571-1582.	1.5	8
2381	Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 669474.	2.2	124
2382	Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 191-207.	3.0	5

#	ARTICLE	IF	CITATIONS
2383	Identification of Precise Therapeutic Targets and Characteristic Prognostic Genes Based on Immune Gene Characteristics in Uveal Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 666462.	1.8	2
2384	High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.	1.5	20
2385	Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 666624.	1.3	5
2386	Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB harmonization project comparing three NGS panels. , 2021, 9, e001904.		16
2387	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. <i>Frontiers in Immunology</i> , 2021, 12, 663865.	2.2	17
2388	AutoEncoder-Based Computational Framework for Tumor Microenvironment Decomposition and Biomarker Identification in Metastatic Melanoma. <i>Frontiers in Genetics</i> , 2021, 12, 665065.	1.1	0
2389	PD-L1 expression and immune cells in anaplastic carcinoma and poorly differentiated carcinoma of the human thyroid gland: A retrospective study. <i>Oncology Letters</i> , 2021, 22, 553.	0.8	16
2390	Turning tumors from cold to inflamed to improve immunotherapy response. <i>Cancer Treatment Reviews</i> , 2021, 101, 102227.	3.4	42
2391	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
2392	Applications of single-cell and bulk RNA sequencing in onco-immunology. <i>European Journal of Cancer</i> , 2021, 149, 193-210.	1.3	62
2394	Influence of low tumor content on tumor mutational burden estimation by whole-exome sequencing and targeted panel sequencing. <i>Clinical and Translational Medicine</i> , 2021, 11, e415.	1.7	7
2395	Harnessing Genomic Stress for Antitumor Immunity. <i>Antioxidants and Redox Signaling</i> , 2021, 34, 1128-1150.	2.5	5
2396	Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell Omics and Targeted Therapies. <i>Gastroenterology</i> , 2021, 160, 1947-1960.	0.6	42
2397	Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	7.7	179
2398	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	1.7	15
2399	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
2401	Systematic identification of the cancer pathways and molecules related with breast cancer immunogenicity. <i>Medical Oncology</i> , 2021, 38, 79.	1.2	0
2402	Explant Modeling of the Immune Environment of Head and Neck Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 611365.	1.3	6

#	ARTICLE	IF	CITATIONS
2403	PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 79-92.	0.2	2
2404	Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1117-1131.	0.6	7
2405	FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 683419.	1.3	84
2406	The landscape of PD-L1 expression and somatic mutations in hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1132-1140.	0.6	5
2407	Correlation Between the Evolution of Somatic Alterations During Lymphatic Metastasis and Clinical Outcome in Penile Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 641869.	1.3	0
2408	Challenges targeting cancer neoantigens in 2021: a systematic literature review. <i>Expert Review of Vaccines</i> , 2021, 20, 827-837.	2.0	13
2410	Neoantigens elicit T cell responses in breast cancer. <i>Scientific Reports</i> , 2021, 11, 13590.	1.6	17
2412	Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions. <i>Cancers</i> , 2021, 13, 3119.	1.7	69
2413	On-treatment C-reactive protein control could predict response to subsequent anti-PD-1 treatment in metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1500-1505.	1.0	2
2414	Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	62
2415	FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burdenâ€“High Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4685-4689.	3.2	216
2416	Immunogenomics in personalized cancer treatments. <i>Journal of Human Genetics</i> , 2021, 66, 901-907.	1.1	10
2417	Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. <i>Cancer Cell</i> , 2021, 39, 845-865.e7.	7.7	503
2418	Immunotherapy in breast cancer: A clinician's perspective. <i>Journal of the National Cancer Center</i> , 2021, 1, 47-57.	3.0	16
2419	Cancer immunotherapy: itâ€™s time to better predict patientsâ€™ response. <i>British Journal of Cancer</i> , 2021, 125, 927-938.	2.9	63
2420	A synDNA vaccine delivering neoAg collections controls heterogenous, multifocal murine lung and ovarian tumors via robust T cell generation. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 278-287.	2.0	7
2421	Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 690499.	2.2	59
2422	<i>CDKN2A</i> Alterations and Response to Immunotherapy in Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4025-4035.	3.2	51

#	ARTICLE	IF	CITATIONS
2423	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
2424	The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. <i>Frontiers in Immunology</i> , 2021, 12, 694079.	2.2	10
2425	Biomarkers of therapeutic response with immune checkpoint inhibitors. <i>Annals of Translational Medicine</i> , 2021, 9, 1040-1040.	0.7	3
2426	Modern Challenges for Early-Phase Clinical Trial Design and Biomarker Discovery in Metastatic Non-Small-Cell Lung Cancer. <i>Journal of Molecular Pathology</i> , 2021, 2, 207-222.	0.5	0
2427	Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 11427.	1.6	3
2428	Detection of von Hippel-Lindau gene mutation in circulating cell-free DNA for clear cell renal cell carcinoma. <i>Cancer Science</i> , 2021, 112, 3363-3374.	1.7	10
2429	KRAS gene status in gastric signet-ring cell carcinoma patients and acts as biomarker of MEK inhibitor. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 1020-1030.	0.6	1
2430	Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 625-644.	12.5	148
2431	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
2432	Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 981-993.	1.6	22
2433	Screening and Validation of the Hypoxia-Related Signature of Evaluating Tumor Immune Microenvironment and Predicting Prognosis in Gastric Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 705511.	2.2	28
2434	Immunotherapy in endometrial cancer: rationale, practice and perspectives. <i>Biomarker Research</i> , 2021, 9, 49.	2.8	53
2435	Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. <i>Vaccines</i> , 2021, 9, 668.	2.1	32
2436	Polycomb repressive complex 2 mutations predict survival benefit in advanced cancer patients treated with immune checkpoint inhibitors. <i>Immuno-Oncology Technology</i> , 2021, 10, 100035.	0.2	3
2437	The Current Lung Cancer Neoantigen Landscape and Implications for Therapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 922-932.	0.5	19
2438	CD8+ T Cell Exhaustion in Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 715234.	2.2	163
2439	Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma. <i>Future Oncology</i> , 2021, 17, 4115-4129.	1.1	4
2440	Negative trade-off between neoantigen repertoire breadth and the specificity of HLA-I molecules shapes antitumor immunity. <i>Nature Cancer</i> , 2021, 2, 950-961.	5.7	13

#	ARTICLE	IF	CITATIONS
2441	Cut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216
2442	Poor Response to Checkpoint Immunotherapy in Uveal Melanoma Highlights the Persistent Need for Innovative Regional Therapy Approaches to Manage Liver Metastases. <i>Cancers</i> , 2021, 13, 3426.	1.7	10
2444	Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113906.	6.6	20
2445	Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer. <i>BMB Reports</i> , 2021, 54, 386-391.	1.1	4
2446	Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2021, 21, 342.	1.8	27
2447	Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3001-3013.	2.0	17
2448	Next-Generation Sequencing Concordance Analysis of Comprehensive Solid Tumor Profiling between a Centralized Specialty Laboratory and the Decentralized Personal Genome Diagnostics elio Tissue Complete Kitted Solution. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1324-1333.	1.2	9
2449	Programmed Death Ligand 1 Expression and Related Markers in Pleuropulmonary Blastoma. <i>Pediatric and Developmental Pathology</i> , 2021, 24, 523-530.	0.5	3
2450	Neoantigen Controversies. <i>Annual Review of Biomedical Data Science</i> , 2021, 4, 227-253.	2.8	9
2451	The Abscopal Effect in the Era of Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7204.	1.8	22
2452	Unraveling the Wide Spectrum of Melanoma Biomarkers. <i>Diagnostics</i> , 2021, 11, 1341.	1.3	55
2453	TMB or not TMB as a biomarker: That is the question. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103374.	2.0	114
2454	Immunotherapy: New insights in breast cancer treatment. <i>Human Antibodies</i> , 2021, 29, 193-202.	0.6	3
2455	Analysis of Interleukin-1 Signaling Alterations of Colon Adenocarcinoma Identified Implications for Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 665002.	2.2	1
2456	Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study. <i>BMC Cancer</i> , 2021, 21, 823.	1.1	9
2457	Development of neoantigens: from identification in cancer cells to application in cancer vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 941-955.	2.0	11
2458	FOXA1 overexpression suppresses interferon signaling and immune response in cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	48
2459	Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing. , 2021, 9, e002595.		31

#	ARTICLE	IF	CITATIONS
2460	Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. , 2021, 9, e002723.		92
2461	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. BMC Medicine, 2021, 19, 154.	2.3	32
2462	Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update. Italian Journal of Dermatology and Venereology, 2021, 156, 322-330.	0.1	4
2463	Using a Recently Approved Tumor Mutational Burden Biomarker to Stratify Patients for Immunotherapy May Introduce a Sex Bias. JCO Precision Oncology, 2021, 5, 1147-1150.	1.5	4
2464	The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC. Frontiers in Immunology, 2021, 12, 638763.	2.2	23
2465	Clinical and Molecular Correlates of NLRC5 Expression in Patients With Melanoma. Frontiers in Bioengineering and Biotechnology, 2021, 9, 690186.	2.0	4
2466	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports, 2021, 36, 109312.	2.9	13
2467	Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers, 2021, 13, 3394.	1.7	9
2469	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. Nature Communications, 2021, 12, 4172.	5.8	16
2470	Immune checkpoint inhibitor induced colitis: A nationwide population-based study. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101778.	0.7	7
2471	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Current Oncology, 2021, 28, 3227-3239.	0.9	2
2472	Tislelizumab combined with apatinib in the treatment of advanced renal clear cell carcinoma: a case report. Anti-Cancer Drugs, 2022, 33, e834-e839.	0.7	2
2473	Neoantigen-Specific T-Cell Immune Responses: The Paradigm of NPM1-Mutated Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2021, 22, 9159.	1.8	7
2474	Toward personalized treatment approaches for non-small-cell lung cancer. Nature Medicine, 2021, 27, 1345-1356.	15.2	338
2475	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	5.8	54
2476	Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nature Reviews Cancer, 2021, 21, 701-717.	12.8	150
2477	Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer. Frontiers in Immunology, 2021, 12, 724541.	2.2	3
2478	Effect of TTN Mutations on Immune Microenvironment and Efficacy of Immunotherapy in Lung Adenocarcinoma Patients. Frontiers in Oncology, 2021, 11, 725292.	1.3	28

#	ARTICLE	IF	CITATIONS
2479	Anti-PD-1 Immune Checkpoint Blockade for Head and Neck Cancer. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 751-759.	0.5	1
2481	Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients. <i>Oncogene</i> , 2021, 40, 6329-6342.	2.6	8
2483	Mutational burden and immune recognition of gliomas. <i>Current Opinion in Oncology</i> , 2021, 33, 626-634.	1.1	5
2484	No evidence that HLA genotype influences the driver mutations that occur in cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 819-827.	2.0	3
2485	TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213.	1.6	71
2486	Tumor-mutation burden as a marker for immunotherapy of pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .	0.7	1
2487	Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 735170.	2.2	31
2488	Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. <i>Cancers</i> , 2021, 13, 4280.	1.7	16
2489	PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study. <i>Scientific Reports</i> , 2021, 11, 16892.	1.6	4
2490	Immunosuppressive microenvironment in oral cancer: implications for cancer immunotherapy. <i>Exploration of Immunology</i> , 0, , .	1.7	2
2491	The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer. <i>Cancer Cell</i> , 2021, 39, 1342-1360.e14.	7.7	119
2492	VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigensâ€™ Prediction. <i>Vaccines</i> , 2021, 9, 880.	2.1	8
2493	Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T. , 2021, 9, e002931.		18
2494	Correlation between LRP1B Mutations and Tumor Mutation Burden in Gastric Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-6.	0.7	13
2495	Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort Study. <i>Cancers</i> , 2021, 13, 4639.	1.7	9
2496	Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2021, 32, 1127-1136.	0.6	34
2497	ISOTOPE: ISOform-guided prediction of epiTOPEs in cancer. <i>PLoS Computational Biology</i> , 2021, 17, e1009411.	1.5	5
2498	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30



#	ARTICLE	IF	CITATIONS
2499	Efficacy and Safety of Actively Personalized Neoantigen Vaccination in the Management of Newly Diagnosed Glioblastoma: A Systematic Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5209-5220.	0.8	4
2501	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. <i>Cancer Treatment Reviews</i> , 2021, 99, 102239.	3.4	13
2502	Prognostic Role of ceRNA Network in Immune Infiltration of Hepatocellular Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 739975.	1.1	7
2503	Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1195-1207.	1.8	19
2504	Resistance to immunotherapy in human malignancies: Mechanisms, research progresses, challenges, and opportunities. <i>Journal of Cellular Physiology</i> , 2022, 237, 346-372.	2.0	13
2505	Differential Expression of the TLR4 Gene in Pan-Cancer and Its Related Mechanism. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 700661.	1.8	18
2506	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
2507	HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy. <i>Trends in Cancer</i> , 2021, 7, 1089-1101.	3.8	32
2508	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	1.7	8
2509	Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Frontiers in Oncology</i> , 2021, 11, 705614.	1.3	19
2510	The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance. <i>Cancer Research</i> , 2021, 81, 5596-5604.	0.4	11
2511	Genomic Profiling Reveals the Molecular Landscape of Gastrointestinal Tract Cancers in Chinese Patients. <i>Frontiers in Genetics</i> , 2021, 12, 608742.	1.1	5
2512	Identification of tumor microenvironment-associated immunological genes as potent prognostic markers in the cancer genome analysis project HOPE. <i>Molecular and Clinical Oncology</i> , 2021, 15, 232.	0.4	6
2513	Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 757804.	2.2	31
2514	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	13.7	36
2515	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisivanbulin). <i>JCI Insight</i> , 2021, 6, .	2.3	7
2516	Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. <i>Cancer</i> , 2021, 127, 4565-4573.	2.0	24
2517	The spliceosome pathway activity correlates with reduced anti-tumor immunity and immunotherapy response, and unfavorable clinical outcomes in pan-cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5428-5442.	1.9	5

#	ARTICLE	IF	CITATIONS
2518	RNA Sequencing Data for FFPE Tumor Blocks Can Be Used for Robust Estimation of Tumor Mutation Burden in Individual Biosamples. <i>Frontiers in Oncology</i> , 2021, 11, 732644.	1.3	6
2519	An autopsy case study of lymphocytic hypophysitis induced by nivolumab treatment for esophageal malignant melanoma. <i>Pathology International</i> , 2021, 71, 831-836.	0.6	8
2520	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. <i>Nature Communications</i> , 2021, 12, 5606.	5.8	76
2521	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
2522	Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden. <i>Journal of Advanced Research</i> , 2021, 33, 153-165.	4.4	49
2523	Personalized cancer immunotherapy. , 2022, , 399-426.		0
2524	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
2525	Immunoediting and cancer priming. , 2022, , 111-136.		1
2526	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
2527	Nucleic acid biomarker technology for cancer immunotherapy. , 2022, , 331-356.		0
2528	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. <i>Open Journal of Obstetrics and Gynecology</i> , 2021, 11, 146-161.	0.1	2
2529	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
2530	Hypoxia and the phenomenon of immune exclusion. <i>Journal of Translational Medicine</i> , 2021, 19, 9.	1.8	63
2531	PD-L1 "inhibitors in neuroendocrine neoplasia. <i>Medicine (United States)</i> , 2021, 100, e23835.	0.4	7
2532	Targeting metastatic cancer. <i>Nature Medicine</i> , 2021, 27, 34-44.	15.2	447
2533	Biomarkers: Is Tumor Mutational Burden the New Prognostic Grail?. <i>Current Cancer Research</i> , 2021, , 27-54.	0.2	0
2534	Metastatic Urothelial Cancer: a rapidly changing treatment landscape. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	1.4	19
2535	Molecular Biology of Gynaecological Cancers. , 2021, , 577-586.		0

#	ARTICLE	IF	CITATIONS
2536	Autoanticuerpos: una manifestaci3n de los eventos adversos inmunol3gicos de la inmunoterapia en c3ncer. Revista Colombiana De Reumatolog3a, 2021, 29, 3-3.	0.0	0
2537	Interruption of Thymic Activity in Adult Mice Improves Responses to Tumor Immunotherapy. Journal of Immunology, 2021, 206, 978-986.	0.4	2
2538	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	3.2	25
2539	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	3.2	13
2540	High gene expression of estrogen and progesterone receptors is associated with decreased t cell infiltration in patients with NSCLC. Cancer Treatment and Research Communications, 2021, 27, 100317.	0.7	9
2541	CancerSCEM: a database of single-cell expression map across various human cancers. Nucleic Acids Research, 2022, 50, D1147-D1155.	6.5	47
2542	Unleashing the Therapeutic Potential of Dendritic and T Cell Therapies Using RNA Interference. Methods in Molecular Biology, 2020, 2115, 259-280.	0.4	3
2543	Status of Immune Oncology: Challenges and Opportunities. Methods in Molecular Biology, 2020, 2055, 3-21.	0.4	6
2544	Measuring Tumor Mutational Burden Using Whole-Exome Sequencing. Methods in Molecular Biology, 2020, 2055, 63-91.	0.4	6
2545	Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies. Methods in Molecular Biology, 2020, 2055, 93-117.	0.4	4
2546	Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167.	1.8	9
2547	Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. Advances in Experimental Medicine and Biology, 2019, 1168, 9-30.	0.8	114
2548	Role of Next-Generation Sequencing Technologies in Personalized Medicine. , 2020, , 125-154.		13
2550	Overview of Basic Immunology and Clinical Application. Advances in Experimental Medicine and Biology, 2020, 1244, 1-36.	0.8	8
2551	Immunotherapy in Gastrointestinal Malignancies. Advances in Experimental Medicine and Biology, 2020, 1244, 93-106.	0.8	7
2552	Challenges of Immunotherapy. , 2016, , 419-434.		1
2553	Parallel-Tempered Feature Allocation for Large-Scale Tumor Heterogeneity with Deep Sequencing Data. Springer Proceedings in Mathematics and Statistics, 2019, , 233-247.	0.1	1
2554	Hereditary Colorectal Cancer: Immunotherapy Approaches. , 2018, , 385-399.		1

#	ARTICLE	IF	CITATIONS
2555	Antibody Therapies in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 1-67.	0.8	8
2557	Cancer Genomics in Precision Oncology: Applications, Challenges, and Prospects. , 2020, , 453-499.		9
2558	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
2559	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.	0.8	5
2560	Immunotherapy for Lynch Syndrome Patients. , 2020, , 117-122.		1
2561	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	5.8	140
2562	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. <i>Scientific Reports</i> , 2020, 10, 22087.	1.6	21
2563	The T cell differentiation landscape is shaped by tumour mutations in lung cancer. <i>Nature Cancer</i> , 2020, 1, 546-561.	5.7	74
2564	Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. <i>Onc Immunology</i> , 2020, 9, 1684714.	2.1	12
2565	Latency-associated Peptide Identifies Immuno-evasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness. <i>Annals of Surgery</i> , 2022, 275, e163-e173.	2.1	17
2590	Differences in the immunosurveillance pattern associated with DNA mismatch repair status between right-sided and left-sided colorectal cancer. <i>Cancer Science</i> , 2020, 111, 3032-3044.	1.7	19
2591	Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. , 2020, 8, e000200.		99
2592	Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. , 2020, 8, e000319.		67
2593	Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2018, 24, 4820-4833.	3.2	225
2594	Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. <i>JCI Insight</i> , 2018, 3, .	2.3	128
2595	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. <i>JCI Insight</i> , 2018, 3, .	2.3	128
2596	Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer. <i>JCI Insight</i> , 2018, 3, .	2.3	120
2597	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. <i>JCI Insight</i> , 2019, 4, .	2.3	345

#	ARTICLE	IF	CITATIONS
2598	Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight, 2019, 4, .	2.3	104
2599	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight, 2016, 1, e85902.	2.3	179
2600	Lymphocyte activation gene 3 and coronary artery disease. JCI Insight, 2016, 1, e88628.	2.3	32
2601	Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy. JCI Insight, 2017, 2, .	2.3	62
2602	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170
2603	DNA repair defects and implications for immunotherapy. Journal of Clinical Investigation, 2018, 128, 4236-4242.	3.9	59
2604	PARP inhibition enhances tumor cell intrinsic immunity in ERCC1-deficient non-small cell lung cancer. Journal of Clinical Investigation, 2019, 129, 1211-1228.	3.9	222
2605	Endogenous T cells prevent tumor immune escape following adoptive T cell therapy. Journal of Clinical Investigation, 2019, 129, 5400-5410.	3.9	76
2606	Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Journal of Clinical Investigation, 2019, 129, 4992-5004.	3.9	107
2607	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. Journal of Clinical Investigation, 2020, 130, 1595-1607.	3.9	10
2608	Immune profiling of pediatric solid tumors. Journal of Clinical Investigation, 2020, 130, 3391-3402.	3.9	27
2609	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. Journal of Clinical Investigation, 2015, 125, 3377-3383.	3.9	146
2610	Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. Journal of Clinical Investigation, 2016, 126, 2334-2340.	3.9	312
2611	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. Journal of Clinical Investigation, 2018, 128, 1338-1354.	3.9	64
2612	Tumor-infiltrating BRAFV600E-specific CD4+ T cells correlated with complete clinical response in melanoma. Journal of Clinical Investigation, 2018, 128, 1563-1568.	3.9	93
2613	EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Medicine, 2021, 19, 26.	2.3	27
2614	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients. EJNMMI Research, 2020, 10, 150.	1.1	9
2615	Strategies for developing and optimizing cancer vaccines. F1000Research, 2019, 8, 654.	0.8	43

#	ARTICLE	IF	CITATIONS
2616	Recent advances in T-cell engineering for use in immunotherapy. <i>F1000Research</i> , 2016, 5, 2344.	0.8	14
2617	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
2618	Biomarkers for immune therapy in melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2018, 37, 120-126.	1.6	2
2619	High-Accuracy HLA Type Inference from Whole-Genome Sequencing Data Using Population Reference Graphs. <i>PLoS Computational Biology</i> , 2016, 12, e1005151.	1.5	87
2620	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis. <i>PLoS Medicine</i> , 2016, 13, e1002193.	3.9	75
2621	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
2622	Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. <i>PLoS ONE</i> , 2015, 10, e0130518.	1.1	53
2623	Multiplex Identification of Antigen-Specific T Cell Receptors Using a Combination of Immune Assays and Immune Receptor Sequencing. <i>PLoS ONE</i> , 2015, 10, e0141561.	1.1	111
2624	Systematic genomic and translational efficiency studies of uveal melanoma. <i>PLoS ONE</i> , 2017, 12, e0178189.	1.1	34
2625	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0179726.	1.1	216
2626	Biomarkers for Checkpoint Inhibition. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 205-209.	1.8	12
2627	A cancer vaccine with dendritic cells differentiated with GM-CSF and IFN $\gamma$ and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model. <i>BioImpacts</i> , 2018, 8, 211-221.	0.7	23
2628	Melanoma Immunotherapy: Mechanisms and Opportunities. <i>Investigative Dermatology and Venereology Research</i> , 2016, 2, 1-7.	0.1	1
2629	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
2630	Glioblastoma: To Target the Tumor Cell or the Microenvironment?. , 0, , 315-340.		31
2631	PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies. <i>Aging</i> , 2020, 12, 1577-1590.	1.4	8
2632	The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy. <i>Aging</i> , 2020, 12, 4603-4616.	1.4	16
2633	GBM-associated mutations and altered protein expression are more common in young patients. <i>Oncotarget</i> , 2016, 7, 69466-69478.	0.8	27

#	ARTICLE	IF	CITATIONS
2634	Addressing intra-tumoral heterogeneity and therapy resistance. <i>Oncotarget</i> , 2016, 7, 72322-72342.	0.8	67
2635	Cancer cell-binding peptide fused Fc domain activates immune effector cells and blocks tumor growth. <i>Oncotarget</i> , 2016, 7, 75940-75953.	0.8	6
2636	Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. <i>Oncotarget</i> , 2016, 7, 82504-82510.	0.8	64
2637	SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. <i>Oncotarget</i> , 2016, 7, 83088-83100.	0.8	16
2638	MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy. <i>Oncotarget</i> , 2017, 8, 14719-14735.	0.8	21
2639	A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "œpan-leukemia" antigens. <i>Oncotarget</i> , 2017, 8, 43915-43924.	0.8	12
2640	Comprehensive analysis of PD-L1 expression in glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 42214-42225.	0.8	81
2641	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model. <i>Oncotarget</i> , 2017, 8, 28312-28327.	0.8	29
2642	Multi-omics study revealing the complexity and spatial heterogeneity of tumor-infiltrating lymphocytes in primary liver carcinoma. <i>Oncotarget</i> , 2017, 8, 34844-34857.	0.8	31
2643	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. <i>Oncotarget</i> , 2017, 8, 41242-41255.	0.8	89
2644	Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response. <i>Oncotarget</i> , 2017, 8, 47400-47411.	0.8	21
2645	Genetic defects of the IRF1-mediated major histocompatibility complex class I antigen presentation pathway occur prevalently in the <i>JAK2</i> gene in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 60975-60986.	0.8	15
2646	Expression differences of programmed death ligand 1 in de-novo and recurrent glioblastoma multiforme. <i>Oncotarget</i> , 2017, 8, 74170-74177.	0.8	21
2647	Therapeutic vaccine to cure large mouse hepatocellular carcinomas. <i>Oncotarget</i> , 2017, 8, 52061-52071.	0.8	13
2648	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. <i>Oncotarget</i> , 2018, 9, 464-476.	0.8	23
2649	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	0.8	73
2650	Molecular and clinical features of the <i>TP53</i> signature gene expression profile in early-stage breast cancer. <i>Oncotarget</i> , 2018, 9, 14193-14206.	0.8	11
2651	Immune response characterization of endometrial cancer. <i>Oncotarget</i> , 2019, 10, 982-992.	0.8	13



#	ARTICLE	IF	CITATIONS
2652	A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors. <i>Oncotarget</i> , 2019, 10, 1669-1687.	0.8	12
2653	A global immune gene expression signature for human cancers. <i>Oncotarget</i> , 2019, 10, 1993-2005.	0.8	9
2654	Tumor mutational burden in lung cancer: a systematic literature review. <i>Oncotarget</i> , 2019, 10, 6604-6622.	0.8	72
2655	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
2656	Survival correlation of immune response in human cancers. <i>Oncotarget</i> , 2019, 10, 6885-6897.	0.8	3
2657	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2669-2683.	0.8	14
2658	Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. <i>Oncotarget</i> , 2020, 11, 3118-3128.	0.8	18
2659	Targeting the tumor microenvironment to enhance antitumor immune responses. <i>Oncotarget</i> , 2015, 6, 1359-1381.	0.8	59
2660	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	0.8	148
2661	A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. <i>Oncotarget</i> , 2015, 6, 28999-29015.	0.8	53
2662	Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. <i>Oncotarget</i> , 2015, 6, 32602-32609.	0.8	15
2663	Mutational profiling of colorectal cancers with microsatellite instability. <i>Oncotarget</i> , 2015, 6, 42334-42344.	0.8	69
2664	Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. <i>Oncotarget</i> , 2016, 7, 25087-25102.	0.8	60
2665	Collaboration between tumor-specific CD4+ T cells and B cells in anti-cancer immunity. <i>Oncotarget</i> , 2016, 7, 30211-30229.	0.8	15
2666	Future paradigms for precision oncology. <i>Oncotarget</i> , 2016, 7, 46813-46831.	0.8	23
2667	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3
2668	Cell-mediated immune resistance in cancer. , 2020, 3, 232-251.		9
2669	Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. , 2020, 3, 356-370.		15

#	ARTICLE	IF	CITATIONS
2670	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
2671	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	0.7	9
2672	Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines. Annals of Translational Medicine, 2016, 4, 266-266.	0.7	24
2673	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	0.7	17
2674	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
2675	DNA damage, tumor mutational load and their impact on immune responses against cancer. Annals of Translational Medicine, 2016, 4, 264-264.	0.7	35
2676	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. Annals of Translational Medicine, 2017, 5, 376-376.	0.7	79
2677	Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. Annals of Translational Medicine, 2017, 5, 380-380.	0.7	12
2678	Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM). Annals of Translational Medicine, 2017, 5, 389-389.	0.7	26
2679	New trends in antitumor vaccines in melanoma. Annals of Translational Medicine, 2017, 5, 384-384.	0.7	16
2680	Predictors of response and resistance to checkpoint inhibitors in solid tumors. Annals of Translational Medicine, 2017, 5, 468-468.	0.7	9
2681	Emerging biomarkers and targeted therapies in urothelial carcinoma. Annals of Translational Medicine, 2018, 6, 250-250.	0.7	33
2682	Immunotherapy for head and neck cancer: where are we now and where are we going?. Annals of Translational Medicine, 2019, 7, S75-S75.	0.7	35
2683	Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Chinese Clinical Oncology, 2016, 5, 23-23.	0.4	30
2684	Resistance patterns to anti-PD-1 therapy in metastatic melanoma. Chinese Clinical Oncology, 2016, 5, 75-75.	0.4	3
2685	PREDICTIVE RESPONSE MARKERS FOR IMMUNE RESPONSE BLOCKS. Siberian Journal of Oncology, 2020, 19, 123-131.	0.1	4
2686	Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy. Open Dentistry Journal, 2018, 12, 455-465.	0.2	9
2687	Immune Blockade Inhibition in Breast Cancer. Anticancer Research, 2016, 36, 5607-5622.	0.5	37

#	ARTICLE	IF	CITATIONS
2688	Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. <i>Anticancer Research</i> , 2017, 37, 1321-1328.	0.5	6
2689	Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 1947-1955.	0.5	8
2690	Monoclonal Antibodies for the Treatment of Cancer. <i>Anticancer Research</i> , 2017, 37, 5935-5939.	0.5	79
2691	The Positive Relationship Between $\gamma$ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. <i>In Vivo</i> , 2018, 32, 171-177.	0.6	10
2692	Biomarkers Predicting for Response and Relapse with Melanoma Systemic Therapy. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00142.	0.6	3
2693	Updates to Clinical Information on Anticancer Immunotherapy. <i>Korean Journal of Clinical Pharmacy</i> , 2018, 28, 65-75.	0.0	3
2694	Cloning and expansion of antigen-specific T cells using iPSC technology: A novel strategy for cancer immunotherapy. <i>Inflammation and Regeneration</i> , 2015, 35, 220-225.	1.5	1
2695	Changing paradigm of cancer therapy: precision medicine by next-generation sequencing. <i>Cancer Biology and Medicine</i> , 2016, 13, 12-8.	1.4	19
2696	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. <i>Deutsches <math>\times</math>0308;rzteblatt International</i> , 2019, 116, 497-504.	0.6	15
2697	Oncolytic virotherapy: new weapon for breast cancer treatment. <i>Ecancermedicalscience</i> , 2020, 14, 1149.	0.6	12
2698	KIT and Melanoma: Biological Insights and Clinical Implications. <i>Yonsei Medical Journal</i> , 2020, 61, 562.	0.9	67
2699	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 339.	2.2	77
2700	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020, 12, 2835.	1.7	8
2701	Current Trends and Future Prospects of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 240.	1.8	101
2702	Harnessing B Cells for Cancer Immunotherapy. , 2016, 01, .		1
2703	Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond. <i>World Journal of Gastroenterology</i> , 2018, 24, 2686-2697.	1.4	23
2704	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. <i>Endocrinology and Metabolism</i> , 2020, 35, 44.	1.3	21
2705	Latest evidence on immunotherapy for cholangiocarcinoma (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	23

#	ARTICLE	IF	CITATIONS
2706	Immunotherapy for synovial sarcoma. <i>AIMS Medical Science</i> , 2019, 6, 191-200.	0.2	1
2707	New strategies in immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 553-9.	1.3	35
2708	Novel therapies in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 533-44.	1.3	45
2709	Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity. <i>Translational Lung Cancer Research</i> , 2015, 4, 721-7.	1.3	26
2710	Cellular and molecular biology of small cell lung cancer: an overview. <i>Translational Lung Cancer Research</i> , 2016, 5, 2-15.	1.3	52
2711	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , 2015, 4, 22.	0.4	16
2712	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27
2713	Immune checkpoint inhibitors: therapeutic advances in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 267.	0.7	47
2714	Perspectives on the clinical development of immunotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 253.	0.8	13
2715	Hyperprogressive disease after nivolumab in a patient with microsatellite instability-high ampullary cancer. <i>Journal of Cancer Research and Practice</i> , 2019, 6, 50.	0.2	2
2716	Review of Immunogenomics and the Role of Tumor Mutational Burden as a Biomarker for Immunotherapy Response. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 144-151.	0.6	4
2717	Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives. <i>Journal of Pathology and Translational Medicine</i> , 2016, 50, 1-9.	0.4	21
2718	PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future. <i>Journal of Pathology and Translational Medicine</i> , 2019, 53, 199-206.	0.4	51
2719	Tumor immune response and immunotherapy in gastric cancer. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 20-33.	0.4	59
2720	Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. <i>Translational Oncogenomics</i> , 2015, Suppl. 1, 1-11.	1.7	19
2721	Issues to Consider in Designing Immunotherapy Clinical Trials for Glioblastoma Management. <i>Journal of Cancer Therapy</i> , 2016, 07, 573-585.	0.1	1
2722	Identification of genomic features associated with immunotherapy response in gastrointestinal cancers. <i>World Journal of Gastrointestinal Oncology</i> , 2019, 11, 270-280.	0.8	8
2723	Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors. <i>World Journal of Clinical Oncology</i> , 2017, 8, 320.	0.9	8

#	ARTICLE	IF	CITATIONS
2724	Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 644-648.	2.3	14
2725	Tumor Mutation Burden and Depression in Lung Cancer: Association With Inflammation. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 434-442.	2.3	10
2726	Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 517-521.	2.3	25
2727	Tumor immune microenvironment characterization and response to anti-PD-1 therapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 74-8.	1.4	60
2728	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	1.4	28
2729	An open-source computational and data resource to analyze digital maps of immunopeptidomes. <i>ELife</i> , 2015, 4, .	2.8	107
2730	Rejection of immunogenic tumor clones is limited by clonal fraction. <i>ELife</i> , 2018, 7, .	2.8	88
2731	Systematic identification of cancer cell vulnerabilities to natural killer cell-mediated immune surveillance. <i>ELife</i> , 2019, 8, .	2.8	69
2732	Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. <i>ELife</i> , 2019, 8, .	2.8	214
2733	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
2734	Tumor immunity landscape in non-small cell lung cancer. <i>PeerJ</i> , 2018, 6, e4546.	0.9	10
2735	Molecular characterization of squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2423-2437.	0.6	7
2736	The Dog as a Model to Study the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 123-152.	0.8	3
2737	Identification of pyroptosis-related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in colorectal cancer. <i>OncImmunology</i> , 2021, 10, 1987636.	2.1	81
2738	Cancer Immunotherapy Strategies: Basic Principles. <i>Bioanalysis</i> , 2021, , 29-49.	0.1	0
2739	Establishment of a novel ferroptosis-related lncRNA pair prognostic model in colon adenocarcinoma. <i>Aging</i> , 2021, 13, 23072-23095.	1.4	18
2740	Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. <i>Advanced Materials</i> , 2022, 34, e2103790.	11.1	81
2741	Mutational Characterization of Cutaneous Melanoma Supports Divergent Pathways Model for Melanoma Development. <i>Cancers</i> , 2021, 13, 5219.	1.7	5

#	ARTICLE	IF	CITATIONS
2742	Challenges and Prospects for Designer T and NK Cells in Glioblastoma Immunotherapy. <i>Cancers</i> , 2021, 13, 4986.	1.7	6
2743	The miRNA Profile of Inflammatory Colorectal Tumors Identify TGF- $\beta$ 2 as a Companion Target for Checkpoint Blockade Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 754507.	1.8	3
2744	A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. <i>Nature Genetics</i> , 2021, 53, 1504-1516.	9.4	69
2745	The role of the tumor microbe microenvironment in the tumor immune microenvironment: bystander, activator, or inhibitor?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 327.	3.5	47
2746	Alloantigen-activated (AAA) CD4+ T cells reinvigorate host endogenous T cell immunity to eliminate pre-established tumors in mice. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 314.	3.5	1
2747	Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. <i>Annals of Oncology</i> , 2022, 33, 42-56.	0.6	56
2748	Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model. <i>Clinical and Translational Medicine</i> , 2021, 11, e551.	1.7	3
2749	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. <i>Nature Communications</i> , 2021, 12, 6023.	5.8	21
2750	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
2751	Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 747985.	1.8	2
2752	Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5134.	1.7	8
2753	Serological assessment of collagen fragments and tumor fibrosis may guide immune checkpoint inhibitor therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 326.	3.5	19
2754	Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. , 2021, 9, e002663.		9
2755	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
2756	Emerging biomarkers in metastatic urothelial carcinoma: tumour mutational burden, PD-L1 expression and APOBEC polypeptide-like signature in a patient with complete response to anti-programmed cell death protein-1 inhibitor. <i>Ecancermedicallscience</i> , 2021, 15, 1306.	0.6	2
2757	Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN- $\gamma$ signaling and tumor-infiltrating lymphocytes. <i>Journal of Hematology and Oncology</i> , 2021, 14, 160.	6.9	37
2758	Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. <i>Pharmaceutics</i> , 2021, 13, 1617.	2.0	11
2761	ãfã,ã,ãfžãf¼ã,«ãf¼UPDATE. <i>Skin Cancer</i> , 2015, 30, 62-63.	0.1	0

#	ARTICLE	IF	CITATIONS
2762	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
2763	Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). , 2015, , 63-84.		0
2764	Anal Melanoma: A General Surgical Experience. Journal of Clinical Case Reports, 2015, 05, .	0.0	1
2765	Ewolucja systemowego leczenia przeciwnowotworowego. Nowotwory, 2015, 65, 1-6.	0.1	0
2766	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. Oncotarget, 2015, 6, 25452-25465.	0.8	3
2768	Metastatic Melanoma. , 2016, , 674-685.		0
2769	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
2770	Targeted Cancer Therapy. Nishinohon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
2771	New Treatments for Advanced Melanoma. Nishinohon Journal of Dermatology, 2016, 78, 5-12.	0.0	0
2772	Cancer Vaccines in Castration Resistant Prostate Cancerâ€”An Evolution in Design. , 2016, , 107-124.		0
2773	Liens entre gÃ©nÃ©tique et immunologie : mutations et antigÃ©nes. Bulletin De L'Academie Nationale De Medecine, 2016, 200, 67-79.	0.0	0
2774	Translational Research and Immunotherapy in Lung Cancer. , 2016, , 255-296.		0
2775	Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer. Forum of Clinical Oncology, 2016, 7, 4-16.	0.1	0
2780	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267.	0.5	0
2782	Translational Aspects in Drug Discovery. , 2017, , 495-529.		1
2783	Scalp Melanoma Treated with Ipilimumab in Elderly Patient: A Complete Response to Treatmentâ€”Case Report. Journal of Pharmacy and Pharmacology, 2017, 5, .	0.1	0
2784	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0
2785	Melanoma Genetics and Genomics. , 2017, , 63-93.		0



#	ARTICLE	IF	CITATIONS
2786	Šířka et al. Overview & future directions. <i>Skin Cancer</i> , 2017, 135-140.		140.
2787	Immunotherapy for Gynecologic Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 69-85.	0.0	0
2788	Šířka et al. Skin Cancer, 2017, 32, 140.		140.
2794	Origins of cancer: tackling provocative questions. <i>Genes and Cancer</i> , 2017, 8, 608-612.	0.6	0
2796	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. <i>IssledovaniĀ I Praktika V Medicine</i> , 2017, 4, 51-65.	0.1	4
2799	Molecular Genetics of Melanocytic Neoplasia. , 2018, , 1-23.		1
2801	Front line of cancer immunotherapy development. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 2645-2658.	0.0	0
2802	Immunotherapy of advanced melanoma. <i>Skin Cancer</i> , 2018, 33, 107-111.	0.1	0
2803	Current Advances in Immuno-oncology for Head and Neck Cancer. <i>International Journal of Head and Neck Surgery</i> , 2018, 9, 78-86.	0.1	0
2804	Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer. <i>Oncology &amp; Hematology Review</i> , 2018, 14, 67.	0.2	0
2805	Pan-Cancer Analysis of Heritable Genetic Variations Reveals Cancer-Specific Activation of Dormant Oncogenic Pathways. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2812	Melanoma Vaccines. , 2019, , 1-23.		0
2813	Genomics Role in Cancer Immunosurveillance: Impact on Immunotherapy Response. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	1
2814	ToxicitĀs sĀvĀres des immunothĀrapies du cancer. <i>Medicine Intensive Reanimation</i> , 2018, 27, 522-536.	0.1	0
2815	Immune Response and Immunotherapy in GIST. , 2019, , 17-31.		0
2816	Genomic Applications in Colorectal Carcinomas. , 2019, , 393-399.		1
2817	Novel Approaches to Immunotherapy in Triple Negative Breast Cancer. <i>International Journal of Cancer Management</i> , 2018, In Press, .	0.2	1
2818	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3

#	ARTICLE	IF	CITATIONS
2820	Immunogenomics. , 2019, , 99-110.		0
2822	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
2823	Immunology of Melanoma. , 2019, , 1-32.		0
2824	Mechanism of resistance to immune checkpoint inhibitors. Cancer Drug Resistance (Alhambra, Calif ), 2019, 2, 178-188.	0.9	3
2829	Checkmate with Checkpoint Inhibitors: Hope and Hype. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 159-162.	0.1	0
2832	Biomarkers in immuno-oncology: A review article. International Journal of Molecular and Immuno Oncology, 2019, 4, 41-49.	0.0	1
2834	Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment. Current Cancer Therapy Reviews, 2019, 15, 110-119.	0.2	0
2839	Society of Internal Medicine, 2019, 108, 1777-1787.	0.0	0
2840	Clinicopathological correlation of immune response in human cancers. Oncotarget, 2019, 10, 5859-5870.	0.8	0
2843	Targeting the Tumor Microenvironment. , 2020, , 219-231.		0
2844	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. , 2020, , 17-44.		0
2845	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164.		0
2846	Pegylated recombinant human granulocyte colonyâ€stimulating factor regulates the immune status of patients with small cell lung cancer. Thoracic Cancer, 2020, 11, 713-722.	0.8	3
2847	Longâ€term response to ipilimumab after nivolumab failure in a case of anorectal melanoma with an intermediate tumor mutation burden and negative for PDâ€L1 expression. Molecular and Clinical Oncology, 2020, 13, 175-178.	0.4	2
2852	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
2853	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 2021, 39, 1497-1518.e11.	7.7	126
2854	Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy. International Journal of Molecular Sciences, 2021, 22, 11726.	1.8	3
2855	Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Scientific Reports, 2021, 11, 21072.	1.6	9

#	ARTICLE	IF	CITATIONS
2856	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 5411.	1.7	1
2857	Dynamics of Early Serum Tumour Markers and Neutrophil-to-Lymphocyte Ratio Predict Response to PD-1/PD-L1 Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 8241-8255.	0.9	11
2858	Prognostic value of preoperative soluble interleukin 2 receptor $\hat{\pm}$ as a novel immune biomarker in epithelial ovarian cancer. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1519-1530.	2.0	1
2859	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
2860	Synergy between <i>Toxoplasma gondii</i> type I $\hat{\pm}$ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors. , 2021, 9, e002970.		19
2862	Immunology of Melanoma. , 2020, , 41-72.		0
2863	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2020, , 761-783.		1
2864	The Biology of Immune-Active Cancers and Their Regulatory Mechanisms. <i>Cancer Treatment and Research</i> , 2020, 180, 149-172.	0.2	5
2866	Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?. <i>Translational Andrology and Urology</i> , 2020, 9, 2479-2482.	0.6	1
2868	Emerging clinical pharmacology topics in drug development and precision medicine. , 2022, , 691-708.		0
2869	Molecular Mechanism of Lynch Syndrome. , 2020, , 1-20.		0
2870	Acral Lentiginous Melanoma. , 2020, , 897-924.		0
2871	Melanoma Vaccines. , 2020, , 1243-1265.		0
2873	PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. <i>Oncology Letters</i> , 2020, 19, 2481-2488.	0.8	4
2874	Pharmacogenomics of Antitumor Targeted Agent and Immunotherapy. , 2020, , 55-82.		0
2875	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
2876	Experience with Large Panel Next-generation Sequencing in Patients with Advanced Solid Cancers at Juntendo University Hospital. <i>Juntendo Medical Journal</i> , 2020, 66, 392-402.	0.1	0
2879	Ferroptosis-Related Gene Signature Predicts the Prognosis of Skin Cutaneous Melanoma and Response to Immunotherapy. <i>Frontiers in Genetics</i> , 2021, 12, 758981.	1.1	16

#	ARTICLE	IF	CITATIONS
2880	miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. <i>Biomolecules</i> , 2021, 11, 1648.	1.8	15
2881	Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 721409.	2.2	17
2882	Immunopotential of galangal ( <i>Alpinia galanga</i> L.) when combined with T-cells against metastatic triple-negative breast cancer, MDA-MB 231. <i>Journal of Applied Pharmaceutical Science</i> , 0, , .	0.7	1
2883	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6
2884	Blockading a new NSCLC immunosuppressive target by pluripotent autologous tumor vaccines magnifies sequential immunotherapy. <i>Bioactive Materials</i> , 2022, 13, 223-238.	8.6	24
2885	Immunological and clinical immunotherapy implications of NLRP3 mutations in melanoma. <i>Aging</i> , 2021, 13, 24271-24289.	1.4	6
2887	The incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 182-189.	0.5	8
2889	Immunotherapy in Patients with mCRC. , 2021, , 183-186.		0
2890	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
2891	Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors. <i>Onkologie (Czech Republic)</i> , 2020, 14, 205-212.	0.0	0
2892	ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration. <i>Aging</i> , 2021, 13, 351-363.	1.4	18
2893	Shedding light on the molecular determinants of response to anti-PD-1 therapy. <i>Translational Lung Cancer Research</i> , 2015, 4, 816-9.	1.3	18
2894	Mismatch repair-based stratification for immune checkpoint blockade therapy. <i>American Journal of Cancer Research</i> , 2018, 8, 1977-1988.	1.4	8
2895	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. <i>American Journal of Cancer Research</i> , 2018, 8, 1947-1956.	1.4	6
2896	The role of the immune system in brain metastasis. <i>Current Neurobiology</i> , 2019, 10, 33-48.	1.0	21
2898	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. <i>Reviews in Urology</i> , 2019, 21, 85-92.	0.9	3
2899	Immunotherapy in anaplastic thyroid cancer. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 974-988.	0.0	10
2900	Laboratory biomarkers of an effective antitumor immune response. Clinical significance.. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100489.	0.7	2

#	ARTICLE	IF	CITATIONS
2901	Association of HLA-restricted HERV-derived peptide-related cytotoxic T-lymphocyte induction and sex bias in therapeutic responses in gastric cancer: Secondary Analysis of Data from 3 Randomized Trials and an Observational Study from 1977 to 2011. <i>Annals of Cancer Research and Therapy</i> , 2021, 29, 135-152.	0.1	3
2902	Association of CSMD1 with Tumor Mutation Burden and Other Clinical Outcomes in Gastric Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 8293-8299.	0.8	4
2903	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5275-5291.	1.0	5
2904	Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
2905	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?. <i>Cancers</i> , 2021, 13, 5788.	1.7	3
2906	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 762478.	1.8	8
2907	An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer. <i>International Journal of General Medicine</i> , 2021, Volume 14, 9031-9049.	0.8	0
2908	A Personalized Neoantigen Vaccine in Combination with Platinum-Based Chemotherapy Induces a T-Cell Response Coinciding with a Complete Response in Endometrial Carcinoma. <i>Cancers</i> , 2021, 13, 5801.	1.7	2
2909	Melanoma Targeted Therapies beyond BRAF-Mutant Melanoma: Potential Druggable Mutations and Novel Treatment Approaches. <i>Cancers</i> , 2021, 13, 5847.	1.7	16
2910	A Hypothetical Model Suggesting Some Possible Ways That the Progesterone Receptor May Be Involved in Cancer Proliferation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12351.	1.8	3
2911	Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma. <i>Frontiers in Medicine</i> , 2021, 8, 755657.	1.2	2
2912	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
2913	Geometric network analysis provides prognostic information in patients with high grade serous carcinoma of the ovary treated with immune checkpoint inhibitors. <i>Npj Genomic Medicine</i> , 2021, 6, 99.	1.7	13
2914	Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines. <i>Biomaterials</i> , 2022, 280, 121297.	5.7	27
2915	From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. <i>Cells</i> , 2021, 10, 3231.	1.8	18
2916	Shrinkage of a pituitary metastasis of melanoma induced by pembrolizumab: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 555.	0.4	2
2917	Relationship between Tumor Mutational Burden, PD-L1, Patient Characteristics, and Response to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5733.	1.7	13
2918	Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. <i>BMC Cancer</i> , 2021, 21, 1222.	1.1	28

#	ARTICLE	IF	CITATIONS
2919	WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	22
2920	Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 785400.	2.2	5
2921	Predictive molecular markers for the treatment with immune checkpoint inhibitors in colorectal cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24141.	0.9	12
2922	Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. , 2021, 9, e003683.		9
2923	Clinical, pathological, and genetic profile of clear cell sarcoma-like tumour of jejunum: report of a rare aggressive tumour of small bowel. <i>Clinical Journal of Gastroenterology</i> , 2021, 15, 107.	0.4	1
2924	CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities. <i>Life</i> , 2021, 11, 1282.	1.1	18
2925	Sarcopenia's Prognostic Impact on Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 5329.	1.0	8
2926	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. <i>Cell Reports</i> , 2021, 37, 110021.	2.9	21
2927	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. <i>Cancers</i> , 2021, 13, 6061.	1.7	5
2928	Association of <i>PTPRT</i> mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer. <i>Cancer Medicine</i> , 2022, 11, 676-691.	1.3	18
2929	Immune System in Action. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 1-43.	0.8	0
2930	Tumor Mutational Burden as a Biomarker for Advanced Biliary Tract Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110623.	0.8	11
2931	Immunotherapy in Gastrointestinal Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 259-272.	0.8	3
2932	Development and Validation of a Tumor Mutation Burden-Related Immune Prognostic Signature for Ovarian Cancers. <i>Frontiers in Genetics</i> , 2021, 12, 688207.	1.1	7
2933	Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 812713.	2.2	3
2934	Biomarker-driven immunotherapy for precision medicine in prostate cancer. <i>Personalized Medicine</i> , 2022, 19, 51-66.	0.8	1
2935	Targets and Strategies for Cancer. <i>Methods in Molecular Biology</i> , 2022, 2435, 7-17.	0.4	0
2936	Prognostic biomarkers of cutaneous melanoma. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2022, 38, 418-434.	0.7	15

#	ARTICLE	IF	CITATIONS
2937	Personalized therapy with peptide-based neoantigen vaccine (EVX-01) including a novel adjuvant, CAF-09b, in patients with metastatic melanoma. <i>Oncolimmunology</i> , 2022, 11, 2023255.	2.1	18
2938	Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103573.	2.0	2
2939	Basics of immunotherapy for epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2022, 51, 102283.	0.6	4
2940	Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. <i>ESMO Open</i> , 2022, 7, 100336.	2.0	103
2941	Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 1821-1829.	1.5	17
2942	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
2943	Eosinophils and melanoma: Implications for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 192-202.	1.5	5
2944	Expression of Fibroblast Activation Protein Is Enriched in Neuroendocrine Prostate Cancer and Predicts Worse Survival. <i>Genes</i> , 2022, 13, 135.	1.0	7
2945	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. <i>Molecular Cancer</i> , 2022, 21, 20.	7.9	55
2946	Multi-Omics Analyses Revealed GOLT1B as a Potential Prognostic Gene in Breast Cancer Probably Regulating the Immune Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 805273.	1.3	3
2947	The co-mutation of EGFR and tumor-related genes leads to a worse prognosis and a higher level of tumor mutational burden in Chinese non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2022, 14, 185-193.	0.6	7
2948	Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets. <i>BMC Cancer</i> , 2022, 22, 13.	1.1	15
2949	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2951	Retinoblastoma protein regulates carcinogen susceptibility at heterochromatic cancer driver loci. <i>Life Science Alliance</i> , 2022, 5, e202101134.	1.3	4
2952	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 785526.	2.2	6
2953	Experience of the nivolumab use in patients with metastatic renal cell carcinoma provided under the expanded access program in Russia. Subgroup analysis of the correlation between expression markers and the effectiveness of nivolumab therapy. <i>Malignant Tumours</i> , 2022, 11, 23-35.	0.1	0
2954	Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function. <i>Frontiers in Immunology</i> , 2021, 12, 816658.	2.2	5
2955	The Impact of Hyaluronan on Tumor Progression in Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 811434.	1.3	6



#	ARTICLE	IF	CITATIONS
2956	A Systematic Review of Expression and Immunogenicity of Human Endogenous Retroviral Proteins in Cancer and Discussion of Therapeutic Approaches. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1330.	1.8	14
2958	Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. <i>Cancer Cell</i> , 2022, 40, 88-102.e7.	7.7	64
2959	mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2960	Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 798474.	2.2	10
2961	Systematic analysis of the role of SLC52A2 in multiple human cancers. <i>Cancer Cell International</i> , 2022, 22, 8.	1.8	7
2962	High tumor mutation burden indicates a poor prognosis in patients with intrahepatic cholangiocarcinoma. <i>World Journal of Clinical Cases</i> , 2022, 10, 790-801.	0.3	6
2963	Pioneer Role of Extracellular Vesicles as Modulators of Cancer Initiation in Progression, Drug Therapy, and Vaccine Prospects. <i>Cells</i> , 2022, 11, 490.	1.8	21
2964	Mutations in the TTN Gene are a Prognostic Factor for Patients with Lung Squamous Cell Carcinomas. <i>International Journal of General Medicine</i> , 2022, Volume 15, 19-31.	0.8	9
2965	Quantification of T- and B-cell Immune Receptor Distribution Diversity Characterizes Immune Cell Infiltration and Lymphocyte Heterogeneity in Clear Cell Renal Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 929-942.	0.4	13
2966	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9
2967	Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis. <i>Cancers</i> , 2022, 14, 415.	1.7	8
2968	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	5.7	21
2969	Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer. <i>Journal of Ovarian Research</i> , 2022, 15, 18.	1.3	7
2970	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. <i>Cancers</i> , 2022, 14, 631.	1.7	19
2971	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 818411.	2.2	1
2972	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
2973	Insignificant effects of loss of heterozygosity in HLA in the efficacy of immune checkpoint blockade treatment. <i>Genes and Genomics</i> , 2022, 44, 509-515.	0.5	2
2974	Association of mutations in DNA polymerase epsilon with increased CD8+ cell infiltration and prolonged progression-free survival in patients with meningiomas. <i>Neurosurgical Focus</i> , 2022, 52, E7.	1.0	4

#	ARTICLE	IF	CITATIONS
2975	Identification of neoantigens for individualized therapeutic cancer vaccines. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 261-282.	21.5	173
2976	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
2977	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
2978	A mathematical model to study the impact of intra-tumour heterogeneity on anti-tumour CD8+ T cell immune response. <i>Journal of Theoretical Biology</i> , 2022, 538, 111028.	0.8	12
2979	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€‘positive melanoma. <i>Annals of Oncology</i> , 2022, 33, 544-555.	0.6	12
2980	T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 833017.	2.2	13
2981	Gut Microbiota Modulates the Efficiency of Programmed Cell Death Protein 1 Cancer Immunotherapies. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2022, 21, 1-11.	0.3	1
2982	Intron-Retention Neoantigen Load Predicts Favorable Prognosis in Pancreatic Cancer. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100124.	1.0	6
2983	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 6366.	1.7	10
2984	Autoantibodies: A manifestation of immune related adverse events of cancer immunotherapy. <i>Revista Colombiana De ReumatologÃa (English Edition)</i> , 2022, 29, 3-8.	0.1	0
2985	Pan-Cancer Indicators of Long-Term Survival Benefits After Immune Checkpoint Inhibitor Therapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2986	Cross-presentation-based nanovaccine for cancer immunotherapy. , 2022, , 349-396.		1
2987	Clinical Impact of <i>STK11</i> Mutation in Advanced-Stage Non-Small-Cell Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2988	Advances in the Application of Tumor Mutation Burden in Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 1724-1729.	0.0	0
2990	Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma. <i>Melanoma Research</i> , 2022, 32, 112-119.	0.6	4
2991	Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies. <i>Current Oncology</i> , 2022, 29, 1390-1407.	0.9	11
2992	Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. <i>Cell Reports Medicine</i> , 2022, 3, 100500.	3.3	13
2993	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 799988.	2.2	7

#	ARTICLE	IF	CITATIONS
2994	RAS pathway regulation in melanoma. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	1.2	11
2995	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
2996	TCR-Directed Therapy in the Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 1215.	1.7	8
2997	A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. <i>Genome Medicine</i> , 2022, 14, 20.	3.6	26
2998	Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types. <i>Genes</i> , 2022, 13, 365.	1.0	3
2999	Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2594.	1.8	14
3000	TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 833-840.	1.2	6
3001	Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2022.	1.8	13
3002	Neoantigen vaccine-induced CD4 T cells confer protective immunity in a mouse model of multiple myeloma through activation of CD8 T cells against non-vaccine, tumor-associated antigens. , 2022, 10, e003572.		9
3004	A transformer-based model to predict peptideâ€“HLA class I binding and optimize mutated peptides for vaccine design. <i>Nature Machine Intelligence</i> , 2022, 4, 300-311.	8.3	55
3006	High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers. <i>Journal of Clinical Medicine</i> , 2022, 11, 1605.	1.0	2
3007	Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790920.	1.8	10
3008	<i>In Vivo</i> Modeling of Tumor Heterogeneity for Immunoâ€“Oncology Studies: Failures, Improvements, and Hopes. <i>Current Protocols</i> , 2022, 2, e377.	1.3	1
3009	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
3011	NeoScore Integrates Characteristics of the Neoantigen:MHC Class I Interaction and Expression to Accurately Prioritize Immunogenic Neoantigens. <i>Journal of Immunology</i> , 2022, 208, 1813-1827.	0.4	4
3012	Systematic review and metaâ€“analysis of genomic alterations in acral melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 369-386.	1.5	6
3013	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	0.8	5
3014	The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 748674.	1.6	27

#	ARTICLE	IF	CITATIONS
3016	Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. <i>Clinical Science</i> , 2022, 136, 383-404.	1.8	8
3017	The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space. <i>Journal of Molecular Diagnostics</i> , 2022, , .	1.2	0
3018	Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 839136.	1.8	6
3019	TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types. <i>Aging</i> , 2022, 14, 2868-2879.	1.4	0
3020	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
3021	Ultrasensitive profiling of UV-induced mutations identifies thousands of subclinical facial tumors in tuberous sclerosis complex. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	6
3022	Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy. <i>Cancers</i> , 2022, 14, 1580.	1.7	17
3024	PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. , 2022, 10, e003402.		21
3025	HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade. <i>Annals of Oncology</i> , 2022, 33, 728-738.	0.6	12
3026	DEPTH2: an mRNA-based algorithm to evaluate intratumor heterogeneity without reference to normal controls. <i>Journal of Translational Medicine</i> , 2022, 20, 150.	1.8	8
3027	Chasing neoantigens; invite naïve T cells to the party. <i>Current Opinion in Immunology</i> , 2022, 75, 102172.	2.4	3
3028	Cross-reactivity between microbial and tumor antigens. <i>Current Opinion in Immunology</i> , 2022, 75, 102171.	2.4	16
3029	Ubiquitin ligase STUB1 destabilizes IFN $\beta$ -receptor complex to suppress tumor IFN $\beta$ signaling. <i>Nature Communications</i> , 2022, 13, 1923.	5.8	18
3030	Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. <i>Journal of Clinical Oncology</i> , 2022, 40, 1231-1258.	0.8	96
3031	Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2022, 12, 1336-1355.	7.7	56
3032	Radiation therapy-induced remodeling of the tumor immune microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 737-747.	4.3	30
3033	A Novel Quantification System Combining iTRAQ Technology and Multi-Omics Assessment to Predict Prognosis and Immunotherapy Efficacy in Colon Cancer. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 862619.	2.0	1
3034	Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. <i>Clinical Cancer Research</i> , 2022, 28, 2994-3001.	3.2	15

#	ARTICLE	IF	CITATIONS
3035	Multimodal predictors for precision immunotherapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100071.	0.2	4
3036	The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis. <i>Translational Oncology</i> , 2022, 20, 101375.	1.7	15
3037	Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. <i>Cancers</i> , 2022, 14, 109.	1.7	21
3038	Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides. <i>Journal of Translational Medicine</i> , 2021, 19, 526.	1.8	3
3039	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
3040	Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 689076.	2.2	21
3041	Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 124.	1.0	9
3042	Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives. <i>Cells</i> , 2022, 11, 20.	1.8	17
3043	Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines. <i>Methods in Molecular Biology</i> , 2022, 2410, 649-670.	0.4	11
3044	Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid Biopsy. <i>Cancers</i> , 2021, 13, 6217.	1.7	9
3045	Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. <i>Expert Review of Vaccines</i> , 2022, 21, 173-184.	2.0	17
3047	ENPEP as a potential predictor of immune checkpoint inhibitor efficacy. <i>Cancer Medicine</i> , 2022, 11, 880-887.	1.3	5
3048	PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study. <i>Cancers</i> , 2021, 13, 6295.	1.7	0
3049	PAX5 haploinsufficiency induces low T cell infiltration in the cancer microenvironment via reduced chemokines. <i>Current Molecular Medicine</i> , 2021, 21, .	0.6	0
3050	Development of Tissue-Agnostic Treatments for Patients with Cancer. <i>Annual Review of Cancer Biology</i> , 2022, 6, 147-165.	2.3	8
3051	Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, 190.	4.2	25
3052	PAGER Web APP: An Interactive, Online Gene Set and Network Interpretation Tool for Functional Genomics. <i>Frontiers in Genetics</i> , 2022, 13, 820361.	1.1	2
3054	Activation of T cell checkpoint pathways during $\hat{I}^2$ cell antigen presentation by engineered dendritic cells promotes protection from type 1 diabetes. <i>Immunology</i> , 2022, 166, 341-356.	2.0	2

#	ARTICLE	IF	CITATIONS
3055	A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. <i>Cell Reports Medicine</i> , 2022, 3, 100602.	3.3	1
3168	A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers. <i>Cancer Cell</i> , 2022, 40, 479-493.e6.	7.7	64
3169	Rules of Engagement: The Lymphocyte Receptor Ecosystem in Renal Cell Carcinoma. <i>Cancer Research</i> , 2022, 82, 764-765.	0.4	1
3170	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	3.2	3
3171	Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-PD-1 Naïve and Experienced Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3042-3052.	3.2	18
3172	Histological diversity of anti-PD1-induced colitis. <i>Histology and Histopathology</i> , 2022, , 18456.	0.5	1
3176	Integrin signaling gene alterations and outcomes of cancer patients receiving immune checkpoint inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 12386-12394.	0.0	0
3177	APOBEC3F expression in triple-negative breast cancer is associated with tumor microenvironment infiltration and activation of cancer immunity and improved survival. <i>American Journal of Cancer Research</i> , 2022, 12, 744-762.	1.4	0
3178	PPRX-1701, a Nanoparticle Formulation of 6 <sup>TM</sup> -Bromoindirubin Acetoxime, Improves Delivery and Shows Efficacy in Immune Competent Preclinical GBM Models. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3180	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
3181	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies. <i>Cancers</i> , 2022, 14, 2177.	1.7	2
3182	Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival. <i>Cancers</i> , 2022, 14, 2090.	1.7	5
3183	A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. <i>Frontiers in Pharmacology</i> , 2022, 13, .	1.6	1
3185	Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5384.	1.8	28
3186	Relationship between tumor mutational burden, gene mutation status, and clinical characteristics in 340 cases of lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, , .	1.3	2
3187	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5097.	1.8	3
3188	Analysis of possible markers of effective antitumor cellular immune response before starting therapy with immune check-point inhibitors. <i>Siberian Journal of Oncology</i> , 2022, 21, 109-117.	0.1	0
3189	Self-assembled polysaccharide nanogel delivery system for overcoming tumor immune resistance. <i>Journal of Controlled Release</i> , 2022, 347, 175-182.	4.8	22

#	ARTICLE	IF	CITATIONS
3190	Genomic landscape of microsatellite instability in Chinese tumors: A comparison of Chinese and <scp>TCGA</scp> cohorts. <i>International Journal of Cancer</i> , 2022, 151, 1382-1393.	2.3	9
3191	Personalized treatment for hepatocellular carcinoma: Current status and future perspectives. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1197-1206.	1.4	13
3192	Cancer vaccines: past, present and future; a review article. <i>Discover Oncology</i> , 2022, 13, 31.	0.8	24
3193	Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape. <i>Medical Oncology</i> , 2022, 39, 92.	1.2	0
3194	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15
3195	The role of biomarkers in personalized immunotherapy. <i>Biomarker Research</i> , 2022, 10, 32.	2.8	27
3196	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 781-794.	1.8	10
3197	Association of mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors.. <i>American Journal of Cancer Research</i> , 2022, 12, 1766-1783.	1.4	0
3199	Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2022, , 163-192.	1.6	3
3201	Comprehensive Analysis of the Butyrate-Metabolism-Related Gene Signature in Tumor Microenvironment-Infiltrating Immune Cells in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	4
3202	Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
3203	Prognostic and Immunological Role of PPP1R14A as a Pan-Cancer Analysis Candidate. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0
3204	The role of neoantigens in tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113118.	2.5	17
3205	Antigenic Molecular Mimicry in Viral-Mediated Protection from Cancer: The HIV Case. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
3206	Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
3207	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
3209	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
3210	Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden. <i>Human Cell</i> , 2022, 35, 1192-1206.	1.2	6



#	ARTICLE	IF	CITATIONS
3211	Cutaneous Breast Cancer Metastasis Is Effectively Treated With Intralesional Interleukin-2 and Imiquimod: A Case Report and Brief Literature Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3212	Prediction of Tumor Mutation Load in Colorectal Cancer Histopathological Images Based on Deep Learning. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3213	The Chemokines Initiating and Maintaining Immune Hot Phenotype Are Prognostic in ICB of HNSCC. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	0
3214	Estimating tumor mutational burden from RNA-sequencing without a matched-normal sample. <i>Nature Communications</i> , 2022, 13, .	5.8	4
3216	Understanding the tumor microenvironment in head and neck squamous cell carcinoma. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
3217	Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges. <i>Clinical Medicine Insights: Oncology</i> , 2022, 16, 117955492210998.	0.6	10
3220	Update on prognostic and predictive biomarkers of breast cancer. <i>Seminars in Diagnostic Pathology</i> , 2022, 39, 322-332.	1.0	20
3221	Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides. <i>Cell Reports</i> , 2022, 39, 110916.	2.9	28
3222	Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
3223	Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations. <i>Npj Precision Oncology</i> , 2022, 6, .	2.3	11
3224	Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. <i>Journal of Hepatology</i> , 2022, 77, 1359-1372.	1.8	30
3225	Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
3226	Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation. <i>Cancer Research and Treatment</i> , 2023, 55, 155-166.	1.3	1
3227	Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	9
3228	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. <i>Immunotherapy</i> , 0, , .	1.0	3
3229	A Novel Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response of Glioma. <i>BioMed Research International</i> , 2022, 2022, 1-19.	0.9	3
3230	Lighting a Fire: Gasdermin-Mediated Pyroptosis Remodels the Glioma Microenvironment and Promotes Immune Checkpoint Blockade Response. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
3231	Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
3232	Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3233	Immune signature as a potential marker for predicting response to immunotherapy in obesity-associated colorectal cancer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 1579-1587.	1.4	1
3234	CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer. <i>Current Molecular Medicine</i> , 2023, 23, 521-526.	0.6	3
3235	Therapeutic cancer vaccines: From biological mechanisms and engineering to ongoing clinical trials. <i>Cancer Treatment Reviews</i> , 2022, 109, 102429.	3.4	30
3236	Clinical impact of STK11 mutation in advanced-stage non-small cell lung cancer. <i>European Journal of Cancer</i> , 2022, 172, 85-95.	1.3	20
3237	Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
3238	The immune landscape of solid pediatric tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	13
3239	DNA damage in peripheral blood mononuclear cells in patients with melanoma. <i>Siberian Journal of Oncology</i> , 2022, 21, 33-41.	0.1	0
3240	Ferroptosis in Glioma Immune Microenvironment: Opportunity and Challenge. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3241	Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics. <i>Cancer Medicine</i> , 0, , .	1.3	1
3242	Development and validation of a molecular tool to predict pathologic complete response in esophageal adenocarcinoma. <i>Ecological Management and Restoration</i> , 2022, 35, .	0.2	1
3243	Can Radiotherapy Empower the Host Immune System to Counterattack Neoplastic Cells? A Systematic Review on Tumor Microenvironment Radiomodulation. <i>Current Oncology</i> , 2022, 29, 4612-4624.	0.9	5
3244	Inactivation of the Hippo tumor suppressor pathway promotes melanoma. <i>Nature Communications</i> , 2022, 13, .	5.8	10
3245	Prognostic attributes of immune signatures in soft tissue sarcomas show differential dependencies on tumor mutational burden. <i>Cancer</i> , 0, , .	2.0	0
3246	TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine. <i>EPMA Journal</i> , 2022, 13, 519-534.	3.3	4
3247	HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer. <i>Cancers</i> , 2022, 14, 3495.	1.7	6
3248	Dendritic cell-mediated cross presentation of tumor-derived peptides is biased against plasma membrane proteins. , 2022, 10, e004159.		5
3249	Genotypes of Papillary Thyroid Carcinoma With High Lateral Neck Metastasis in Chinese Population. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2

#	ARTICLE	IF	CITATIONS
3250	Recurrent somatic mutations as predictors of immunotherapy response. <i>Nature Communications</i> , 2022, 13, .	5.8	12
3251	Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 226-244.	2.0	4
3252	STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	44
3253	<i>PAPPA2</i> mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer. <i>Cell Proliferation</i> , 2022, 55, .	2.4	5
3254	Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study. <i>Clinical Cancer Research</i> , 2022, 28, 3489-3498.	3.2	35
3255	Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
3256	Mechanisms of resistance to immune checkpoint inhibitors. <i>Cancer Science</i> , 2022, 113, 3303-3312.	1.7	12
3257	The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7839.	1.8	13
3258	Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, .	1.2	0
3260	Exploring immunotherapy in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	104
3261	Comprehensive Pan-Cancer Analysis of Senescence With Cancer Prognosis and Immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
3262	Characterization of the Immunological Status of Hypermutated Solid Tumors in the Cancer Genome Analysis Project HOPE. <i>Anticancer Research</i> , 2022, 42, 3537-3549.	0.5	2
3263	The Potential and Emerging Role of Quantitative Imaging Biomarkers for Cancer Characterization. <i>Cancers</i> , 2022, 14, 3349.	1.7	2
3264	The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 169-181.	2.0	9
3265	Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma. <i>Cancers</i> , 2022, 14, 3342.	1.7	9
3266	Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	2
3267	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
3268	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
3269	Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. , 2022, 10, e004695.		16
3270	Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3271	Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors. <i>British Journal of Cancer</i> , 0, , .	2.9	0
3272	A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 413-425.	2.3	9
3273	Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 3065-3073.	1.2	6
3274	Advances in Cutaneous Squamous Cell Carcinoma Management. <i>Cancers</i> , 2022, 14, 3653.	1.7	14
3275	Immune-checkpoint inhibitors for glioblastoma: what have we learned?. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 266-269.	0.3	5
3276	A Signature Based on Costimulatory Molecules for the Assessment of Prognosis and Immune Characteristics in Patients With Stomach Adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3277	The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer. <i>Cancers</i> , 2022, 14, 3563.	1.7	22
3278	Inhibition of stearyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating $\beta$ -catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. , 2022, 10, e004616.		25
3279	NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
3280	Benchmarking bioinformatics approaches for tumour mutational burden evaluation from a large cancer panel against whole-exome sequencing. <i>Journal of Clinical Pathology</i> , 2023, 76, 276-280.	1.0	1
3281	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
3282	Ageing-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
3283	Prognostic Impact of TP53 Mutations and Tumor Mutational Load in Colorectal Cancer. <i>Gastrointestinal Disorders</i> , 2022, 4, 165-179.	0.4	3
3284	Human microbiota colonization and pancreatic ductal carcinoma. <i>Critical Reviews in Microbiology</i> , 2023, 49, 455-468.	2.7	1
3285	Lactate score predicts survival, immune cell infiltration and response to immunotherapy in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
3286	Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. <i>Anticancer Research</i> , 2022, 42, 4477-4484.	0.5	8

#	ARTICLE	IF	CITATIONS
3287	Secretory co-factors in next-generation cellular therapies for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
3288	Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1619-1629.	15.2	56
3289	Analytical Principles of Cancer Next Generation Sequencing. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 395-408.	0.7	3
3290	Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 288-307.	2.8	14
3291	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
3292	<i>FAT2</i> mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	0
3293	Identification of a prognostic model based on costimulatory molecule-related subtypes and characterization of tumor microenvironment infiltration in acute myeloid leukemia. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
3294	Total mutational load and clinical features as predictors of the metastatic status in lung adenocarcinoma and squamous cell carcinoma patients. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	1
3295	A Paradoxical Role for Regulatory T Cells in the Tumor Microenvironment of Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 3862.	1.7	8
3296	Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
3297	An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
3298	Investigation of CTLA4 <sup>TM</sup> s Application in Advanced Melanoma with Ipilimumab and Nivolumab. , 0, 8, 481-489.		0
3299	Intracranial Metastatic Melanoma. , 0, , .		0
3300	Tumor mutation burden-assisted risk stratification for papillary thyroid cancer. <i>Endocrine</i> , 2022, 78, 296-305.	1.1	3
3301	The epiphany derived from T-cell <sup>TM</sup> inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
3302	The pyroptosis-related gene signature predicts prognosis and reveals characterization of the tumor immune microenvironment in acute myeloid leukemia. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
3303	A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20
3304	A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6

#	ARTICLE	IF	CITATIONS
3305	Systematic pan-cancer analysis identifies RBM39 as an immunological and prognostic biomarker. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4859-4871.	1.6	4
3306	Solving the puzzle of what makes immunotherapies work. <i>Trends in Cancer</i> , 2022, 8, 890-900.	3.8	7
3307	A cuproptosis-related lncRNAs signature for prognosis, chemotherapy, and immune checkpoint blockade therapy of low-grade glioma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
3308	Prognostic Value of MUC16 Mutation and Its Correlation with Immunity in Hepatocellular Carcinoma Patients. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-9.	0.5	2
3309	Immune cellular components and signaling pathways in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2022, 86, 187-201.	4.3	18
3310	Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e058692.	0.8	3
3311	An anti-CTLA-4 heavy chain-only antibody with enhanced T <sub>reg</sub> depletion shows excellent preclinical efficacy and safety profile. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
3312	High IGC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9124.	1.8	7
3313	Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113464.	2.5	4
3314	Immunotherapy of cholangiocarcinoma: Therapeutic strategies and predictive biomarkers. <i>Cancer Letters</i> , 2022, 546, 215853.	3.2	9
3315	Novel approaches for treatment of endometrial carcinoma. <i>Current Problems in Cancer</i> , 2022, 46, 100895.	1.0	7
3316	Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166516.	1.8	0
3317	Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
3318	The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	21
3319	Cancer genome and tumor microenvironment: Reciprocal crosstalk shapes lung cancer plasticity. <i>ELife</i> , 0, 11, .	2.8	10
3320	Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen-specific T cells. <i>Cancer Science</i> , 0, , .	1.7	1
3321	Anti-neoplastic Immunomodulatory Treatments and the Pituitary. , 2022, , 309-320.		0
3322	Current and future perspectives on CAR-T cell therapy for renal cell carcinoma: A comprehensive review. <i>Investigative and Clinical Urology</i> , 2022, 63, 486.	1.0	7

#	ARTICLE	IF	CITATIONS
3323	New opportunities for immunomodulation of the tumour microenvironment using chemical tools. <i>Chemical Society Reviews</i> , 2022, 51, 7944-7970.	18.7	15
3324	Gut microbiota shed new light on the management of immune-related adverse events. <i>Thoracic Cancer</i> , 2022, 13, 2681-2691.	0.8	10
3325	High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. <i>Biomedicines</i> , 2022, 10, 2109.	1.4	0
3326	Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
3328	m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3329	Biomarkers for immune checkpoint inhibitors in solid tumors. <i>Clinical and Translational Oncology</i> , 2023, 25, 126-136.	1.2	3
3330	Identification of N6-methyladenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
3331	Transcriptome profiles of fatty acid metabolism-related genes and immune infiltrates identify hot tumors for immunotherapy in cutaneous melanoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
3333	Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade. <i>BioMed Research International</i> , 2022, 2022, 1-9.	0.9	1
3334	Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10131.	1.8	16
3335	Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	23
3336	TMBcat: A multi-endpoint p-value criterion on different discrepancy metrics for superiorly inferring tumor mutation burden thresholds. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
3337	Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. <i>Molecular Cancer</i> , 2022, 21, .	7.9	58
3338	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2023, 22, 112-122.	1.9	3
3341	Big data in basic and translational cancer research. <i>Nature Reviews Cancer</i> , 2022, 22, 625-639.	12.8	67
3342	Necroptosis-related lncRNA signature predicts prognosis and immune response for cervical squamous cell carcinoma and endocervical adenocarcinomas. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
3343	A novel pathway mutation perturbation score predicts the clinical outcomes of immunotherapy. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	7
3344	Molecular Biomarkers of Response to Cancer Immunotherapy. <i>Clinics in Laboratory Medicine</i> , 2022, 42, 469-484.	0.7	3



#	ARTICLE	IF	CITATIONS
3345	Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy. <i>Cells</i> , 2022, 11, 2802.	1.8	4
3346	Two subtypes of cutaneous melanoma with distinct mutational signatures and clinico-genomic characteristics. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
3347	Nanocarriers for cancer nano-immunotherapy. <i>Drug Delivery and Translational Research</i> , 2023, 13, 1936-1954.	3.0	17
3348	Clinical neutrophil-associated genes as reliable predictors of hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
3349	The DNA damage induced immune response: Implications for cancer therapy. <i>DNA Repair</i> , 2022, 120, 103409.	1.3	6
3350	Plasma, cancer, immunity. <i>Journal Physics D: Applied Physics</i> , 2022, 55, 473003.	1.3	8
3351	Relationships of Ferroptosis and Pyroptosis-Related Genes with Clinical Prognosis and Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-47.	1.9	5
3353	NOAEL Cancer Therapy: Tumor Targetable Docetaxel-Inorganic Polymer Nanohybrid Prevents Drug-Induced Neutropenia. <i>Journal of Materials Chemistry B</i> , 0, , .	2.9	0
3354	Prognostic and Immunological Role of STK38 across Cancers: Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11590.	1.8	2
3355	Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	7
3356	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. <i>Biology of Sex Differences</i> , 2022, 13, .	1.8	9
3357	SERS Multiplex Profiling of Melanoma Circulating Tumor Cells for Predicting the Response to Immune Checkpoint Blockade Therapy. <i>Analytical Chemistry</i> , 2022, 94, 14573-14582.	3.2	9
3360	Subcellular location of source proteins improves prediction of neoantigens for immunotherapy. <i>EMBO Journal</i> , 2022, 41, .	3.5	2
3361	mRNA-Based Approaches to Treating Liver Diseases. <i>Cells</i> , 2022, 11, 3328.	1.8	4
3362	Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5
3363	Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through Fcγ3R engagement and type I interferon signaling. <i>Nature Cancer</i> , 2022, 3, 1336-1350.	5.7	26
3364	Characterization of the CpG island methylator phenotype subclass in papillary thyroid carcinoma. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	4
3365	Combating challenges in CAR-T cells with engineering immunology. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	2

#	ARTICLE	IF	CITATIONS
3366	Efficacy of PD-1/PD-L1 inhibitors in patients with advanced gastroesophageal cancer: An updated meta-analysis based on randomized controlled trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
3368	Prognostic model and immunotherapy prediction based on molecular chaperone-related lncRNAs in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
3369	Antigenic molecular mimicry in viral-mediated protection from cancer: the HIV case. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	3
3370	IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells. , 2022, 10, e005815.		4
3371	Clinical and Translational Advances in Glioma Immunotherapy. <i>Neurotherapeutics</i> , 2022, 19, 1799-1817.	2.1	14
3372	Current Status of Immune Checkpoint Inhibitors. <i>Nihon Kikan Shokudoka Gakkai Kaiho</i> , 2022, 73, 303-307.	0.0	0
3373	The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. <i>Cancers</i> , 2022, 14, 5144.	1.7	8
3374	The Inflammasomes Adaptor Protein PYCARD Is a Potential Pyroptosis Biomarker Related to Immune Response and Prognosis in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4992.	1.7	3
3375	A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood. <i>Immunological Investigations</i> , 2022, 51, 2159-2175.	1.0	3
3378	Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3379	Integrative Genomic Tests in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13129.	1.8	8
3380	A novel oxidative stress- and ferroptosis-related gene prognostic signature for distinguishing cold and hot tumors in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
3381	Enhancer decommissioning by MLL4 ablation elicits dsRNA-interferon signaling and GSDMD-mediated pyroptosis to potentiate anti-tumor immunity. <i>Nature Communications</i> , 2022, 13, .	5.8	14
3382	Characterization of 5-inflammatory-gene signature to affect the immune status and predict prognosis in breast cancer. <i>Central-European Journal of Immunology</i> , 2022, 47, 218-233.	0.4	1
3384	Systematic pan-cancer analysis identifies RALA as a tumor targeting immune therapeutic and prognostic marker. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3385	Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3386	Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3387	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14

#	ARTICLE	IF	CITATIONS
3388	Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3389	External quality assessment (EQA) for tumor mutational burden: results of an international IQN path feasibility pilot scheme. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2023, 482, 347-355.	1.4	3
3390	High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3391	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
3392	Decitabine Treatment Induces a Viral Mimicry Response in Cervical Cancer Cells and Further Sensitizes Cells to Chemotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14042.	1.8	4
3393	CAR T-cells for colorectal cancer immunotherapy: Ready to go?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
3395	Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. <i>Cancers</i> , 2022, 14, 5605.	1.7	4
3396	Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer. <i>Journal of Advanced Research</i> , 2023, 51, 121-134.	4.4	14
3397	Clonal evolution and expansion associated with therapy resistance and relapse of colorectal cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2022, 790, 108445.	2.4	4
3398	Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11
3399	Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. <i>Advances in Clinical Chemistry</i> , 2022, , .	1.8	0
3401	Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients. <i>Cancers</i> , 2022, 14, 5638.	1.7	7
3402	Immune checkpoints and their promising prospect in cholangiocarcinoma treatment in combination with other therapeutic approaches. <i>International Immunopharmacology</i> , 2023, 114, 109526.	1.7	2
3403	Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study. <i>Gynecologic Oncology</i> , 2023, 169, 64-69.	0.6	4
3404	Post-irradiation intratumoral heterogeneity modulates response to immune checkpoint inhibition therapy in a murine melanoma model. <i>Neoplasia</i> , 2023, 36, 100864.	2.3	0
3405	Shifting Treatment Paradigms in Non-Hodgkin Lymphomas. <i>European Medical Journal Hematology</i> , 0, , 35-43.	0.0	0
3406	A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. <i>Cancer Informatics</i> , 2022, 21, 117693512211360.	0.9	1
3407	Experiencia institucional en pacientes portadores de melanoma irreseccable/metastásico con mutaciones infrecuentes de BRAF, tratados con anti PD-1. , 2018, 23, .		0

#	ARTICLE	IF	CITATIONS
3408	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. <i>Cancers</i> , 2022, 14, 5858.	1.7	2
3409	Targeted Therapy for Melanomas Without BRAF V600 Mutation. <i>Current Oncology Reports</i> , 2022, 24, 1873-1881.	1.8	3
3410	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop". <i>OncoTargets and Therapy</i> , 0, Volume 15, 1409-1415.	1.0	2
3411	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
3412	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022, 29, 9046-9065.	0.9	6
3413	Parenteral Nanoemulsions Loaded with Combined Immuno- and Chemo-Therapy for Melanoma Treatment. <i>Nanomaterials</i> , 2022, 12, 4233.	1.9	4
3414	Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer. <i>Cells</i> , 2022, 11, 3841.	1.8	3
3415	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
3416	Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 147.	1.8	1
3417	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
3418	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
3419	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
3420	Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 746-762.	0.5	0
3421	Comprehensive Pan-Cancer Analyses of Immunogenic Cell Death as a Biomarker in Predicting Prognosis and Therapeutic Response. <i>Cancers</i> , 2022, 14, 5952.	1.7	0
3423	Identification of a signature based on non-apoptotic regulatory cell death to improve prognosis prediction in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 0, , .	1.2	1
3424	The potential of PARP inhibitors in targeted cancer therapy and immunotherapy. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	12
3425	Multi-omics characteristics and immunotherapeutic potential of EZH2 in pan-cancer. <i>Bioscience Reports</i> , 0, , .	1.1	2
3426	Resistance to immune checkpoint inhibitors and the tumor microenvironment. <i>Experimental Dermatology</i> , 2023, 32, 240-249.	1.4	5

#	ARTICLE	IF	CITATIONS
3427	Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells. , 0, 1, .		2
3428	Incorporating RNA-based Risk Scores for Genomic Instability to Predict Breast Cancer Recurrence and Immunogenicity in a Diverse Population. <i>Cancer Research Communications</i> , 2023, 3, 12-20.	0.7	1
3429	The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer. <i>BioMed Research International</i> , 2022, 2022, 1-28.	0.9	0
3431	Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. <i>Genome Medicine</i> , 2022, 14, .	3.6	15
3432	ACAP1 Deficiency Predicts Inferior Immunotherapy Response in Solid Tumors. <i>Cancers</i> , 2022, 14, 5951.	1.7	4
3433	Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
3434	Novel immune-related prognostic model and nomogram for breast cancer based on ssGSEA. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
3435	Single-cell transcriptome analysis reveals a cancer-associated fibroblast marker gene signature in hepatocellular carcinoma that predicts prognosis. , 2023, 2, 16-25.		1
3436	Exploring the landscape of immunotherapy approaches in sarcomas. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3437	Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
3438	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	8
3439	Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient/high microsatellite instability/high tumor mutational burden: A case report and literature review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
3440	Extensive molecular profiling of squamous cell anal carcinoma in a phase 2 trial population: Translational analyses of the "CARACAS" study. <i>European Journal of Cancer</i> , 2023, 182, 87-97.	1.3	3
3441	RNA splicing dysregulation and the hallmarks of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 135-155.	12.8	73
3442	Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
3443	Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
3444	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
3445	Melanoma antigens recognized by T cells and their use for immunotherapy. <i>Experimental Dermatology</i> , 0, , .	1.4	3

#	ARTICLE	IF	CITATIONS
3446	Association of RNA-modification "writer" genes with prognosis and response to immunotherapy in patients with low-grade glioma. <i>PLoS ONE</i> , 2023, 18, e0279119.	1.1	0
3448	Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 6059-6066.	1.2	2
3449	An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
3450	PDJ amplicon in triple negative breast cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
3451	PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancers. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
3452	MHC II immunogenicity shapes the neoepitope landscape in human tumors. <i>Nature Genetics</i> , 2023, 55, 221-231.	9.4	5
3453	An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma. <i>Genes</i> , 2023, 14, 124.	1.0	14
3454	Multi-institution analysis of tumor mutational burden and outcomes in pediatric central nervous system tumor patients. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	0.8	2
3455	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
3456	Co-expression of receptor tyrosine kinases and CD8 T-lymphocyte genes is associated with distinct prognoses, immune cell infiltration patterns and immunogenicity in cancers. <i>Translational Research</i> , 2023, 256, 14-29.	2.2	1
3457	High SERPINH1 expression predicts poor prognosis in lung adenocarcinoma. <i>Journal of Thoracic Disease</i> , 2022, 14, 4785-4802.	0.6	5
3458	Immunodeficiencies Push Readmissions in Malignant Tumor Patients: A Retrospective Cohort Study Based on the Nationwide Readmission Database. <i>Cancers</i> , 2023, 15, 88.	1.7	0
3459	Establishment and validation of a nomogram for predicting immune-related prognostic features in trunk melanoma-specific death. <i>Annals of Translational Medicine</i> , 2022, 10, 1371-1371.	0.7	0
3460	Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1719-1729.	3.2	12
3461	What is precision medicine in oncology?. , 2023, , 1-30.		0
3462	Targeting ULK1 Decreases IFN $\gamma$ -Mediated Resistance to Immune Checkpoint Inhibitors. <i>Molecular Cancer Research</i> , 2023, 21, 332-344.	1.5	4
3463	Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. , 2023, 11, e005924.		24
3464	Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor-Based Cellular Therapy. <i>Annual Review of Cancer Biology</i> , 2023, 7, .	2.3	1

#	ARTICLE	IF	CITATIONS
3465	Identification of a novel immune-related gene signature for prognosis and the tumor microenvironment in patients with uveal melanoma combining single-cell and bulk sequencing data. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
3466	A clinically feasible circulating tumor cell sorting system for monitoring the progression of advanced hepatocellular carcinoma. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	5
3467	Base editing screens map mutations affecting interferon- $\beta$ signaling in cancer. <i>Cancer Cell</i> , 2023, 41, 288-303.e6.	7.7	14
3468	Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease. <i>Neuro-Oncology</i> , 0, , .	0.6	0
3469	Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211489.	1.4	2
3470	Immunotherapy and tumor mutational burden in cancer patients with liver metastases: A meta and real word cohort analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
3472	Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. , 2023, 11, e005809.		4
3473	Persistent mutation burden drives sustained anti-tumor immune responses. <i>Nature Medicine</i> , 2023, 29, 440-449.	15.2	35
3474	The application of RNA sequencing in precision cancer medicine. , 2024, , 46-58.		0
3475	Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens. <i>British Journal of Cancer</i> , 2023, 128, 1166-1175.	2.9	5
3476	A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2536-2546.	1.9	4
3477	Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4302.	1.8	0
3478	Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
3479	A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers. <i>International Immunopharmacology</i> , 2023, 116, 109821.	1.7	0
3481	PPRX-1701, a nanoparticle formulation of 6 $\beta$ -bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM models. <i>Cell Reports Medicine</i> , 2023, 4, 101019.	3.3	0
3482	A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer. <i>Translational Oncology</i> , 2023, 33, 101670.	1.7	2
3484	Loss of CDKN2A/B is a Molecular Marker of High-grade Histology and is Associated with Aggressive Behavior in Acinic Cell Carcinoma. <i>Modern Pathology</i> , 2023, 36, 100150.	2.9	2
3486	Identification and characterization of circular RNAs as novel putative biomarkers to predict anti-PD-1 monotherapy response in metastatic melanoma patients Knowledge from two independent international studies. <i>Neoplasia</i> , 2023, 37, 100877.	2.3	3



#	ARTICLE	IF	CITATIONS
3487	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
3488	A novel gene signature related to oxidative stress predicts the prognosis in clear cell renal cell carcinoma. PeerJ, 0, 11, e14784.	0.9	3
3489	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. Cancers, 2023, 15, 1093.	1.7	4
3490	Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report. World Journal of Clinical Cases, 0, 11, 1165-1174.	0.3	1
3491	A novel RNA modification prognostic signature for predicting the characteristics of the tumor microenvironment in gastric cancer. Frontiers in Oncology, 0, 13, .	1.3	1
3492	Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. Frontiers in Immunology, 0, 14, .	2.2	1
3493	Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. Frontiers in Immunology, 0, 14, .	2.2	0
3494	The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination. British Journal of Cancer, 2023, 128, 1777-1787.	2.9	3
3495	Computational methods and challenges in analyzing intratumoral microbiome data. Trends in Microbiology, 2023, 31, 707-722.	3.5	9
3496	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. , 2023, 20, 318-340.		13
3497	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. Frontiers in Immunology, 0, 14, .	2.2	9
3498	Molecular phenotypic linkage between N6-methyladenosine methylation and tumor immune microenvironment in hepatocellular carcinoma. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
3499	Probabilistic Mixture Models Improve Calibration of Panel-derived Tumor Mutational Burden in the Context of both Tumor-normal and Tumor-only Sequencing. Cancer Research Communications, 2023, 3, 501-509.	0.7	1
3501	Immunotherapy of Osteosarcoma. , 2023, , 1-39.		0
3502	Consensus Clustering and Survival-Related Genes of Cuproptosis in Cutaneous Melanoma. Mediators of Inflammation, 2023, 2023, 1-15.	1.4	4
3503	Construction of a prognostic risk assessment model for HER2+ breast cancer based on autophagy-related genes. Breast Cancer, 2023, 30, 478-488.	1.3	0
3504	Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade. Npj Precision Oncology, 2023, 7, .	2.3	3
3505	Case report: Pathological and genetic features of pancreatic undifferentiated carcinoma with osteoclast-like giant cells. Pathology and Oncology Research, 0, 29, .	0.9	0

#	ARTICLE	IF	CITATIONS
3506	Nidogen-2 (NID2) is a Key Factor in Collagen Causing Poor Response to Immunotherapy in Melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 16, 153-172.	0.4	0
3507	A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5332.	1.8	1
3508	Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy. <i>Theranostics</i> , 2023, 13, 1443-1453.	4.6	0
3509	The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. , 2023, , 1-32.		0
3510	Characterization of pancreatic cancer with ultra-low tumor mutational burden. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
3511	Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade. <i>Journal of Clinical Oncology</i> , 2023, 41, 3225-3235.	0.8	4
3512	A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2023, 29, 2052-2065.	3.2	8
3513	Stepwise activities of mSWI/SNF family chromatin remodeling complexes direct T cell activation and exhaustion. <i>Molecular Cell</i> , 2023, 83, 1216-1236.e12.	4.5	13
3514	Definition of a Novel Immunogenic Cell Death-Relevant Gene Signature Associated with Immune Landscape in Gastric Cancer. <i>Biochemical Genetics</i> , 2023, 61, 2092-2115.	0.8	2
3515	Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma. <i>Oncology and Therapy</i> , 2023, 11, 185-198.	1.0	2
3516	Epigenetic state determines the in vivo efficacy of STING agonist therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	12
3517	A Therapeutic Vaccine Targeting Rat BORIS (CTCF1) for the Treatment of Rat Breast Cancer Tumors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5976.	1.8	1
3519	T cells in the heterogeneous tumour immune microenvironment of hepatocellular carcinoma: Implications for immune checkpoint inhibitor therapy. <i>Liver Cancer International</i> , 2023, 4, 58-72.	0.2	0
3520	Immune Checkpoint Blockade Response Biomarkers. , 2023, , 1-34.		0
3522	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. <i>Biomedicines</i> , 2023, 11, 1020.	1.4	6
3523	LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2023, 12, 510-529.	1.3	2
3524	Targeting the Molecular and Immunologic Features of Leiomyosarcoma. <i>Cancers</i> , 2023, 15, 2099.	1.7	5
3525	The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6710.	1.8	7

#	ARTICLE	IF	CITATIONS
3526	Advancing Cancer Immunotherapy Through Integrating Molecular and Computational Approaches. , 2023, , 1-22.		0
3527	The peptide woods are lovely, dark and deep: Hunting for novel cancer antigens. Seminars in Immunology, 2023, 67, 101758.	2.7	4
3528	The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating. Cancer Immunology, Immunotherapy, 2023, 72, 2483-2498.	2.0	1
3529	Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell, 2023, 186, 1846-1862.e26.	13.5	92
3530	Mechanisms of resistance to melanoma immunotherapy. Onkologie (Czech Republic), 2023, 17, 51-56.	0.0	0
3531	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. Cancer Cell, 2023, 41, 791-806.e4.	7.7	5
3532	Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. Advances in Anatomic Pathology, 2023, 30, 174-194.	2.4	0
3533	Current Progress on Predictive Biomarkers for Response to Immune Checkpoint Inhibitors in Gastric Cancer: How to Maximize the Immunotherapeutic Benefit?. Cancers, 2023, 15, 2273.	1.7	2
3534	T Cell Based Immunotherapy for Cancer: Approaches and Strategies. Vaccines, 2023, 11, 835.	2.1	9
3535	Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies. , 2023, 20, 694-713.		8
3536	Mutations Status of NOTCH Signaling Pathway Predict Prognosis of Immune Checkpoint Inhibitors in Colorectal Cancer. Journal of Inflammation Research, 0, Volume 16, 1693-1709.	1.6	1
3537	Oncogenic <i>CDK13</i> mutations impede nuclear RNA surveillance. Science, 2023, 380, .	6.0	9
3538	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. Pathology Research and Practice, 2023, 247, 154473.	1.0	1
3539	Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer. International Journal of Molecular Sciences, 2023, 24, 7577.	1.8	2
3540	Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2023, 24, 7640.	1.8	5
3542	Could Inhibiting the DNA Damage Repair Checkpoint Rescue Immune-Checkpoint-Inhibitor-Resistant Endometrial Cancer?. Journal of Clinical Medicine, 2023, 12, 3014.	1.0	0
3555	Vaccines and active immunization against cancer. , 2024, , 177-194.e3.		0
3558	The power of whole genomic sequencing in biomedical research and clinical applications. , 2024, , 1-18.		0

#	ARTICLE	IF	CITATIONS
3566	Local $\hat{I}^3\hat{I}$ T cells: translating promise to practice in cancer immunotherapy. British Journal of Cancer, 2023, 129, 393-405.	2.9	4
3573	Rare subtypes of triple negative breast cancer: Current understanding and future directions. Npj Breast Cancer, 2023, 9, .	2.3	4
3584	Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy. Nature Reviews Clinical Oncology, 2023, 20, 583-603.	12.5	16
3587	The landscape of T cell antigens for cancer immunotherapy. Nature Cancer, 2023, 4, 937-954.	5.7	14
3592	Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors. Strahlentherapie Und Onkologie, 2023, 199, 1152-1163.	1.0	2
3595	Classification and Evolution of Tumor Ecosystem. , 2023, , 655-674.		0
3624	Challenges in developing personalized neoantigen cancer vaccines. Nature Reviews Immunology, 2024, 24, 213-227.	10.6	6
3648	Precision clinical genomics and single subject studies of multi-omics data. , 2024, , 41-56.		0
3665	Computational immunogenomic approaches to predict response to cancer immunotherapies. Nature Reviews Clinical Oncology, 2024, 21, 28-46.	12.5	1
3682	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nature Reviews Immunology, 0, , .	10.6	2
3709	Mapping the single cell spatial immune landscapes of the melanoma microenvironment. Clinical and Experimental Metastasis, 0, , .	1.7	0
3712	Establishing a Correlation of Clinical Characteristics with the Level of Tumor Mutation Burden in Urothelial Bladder Carcinoma. , 2023, , .		0
3751	CTLA-4 Inhibitors for the Treatment of Lung Cancer. , 2024, , 87-99.		0